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ABSTRACT
In recent years, there has been immense interest in the utilization of
photopolymerized hydrogels as carriers for controlled protein delivery and cell scaffolds for
tissue engineering applications.

Although poly(ethylene glycol) (PEG)-based hydrogels

formed from mild photopolymerization methods have been suggested as biocompatible
matrices that allow for safely encapsulating biomolecules including proteins, peptides, DNA,
and cells, the adverse effects of photopolymerization reactions on the encapsulated proteins
have largely been overlooked.

In addition, conventional hydrophilic hydrogels fail to

effectively control protein delivery rates due to their high permeability. These two problems
are critical since the delivery of protein therapeutics from hydrogel matrices in their active
form and in optimal rates usually determine whether a device performs successfully in a
given application.
The development of ideal hydrogel matrices requires a thorough understanding of
protein-polymer interactions and the mechanisms governing protein-delivery rates from a
crosslinked polymer network. The primary foci of this dissertation were to evaluate free
radical-mediated protein-polymer conjugation and to develop synthetic affinity hydrogels for
systematically controlling single and multiple-protein delivery. These research objectives
combine the knowledge of protein chemistry, polymer science and engineering, molecular
transport kinetics, and mathematical modeling.
The initial research efforts were to evaluate the factors causing protein inactivation
during in situ photopolymerization, with the primary focus on photoinitiator chemistry and
concentration (Chapter 3). Next, the undesirable formation of protein-polymer conjugates
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during in situ photopolymerization and their effects on total protein release were
investigated (Chapter 3, 4). Once the adverse effects of protein-polymer conjugates were
identified, a pseudo-specific metal-ion chelating ligand was used to enhance protein
bioavailability (Chapter 4).
Another challenge of using hydrophilic hydrogels for controlled protein delivery is the
networks’ high permeability to encapsulated proteins. This limitation was circumvented by
synthesizing affinity ligands that bind to target proteins and immobilizing them within
otherwise inert hydrogel networks (Chapter 5). This modification provided a unique method
for tuning the protein delivery rates. Two protein-binding mechanisms, namely electrostatic
interaction and metal-ion chelation, were used separately to evaluate the efficacy of proteinligand binding for controlling protein delivery (Chapter 5, 6). A mathematical model was
also developed to predict the release of histidine-tagged protein from metal-chelating ligand
imprinted affinity hydrogels (Chapter 5). Finally, these two binding mechanisms were used
together in a one-step photopolymerized hydrogel matrix to independently control the
delivery rates of two proteins encapsulated simultaneously (Chapter 7).
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CHAPTER ONE
INTRODUCTION
Synthetic hydrogels polymerized from poly(ethylene glycol) (PEG) derivatives have
been extensively used in controlled release [1-8], tissue engineering [1, 4, 9-15], biosensors
[16-18], and other biomedical applications. PEG-based hydrogels are widely used owing to
their demonstrated biocompatibility, non-fouling properties, and well-understood structurefunction relationships. To increase the applicability and cytocompatibility of inert PEG
hydrogels, multiple functionalities including stimuli-responsiveness [8, 19-21] and ligands for
biorecognition and protein-binding [22-24] can be readily tailored into hydrogel networks
through the copolymerization of acrylated/methacrylated monomers, peptides, proteins, or
other functional molecules with vinyl end groups.
A convenient yet efficient route of synthesizing covalently crosslinked PEG-based
hydrogels is through photo-initiated solution polymerization or photopolymerization.
Photopolymerization possesses numerous advantages including its aqueous and ambient
polymerization conditions as well as rapid and facile spatial/temporal control over reaction
kinetics.

The incorporation of functional moieties (e.g. stimuli-responsiveness,

affinity/biorecognition sites) as well as the encapsulation of biomolecules into PEG-based
hydrogels can be achieved simultaneously via one-step photopolymerization. Due to the
mild polymerization conditions and the unique sol-gel transition properties, hydrogels
formed from in situ photopolymerization have been successfully used as injectable
biomaterials for implantable tissue-engineered scaffolds and as vehicles for delivery of cells
and/or therapeutic agents via a minimally invasive manner.
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For controlled delivery

applications, controlled amounts of therapeutic agents can be easily and precisely
incorporated into the in situ-curable gels in a single processing step.
Although in situ photopolymerization offers many advantages, it may lead to
undesired side reactions with encapsulated biomolecules such as DNA [25, 26] and proteins
[27, 28]. These unwanted reactions include protein denaturation/inactivation and proteinpolymer conjugation. The denaturation or inactivation of protein therapeutics not only
causes loss in bioactivity and therapeutic efficacy, but the denatured proteins may also induce
a host immune response. On the other hand, the primary consequence of undesired proteinpolymer conjugation is reduced or incomplete protein release since the polymer in these
materials is at least originally part of a crosslinked, insoluble network. Although the use of
degradable matrices can ensure complete release of the encapsulated proteins, a portion of
these released proteins are in the form of protein-polymer conjugates that may not be as
active as native proteins and may also induce host immune response.
Prior studies on in situ photopolymerization have revealed the detrimental effects of
photoinitiators on DNA [25, 26] and cells [29, 30]. However, damage to encapsulated
proteins has not been extensively studied [27, 28]. The fact that more recombinant protein
therapeutics are becoming indispensable for tissue engineering applications and clinical
treatments makes it critical to develop methods that can safely encapsulate fragile protein
therapeutics.

Hydrogels are ideal candidates for protein encapsulation due to their

hydrophilic and non-fouling properties that help to preserve protein bioactivity. However,
there have been increasing concerns regarding protein stability and bioactivity during in situ
photopolymerization.
phenomenon.

The first part of this dissertation aims to evaluate this critical

The objectives are (1) to understand the mechanisms causing protein

2

inactivation and incomplete protein release, and (2) to enhance total protein delivery from in
situ photopolymerized hydrogels using protein-binding ligands. It was hypothesized that
incomplete protein release is due to the formation of protein-polymer conjugates within in
situ curable hydrogels. Specifically, high-energy free radicals generated by photoinitiators
during UV curing are responsible for these adverse conjugations and hence play a major role
in protein inactivation and incomplete release. With this hypothesis in mind, we attempt to
characterize the factors affecting protein activity during in situ photopolymerization. We
then successfully employ a protein-binding ligand to reduce the extent to which proteinpolymer conjugates are formed, ultimately leading to enhanced protein delivery efficiency.
PEG-based hydrogels are considered biocompatible not only due to their “stealth”
character but also because of their high water contents that resemble natural tissue
properties. The high water content of the hydrophilic hydrogels, however, leads to high
permeability for the encapsulated proteins, which makes sustained protein delivery difficult.
In view of this, several methodologies have been developed in an attempt to systematically
decrease protein delivery rates from highly permeable hydrogels.

Perhaps the most

successful approach to date is the incorporation of protein-binding ligands into the
otherwise inert hydrogel networks. These “affinity” ligands are either derived from natural
polysaccharides such as heparin or cyclodextrin or from synthetic ligands including
methacrylic acid. Despite a wide variety of synthesized affinity ligands, there still exists a
demanding quest for more effective and biocompatible ligands that, upon facile
incorporation into the polymer network, do not compromise the preferential hydrogel
properties. The second part of this dissertation describes the design and application of novel
PEG-based hydrogels copolymerized with synthetic protein binding ligands to address this
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problem of obtaining sustained protein delivery from hydrogel carriers. The goals are (1) to
systematically controll protein delivery using protein-binding ligands without sacrificing the
preferential hydrophilic/biocompatible properties of hydrogels; (2) to predict protein
delivery a priori through mathematical modeling; and (3) to design monolithic hydrogels for
tunable dual-protein delivery.
The global objective of this phase of the research project is to enhance the
performance of hydrogel-based controlled protein delivery devices with the specific aims of
decreasing adverse protein-polymer conjugation and increasing the tunability of protein
delivery from hydrophilic PEG-based hydrogels. The objectives of each chapter in this
dissertation are outlined below:
Chapter 2 reviews the use of hydrogels in controlled release formulation, including the
general design criteria/considerations as well as the mathematical modeling of hydrogelbased controlled delivery devices. Through this extensive review of hydrogel network design
and mathematical modeling, we plan to identify some of the key issues that need to be
addressed toward the development of an ideal hydrogel-based protein delivery device.
Chapter 3 discusses photoinitiator-mediated protein inactivation and its impact on
controlled protein delivery from in situ photopolymerized hydrogels. Lysozyme was used as
a model protein to investigate the adverse effects of photoinitiators during
photopolymerization. Also discussed is the effect of nonacrylated poly(ethylene glycol)
(PEG) and acrylated PEG macromers on the preservation of protein bioactivity. The
specific aim of this chapter is to unravel the critical parameters for causing proteininactivation and to optimize the photopolymerization conditions for preserving protein
bioactivity.
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Chapter 4 investigates the factors causing incomplete protein release from in situ
photopolymerized hydrogels. Bovine serum albumin (BSA) was used as a model protein and
a proof-of-principle protein-protection strategy based on pseudo-specific metal-ion chelating
ligands was developed to enhance total protein release.
Chapter 5 describes the synthesis of affinity PEG hydrogels for sustained protein
delivery. A methacrylated metal-ion chelating ligand was synthesized and copolymerized
into the PEG hydrogels in an attempt to systematically decrease protein delivery rate by
tuning protein-ligand binding affinity. Also developed is a mathematical model accounting
for protein diffusion and reversible protein-ligand binding to enable prediction of total
protein delivery from these affinity hydrogels.
Chapter 6 characterizes stimuli-responsive hydrogels for enhanced protein loading and
sustained delivery. Two protein-loading techniques were used: post-loading and in situloading. The aims are to compare the controlled protein delivery performances using these
two protein-loading techniques.
Chapter 7 details the use of monolithic affinity hydrogels for manipulating dualprotein delivery by selectively adjusting protein-ligand binding affinity. The objective is to
use monolithic, highly swelling hydrogels for independently controlling delivery of one
protein without affecting the release rate of a second, co-encapsulated protein. This novel
strategy may potentially enhance hydrogel-based strategies for regenerating functional tissues
by enabling localized, sustainable, and independently tunable delivery of multiple growth
factors from an injectable tissue scaffold.
Chapter 8 outlines the major conclusions and recommendations for future studies on
the use of in situ photopolymerized hydrogels for controlled protein delivery.
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CHAPTER TWO
HYDROGELS IN CONTROLLED RELEASE FORMULATIONS: NETWORK
DESIGN AND MATHEMATICAL MODELING
(As appearing in Advanced Drug Delivery Review 2006(58):1379-1408)
Abstract
Over the past few decades, advances in hydrogel technologies have spurred
development in many biomedical applications including controlled drug delivery. Many novel
hydrogel-based delivery matrices have been designed and fabricated to fulfill the everincreasing needs of the pharmaceutical and medical fields. Mathematical modeling plays an
important role in facilitating hydrogel network design by identifying key parameters and
molecule release mechanisms. The objective of this article is to review the fundamentals and
recent advances in hydrogel network design as well as mathematical modeling approaches
related to controlled molecule release from hydrogels. In the first section, the niche roles of
hydrogels in controlled release, molecule release mechanisms, and hydrogel design criteria
for controlled release applications are discussed. Novel hydrogel systems for drug delivery
including biodegradable, smart, and biomimetic hydrogels are reviewed in the second
section. Several mechanisms have been elucidated to describe molecule release from polymer
hydrogel systems including diffusion, swelling, and chemically-controlled release. The focus
of the final part of this article is discussion of emerging hydrogel delivery systems and
challenges associated with modeling the performance of these devices.

Keywords: Hydrogels, drug delivery, modeling, controlled release, diffusion, degradation
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2.1 Introduction
2.1.1 Overview of manuscript / Scope of this review
Since the establishment of the first synthetic hydrogels by Wichterle and Lim in 1954
[1], the growth of hydrogel technologies has advanced many fields ranging from food
additives [2] to pharmaceuticals [3] to biomedical implants [4]. In addition, the development
of an ever-increasing spectrum of functional monomers and macromers continue to broaden
the versatility of hydrogel applications. Hydrogels now play a critical role in many tissue
engineering scaffolds, biosensor and BioMEMS devices, and drug carriers. Among these
applications, hydrogel-based drug delivery devices have become a major area of research
interest with several commercial products already developed [5]. A successful drug delivery
device relies not only on intelligent network design but also on accurate a priori
mathematical modeling of drug release profiles. An ordered polymer network composed of
macromers with well understood chemistries yields hydrogels with well-defined
physicochemical properties and reproducible drug-release profiles. In a complimentary
fashion, a quantitative mathematical understanding of material properties, interaction
parameters, kinetic events, and transport phenomena within complex hydrogel systems
assists network design by identifying the key parameters and mechanisms that govern the
rate and extent of drug release. In addition, mathematical modeling accelerates device design
by limiting the number of experiments researchers must perform to understand the release
mechanisms governing a particular delivery system.
Many excellent review articles have been published detailing the modeling of drug
release from polymeric devices including hydrogels. This review builds on the established
literature by not only tracking recent advances in the development of mathematical models

10

for quantitatively predicting drug delivery from hydrogel systems, but also highlights how
these models are playing a critical role in the design of novel hydrogel networks for future
applications. In addition to describing the mechanisms governing drug release from
conventional hydrogels, the fabrication and modeling of several emerging and intelligently
designed hydrogel systems for drug delivery applications are discussed. Specifically, these
novel systems aim to incorporate advanced drug delivery strategies into tissue engineering
scaffolds and other biomedical implants and require rigorous methods for quantifying
multiple phenomena influencing molecule release.
2.1.2 Hydrogel – Definition, Classification, and Network structure
Hydrogels are polymeric networks that absorb large quantities of water while
remaining insoluble in aqueous solutions due to chemical or physical crosslinking of
individual polymer chains. Differing from hydrophobic polymeric networks such as
poly(lactic acid) (PLA) or poly(lactide-co-glycolide) (PLGA) which have limited waterabsorption capabilities (< 5-10 wt%), hydrophilic hydrogels exhibit many unique
physicochemical properties that make them advantageous for biomedical applications
including drug delivery. For example, hydrogels are excellent candidates for encapsulating
biomacromolecules including proteins and DNA due to their lack of hydrophobic
interactions which can denature these fragile species [6]. In addition, compared to commonly
used hydrophobic polymers such as PLGA, the conditions for fabricating hydrogels are
relatively mild. Gel formation usually proceeds at ambient temperature and organic solvents
are rarely required. In situ gelation with cell and drug encapsulation capabilities further
distinguishes hydrogels from the other hydrophobic polymers.
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Hydrogels can be prepared from natural or synthetic polymers [7]. Although hydrogels
made from natural polymers may not provide sufficient mechanical properties and may
contain pathogens or evoke immune/inflammatory responses, they do offer several
advantageous properties such as inherent biocompatibility, biodegradability, and biologically
recognizable moieties that support cellular activities. Synthetic hydrogels, on the other hand,
do not possess these inherent bio-active properties. Fortunately, synthetic polymers usually
have well-defined structures that can be modified to yield tailorable degradability and
functionality. Table 2.1 lists natural polymers as well as synthetic monomers that are
commonly used in hydrogel fabrication.

Table 2.1 Natural polymers and synthetic monomers used in hydrogels fabrications [6, 7].
Natural polymer

Synthetic monomer

Chitosan

Hydroxyethyl methacrylate (HEMA)

Alginate

N-(2-hydroxypropyl) methacrylate (HPMA)

Fibrin

N-vinyl-2-pyrrolidone (NVP)

Collagen

N-isopropyl acrylamide (NIPAAm)

Gelatin

Vinyl acetate (VAc)

Hyaluronic acid

Acrylic acid (AA)

Dextran

Methacrylic acid (MAA)
Polyethylene glycol acrylate/methacrylate
(PEGA/PEGMA)
Polyethylene glycol diacrylate/dimethacrylate
(PEGDA/PEGDMA)
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Since the favorable properties of hydrogels stem from their hydrophilicity, the
characterization of their water-sorption capabilities is the first step towards understanding
the nanoscopic structure of hydrogel networks. Generally, three parameters are critical in
describing the nanostructure of crosslinked hydrogel networks: (1) polymer volume fraction
in the swollen state, v 2,s , (2) number average molecular weight between crosslinks, M c , and
B

B

(3) network mesh size, ξ [8]. For nonporous hydrogels, the amount of liquid being retained
in the hydrogel, the distance between polymer chains, and the flexibility of those chains
together determine the mobility of encapsulated molecules and their rates of diffusion within
a swollen hydrogel matrix.
The polymer volume fraction in the swollen state (v2,s) describes the amount of liquid
that can be imbibed in hydrogels and is described as a ratio of the polymer volume (Vp) to
the swollen gel volume (Vg). It is also a reciprocal of the volumetric swollen ratio (Q) which
can be related to the densities of the solvent (ρ1) and polymer (ρ2) and the mass swollen ratio
(Qm) as described by Eq. (1):

υ 2 ,s =

Vp
Vg

= Q −1 =

1 / ρ2
Qm / ρ 1 + 1 / ρ 2

(1)

The average molecular weight between two adjacent crosslinks ( M c ) represents the
degree of crosslinking of the hydrogel networks. M c in a neutral, divinyl crosslinked
network can be expressed as the following Flory-Rehner Equation [9].

1
Mc

=

2
Mn

[

−

υ 
  ln(1 − υ 2 ,s ) + υ 2 ,s + χ 12υ 2
2 ,s
V 
 1

υ
υ 21,s3 − 2 ,s
2
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]
(2)

Here, M n is the average molecular weight of the linear polymer chains, v is the specific
volume of the polymer, V1 is the molar volume of water, and χ 12 is the polymer-water
interaction parameter. More complex versions of the Flory-Rehner expression have been
developed by Peppas and others to describe the swelling behavior of ionic gels or gels
crosslinked during polymerization [8]. For neutral gels at highly swelling conditions (Q>10),
Equation 2 can be simplified to illustrate how gel swelling scales with the average molecular
weight between crosslinks ( M c ) [10]:
υ (1 / 2 − 2 χ 12 )M c 
Q=

V1



3/ 5

( )3 / 5

=β Mc

(3)

Another important parameter used to describe hydrogel swelling is the network mesh
size (ξ) which can be described as follows [11]:
1/ 2

ξ = v2 ,s −1 / 3  ro2 


( )

1/ 2

Here, ro2



1/ 2

= Q1 / 3  ro2 
 

(4)

is the root-mean-squared end-to-end distance of network chains between two

adjacent crosslinks in the unperturbed state. It can be determined using the following
relationship [11]:

r 2 
 o 
 

1/ 2

= l (C n N )

1/ 2


2M c 

= l Cn


M
r



1/ 2

(5)

where C n is the Flory characteristic ratio, l is the bond length along the polymer backbone, N
B

B

is the number of bonds between adjacent crosslinks, and M r is the molecular weight of the
B

repeating units of the composed polymer.
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Combining Eqs. (4) and (5), one can easily calculate the mesh size of a hydrogel
network and further compare it with the hydrodynamic radii of the molecules to be
delivered. Theoretically, no solute diffusion is possible within the hydrogel matrix when
mesh size approaches the size of the solute as shown in Figure 2.1 [12]. Mesh size is
affected by several factors including (1) degree of crosslinking of the gel; (2) chemical
structure of the composing monomers; and (3) external stimuli such as temperature, pH and
ionic strength. Mesh size is important in determining the physical properties of the hydrogels
including mechanical strength, degradability, and diffusivity of the releasing molecule [10,
13]. Typical mesh sizes reported for biomedical hydrogels range from 5 – 100 nm in their
swollen state [10, 14]. These size scales are much larger than most small-molecule drugs and
therefore diffusion of these drugs are not significantly retarded in swollen hydrogel matrices.
However, the release of macromolecules such as peptides, proteins, and oligonucleotides can
be sustained from swollen hydrogels due to their significant hydrodynamic radii. When
designed appropriately, the structure and mesh size of swollen hydrogels can be tailored to
obtain desired rates of macromolecule diffusion [15]. Alternatively, the rate and degree of gel
swelling or degradation can also be tailored to control the release of molecules much smaller
than the gel mesh size.
2.1.3 Niche roles of hydrogels in drug delivery
The advance in recombinant protein technology has identified numerous protein and
peptide therapeutics for disease treatment. However, the effective delivery of these
biomolecules is challenging mainly because of their large molecular weights and unique
three-dimensional structures. Intravenous or subcutaneous injection is by far the most
commonly used route for drug administration. However, these biomolecules are prone to
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proteolytic degradation and therefore experience extremely short plasma circulation times
and rapid renal clearance, leading to multiple daily injections or increased dosage to maintain
the drug concentration in the therapeutic window. Multiple daily injections decrease patient
compliance while high doses may induce local toxicity and serious systemic immune
responses. Polymeric controlled release formulations such as PLGA offer a sustained release
mechanism in which the drug release rates can be controlled by changing polymer molecular
weight and composition. However, it is well-recognized that these hydrophobic polymers
induce detrimental effects to the encapsulated proteins or peptides during network
preparation and delivery [16] as well as trigger the host immune response [17]. Hydrophilic
hydrogels, on the other hand, provide relatively mild network fabrication and drug
encapsulation conditions that make them suitable for protein delivery [6]. The common
niche for hydrogels in controlled release is the encapsulation (and subsequent release) of
bioactive materials. Therefore, the systems we will focus on in this review deal with delivery
from matrix devices rather than membrane devices. Through proper design, hydrogels can
be used in a variety of applications including sustained, targeted, or stealth biomolecule
delivery.
Protein

Mesh Size

ξ

Degree of crosslinking
Chemical structure

ξ

External stimuli

swollen state

Crosslink

deswollen state

Figure 2.1 Schematic of mesh size in hydrogels at swollen or shrunken states. Adapted from
[12].
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Several unique properties that hydrogels possess make them useful in delivering
biomolecules. For example, stimuli responsiveness can be easily tailored into hydrogel
networks during fabrication [18]. This enables sustained or bolus drug delivery
corresponding to external stimuli such as pH or temperature. For example, pH-sensitive
hydrogels are useful in oral drug delivery as they can protect peptide/protein drugs in the
digestive track [19]. The pH responsiveness of hydrogels also facilitates lysosomal escape
during gene delivery [20, 21]. Such responsiveness changes the mode of drug administration
from merely passive release to active delivery. These exclusive properties of hydrogels can be
attributed to the variety of available network precursors. Acrylic acid (AA) and methacrylic
acid (MAA) [19, 22, 23] are the most commonly used monomers to fabricate anionic pHsensitive hydrogels while 2-(dimethylamino)ethyl methacrylate (DMAEMA) [24, 25] is used
for cationic hydrogel fabrication. N-isopropylacrylamide (NIPAAM) [26-28] and
polypropylene oxide-polyethylene oxide-polypropylene oxide (PPO-PEO-PPO) block
copolymers [28-30] are well-suited for the fabrication of temperature-sensitive hydrogels.
The reversible swell-collapse transition modulates drug release rates and largely enhances the
therapeutic efficacy of biomolecules.
Hydrogels can also be engineered to exhibit bioadhesiveness to facilitate drug
targeting, especially through mucus membranes, for non-invasive drug administration [3134]. Both natural polymers (e.g. chitosan) and synthetic monomers (e.g. AA) provide this
advantageous property. Some bioadhesive polymers have been used to fabricate hydrogels
for oral [6] and buccal drug delivery [35, 36].
Hydrogels offer an important “stealth” characteristic in vivo owing to their
hydrophilicity which increases the in vivo circulation time of the delivery device by evading
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the host immune response and decreasing phagocytic activities [37, 38]. For example,
Hubbell and coworkers developed poly(ethylene glycol)-based hydrogel nanoparticles as
colloidal drug carriers [39]. Several other stealth delivery systems, such as PEGylated gold
nanoparticles [37, 40], have also been developed utilizing a PEG shell as a means of steric
hindrance. This strategy exploits the hydrophilicity of PEG in excluding enzymatic
degradation of the drug to be delivered. When conjugated with other protein therapeutics
such as tumor necrosis factor (TNF), these PEGylated gold nanoparticles are good carriers
for tumor-targeted delivery [41].
Another prospect of hydrogels is their role as scaffolding materials in tissue
engineering applications [42-44]. Excellent examples are cartilage [45, 46] and nerve [47]
tissue engineering. The mild gelling conditions and in situ polymerization capabilities of
hydrogels enable the simultaneous encapsulation of cells and growth factors. Controlled
release of encapsulated growth factors and other agents from these tissue constructs is
critical to providing the necessary cues for cell migration, differentiation, angiogenesis, and
upregulation of extracellular matrix production required for neotissue growth or
regeneration [48, 49].
2.1.4 Drug release mechanisms from hydrogel devices
As discussed in the previous sections, hydrogels have a unique combination of
characteristics that make them useful in drug delivery applications. Due to their
hydrophilicity, hydrogels can imbibe large amounts of water (> 90 wt%). Therefore, the
molecule release mechanisms from hydrogels are very different from hydrophobic polymers.
Both simple and sophisticated models have been previously developed to predict the release
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of an active agent from a hydrogel device as a function of time. These models are based on
the rate-limiting step for controlled release and are therefore categorized as follows:
1. Diffusion-controlled
2. Swelling-controlled
3. Chemically-controlled
Diffusion-controlled is the most widely applicable mechanism for describing drug
release from hydrogels. Fick’s law of diffusion with either constant or variable diffusion
coefficients is commonly used in modeling diffusion-controlled release [13]. Drug
diffusivities are generally determined empirically or estimated a priori using free volume,
hydrodynamic, or obstruction-based theories [13].
Swelling-controlled release occurs when diffusion of drug is faster than hydrogel
swelling. The modeling of this mechanism usually involves moving boundary conditions
where molecules are released at the interface of rubbery and glassy phases of swollen
hydrogels [50]. The release of many small molecule drugs from hydroxypropyl
methylcellulose (HPMC) hydrogel tablets is commonly modeled using this mechanism. For
example, Methocel® matrices, a combination of methylcellulose and HPMC, from Dow
Chemical Company are commercially available for preparing swelling-controlled drug
delivery formulations exhibiting a broad range of delivery timescales [50, 51].
Chemically-controlled release is used to describe molecule release determined by
reactions occurring within a delivery matrix. The most common reactions that occur within
hydrogel delivery systems are cleavage of polymer chains via hydrolytic or enzymatic
degradation or reversible or irreversible reactions occurring between the polymer network
and releasable drug. Under certain conditions the surface or bulk erosion of hydrogels will
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control the rate of drug release. Alternatively, if drug-binding moieties are incorporated in
the hydrogels, the binding equilibrium may determine the drug release rate. Chemicallycontrolled release can be further categorized according to the type of chemical reaction
occurring during drug release. Generally, the liberation of encapsulated or tethered drugs can
occur through the degradation of pendant chains or during surface-erosion or bulkdegradation of the polymer backbone. A more thorough discussion of these mechanisms can
be seen in a later section of this review as well as in several other excellent reviews [6, 13,
52].
2.1.5 Design criteria for hydrogels in drug delivery formulations
Materials selection and network fabrication governs the rate and mode of drug release
from hydrogel matrices. Several design criteria are crucial for drug delivery formulations and
have to be evaluated prior to hydrogel fabrication and drug loading. These criteria are also
important in mathematical modeling of drug release. Table 2.2 lists these important criteria
and variables for designing hydrogel-based drug carriers. Within the realm of transport
properties, the most notable variable is the drug diffusion coefficient, which is affected by
the molecular size of the drug and characteristics of the polymer network. Hydrogel
crosslinking density affects diffusivity to a large extent as shown in Figure 2.1 and as
discussed previously. If special functionalities, such as ionic groups, are introduced into the
hydrogel networks, interactions between these functionalities and encapsulated drugs
certainly affect drug diffusivity. Physical properties of the hydrogel also affect drug release.
For example, polymer molecular weights, composition, and polymer/initiator concentrations
influence hydrogel swelling and also degradation. Finally, the stimuli-responsiveness of a
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hydrogel network can also mediate the amount and rate of drug delivery. The understanding
of transport and physical properties are especially crucial in modeling molecule release.
Even if a hydrogel delivery formulation is designed with the appropriate physical and
transport properties, it may still fail to perform its therapeutic role when implanted in vivo
due to a localized inflammatory response. The formation of a fibrous capsule surrounding
the delivery device creates additional diffusion barriers that may limit drug release rates while
increased proteolytic activity may increase rates of matrix and drug degradation. Proper
material selection, fabrication process, and surface texture of the device are therefore always
critical in designing biocompatible hydrogel formulations for controlled release.

Table 2.2 Design criteria for hydrogels in drug delivery formulations.
Design criteria

Design variables

Transport properties
Molecule diffusion

•
•
•
•
•
•

Physical properties
Gelling mechanisms /conditions
Structural properties
Biodegradability
Stimuli-responsiveness

• Polymer/crosslinker/initiator
concentrations
• Temperature, pH, ionic strength
• Molecular weight of polymer
• Mechanical strength
• Concentration of degradable groups
• Concentration of responsive groups

Biological properties
Biocompatibility

• Cytotoxicity of the hydrogel
• Capsule formation

Molecular weight and size of protein
Molecular weight of polymer
Crosslinking density
Polymer-protein interactions
Hydrogel degradation rate
Additional functionalities
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2.2 Novel engineering of hydrogels for drug delivery
2.2.1 Biodegradable hydrogels
For most biomedical applications, biodegradable hydrogels are favored over nondegradable gels since they degrade in clinically relevant timescales under relatively mild
conditions. Compared to non-degradable hydrogels, degradable carriers eliminate the need
for additional surgeries to recover the implanted gels. However, proper techniques for
predicting hydrogel degradation rates are critical for successful application of these
degradable systems as they facilitate the design of implants with optimal degradation profiles
that result in proper rates of drug release or tissue regeneration and hence maximize
therapeutic effects.
The fabrication and modeling of hydrolytically degradable hydrogels are welldeveloped. For example, West and Hubbell fabricated PLA-b-PEG-b-PLA hydrogels
composed of poly(lactic acid) (PLA) and poly(ethylene glycol) (PEG) block copolymers for
protein release applications [53]. Metters et al. developed scaling laws to predict the
degradation rates of PLA-b-PEG-b-PLA hydrogels based on macroscopic properties such as
compressive modulus and volumetric swelling ratio [54-56]. Mason et al. further applied
these scaling laws to predicting protein diffusion and release during bulk network
degradation [10]. Using a more rigorous approach, Hennink and coworkers recently utilized
a Monte Carlo simulation technique to microscopically predict the degradation and protein
delivery behaviors of hydroxyethyl methacrylated dextran (dex-HEMA) microspheres [57].
In addition to hydrolytically degradable hydrogels, synthetic gels incorporating
biological moieties that can be degraded enzymatically are also under intensive investigation.
One way to fabricate this type of hydrogel is to incorporate peptide substrates for enzymatic
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hydrogel formation [58] and degradation [59, 60]. Alternatively, polymers that can be
naturally degraded by enzymes (e.g. polycaprolactone can be degraded by lipase) can be
copolymerized with PEG to form enzymatically degradable gels [61]. Although hydrogels
derived from natural sources (such as chitosan, gelatin, dextran, etc.) can also be degraded
enzymatically, in many cases synthetic hydrogels containing defined biological moieties are
more favorable because of their tunable physicochemical properties. For example, the
degradation behavior can be more accurately tailored to obtain better control over gel
degradation and drug release rates. Hubbell and colleagues have developed a hydrogel system
containing integrin-binding sites for cell attachment and peptide substrates for matrix
metalloproteinases (MMPs) or plasmin to mimic the natural bidirectional communication
between extracellular matrix and migrating cells. Cells can only infiltrate the designer
matrices once the gels are locally degraded in response to secretion of MMPs by invading
cells [59, 60].
2.2.2 Smart hydrogels
“Smart” hydrogels, or stimuli-sensitive hydrogels, are very different from inert
hydrogels in that they can “sense” changes in environmental properties such as pH and
temperature and respond by increasing or decreasing their degree of swelling. These sensing
capabilities are attractive in many biomedical applications and several review papers have
been published in this field [18, 28]. The volume-changing behavior of ‘smart’ hydrogels is
particularly useful in drug delivery applications as drug release can be triggered upon
environmental changes [18, 29, 62]. For non-ionic hydrogels, the degree of swelling only
depends on the chemical compositions of the polymers and does not respond to external pH
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change. When ionic moieties are incorporated into hydrogels, the swelling depends not only
on the chemical composition of the gel but also on the pH of the surrounding medium.
Generally, anionic hydrogels deprotonate and swell more when external pH is higher than
pKa of the ionizable groups tethered on polymer chains while cationic hydrogels protonate
and swell more when external pH is lower than the pKb of the ionizable groups. Depending
on the ionic monomers used to fabricate the gel, the pH-dependent swelling curves exhibit
one or more inflection points near the pKa/pKb of the ionizable groups as shown in Figure
2.2. Many modeling efforts have been devoted to predicting the dynamic and equilibrium
swelling of ionic hydrogels [23, 63-66]. Because the swelling/deswelling behavior of the ionic
hydrogels is closely related to ion movement, the swelling kinetics depends not only on the
pH but also on the compositions of the external solutions. Hydrogels with pHresponsiveness have been used in a number of applications including oral peptide delivery

Degree of swelling

[67-71], valves for microfluidic devices [72], and artificial muscles [73-75].

anionic gel with single
ionizable group on monomer

cationic gel with
single ionizable
group on monomer

anionic gel with
two ionizable
group on monomer

pH
Figure 2.2. Schematic of relative ionic hydrogel swelling as a function of pH.
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Another important stimulus for causing hydrogel responsiveness is temperature. The
most commonly used synthetic polymer for fabricating temperature-sensitive hydrogels is
poly(N-isopropylacrylamide) (poly(NIPAAM)), which possesses a lower critical solution
temperature (LCST) at around 32○C. The value of the LCST can be increased or decreased
by copolymerizing hydrophilic or hydrophobic polymers with poly(NIPAAM). When the
bulk temperature is higher than the LCST of the polymer, the polymer chains lose their
bound-water. Hydrophobic interactions between the polymer chains lead to a rapid collapse
(deswelling) of the gel [76]. Readers are directed to other more thorough reviews discussing
the mechanisms and applications of thermo-sensitive hydrogels [28, 30]. Temperatureresponsiveness is particularly useful for in-situ formation of drug-delivery devices since it
allows handling of the formulation in the sol-phase at room temperature and solidification of
the carrier upon injection [28].
More recently, studies have been conducted to fabricate and characterize hydrogels
with dual-sensitivities. This was accomplished by copolymerizing a temperature-sensitive
monomer, usually N-isopropylacrylamide, and a pH-sensitive monomer such as acrylic acid
or methacrylic acid [21, 77-82]. For example, Stayton’s group has investigated a series of copolymers containing propylacrylic acid (PAA) and N-isopropylacrylamide pendant chains as
pH- and thermo-sensitive moieties, respectively [20]. This new class of copolymers can sense
environmental changes in the physiological range and has found usefulness in intracellular
drug delivery in which subtle pH differences across the endosomal membrane triggers the
delivery of protein or DNA.
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2.2.3 Biomimetic hydrogels
One drawback of using synthetic and some natural hydrogels for in vivo applications
is that they do not possess biological recognition sites for supporting cellular activities. For
this reason, relatively inert polymer chains can be tailored with select biological moieties to
yield bioactive hydrogels for tissue engineering applications. The Arginine-Glycine-Aspartic
acid (RGD) tri-peptide derived from fibronectin is the most commonly used biological
moiety in this regard as it mediates the adhesion of many cell types through integrin-binding
without the need for protein adsorption on a hydrogel surface [83-86]. Through the selective
presentation of bioactive ligands on otherwise bioinert hydrogel background, researchers are
able to better control cell-hydrogel interactions to fulfill specific biomedical applications.
The controlled incorporation and presentation of biological cues within hydrogel
matrices has also played a role in the development of novel controlled delivery devices. For
example, in vivo observations of the sequestering and protection of proteins by the
extracellular matrix (ECM) have inspired the design of novel biomimetic hydrogels with
specific and reversible protein-binding capabilities [87-89]. This approach is especially useful
in controlled release of growth factors for tissue regeneration as it mimics the mechanism
and temporal profiles of endogenously produced growth factors. Through judicious selection
of network-immobilized ligands with desired protein-binding affinities or by adjusting the
molar ratio of protein to protein-binding ligand, researchers can readily manipulate protein
release rates form these bioactive matrices.
Another biomimetic hydrogel system used in controlled release applications is the
enzymatically-cleavable prodrug system. The main advantage of this approach is that the
degradation rate of the prodrug linkage is directly proportional to the concentration of
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specific enzymes secreted by local cells. Therefore the rate of drug release self-adjusts to the
rate of cellular infiltration and cell-mediated matrix remodeling. Therapeutic proteins such as
vascular endothelial growth factor (VEGF) have been covalently immobilized within
hydrogel networks by enzyme-sensitive oligopeptides [90]. VEGF release is mediated by
proteases (e.g. matrix metalloproteinases or MMPs) secreted by migrating fibroblast and
endothelial cells and is therefore made available only when specific cellular processes occur.
This cell-demanded VEGF release has been shown to not only preserve growth factor
bioactivity but also promote localized angiogenesis.
2.3 Molecule release mechanisms for hydrogel formulations
The physicochemical properties of the hydrogel network as well as the selection of
drug-loading method will determine the mechanism(s) by which the loaded drug is released
from the crosslinked matrix. The incorporation of drugs into hydrogel delivery matrices can
be performed via one of the following ways: (1) Post-loading: absorption of drugs is achieved
after hydrogel networks are formed. If an inert hydrogel system is used, diffusion is the
major driving force for drug uptake and release will be determined by diffusion and/or gel
swelling. In the presence of hydrogels containing drug-binding ligands, terms accounting for
drug-polymer interaction and drug diffusion must both be included in any model description
of release; (2) In-situ loading: drugs or drug-polymer conjugates are mixed with polymer
precursor solution and hydrogel network formation and drug encapsulation are
accomplished simultaneously. In these systems, the release of drugs can be controlled by
diffusion, hydrogel swelling, reversible drug-polymer interactions, or degradation of labile
covalent bonds.
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2.3.1 Diffusion-controlled delivery systems
Understanding the mechanisms and identifying the key parameters that govern drug
release from hydrogels are the first step toward accurately predicting the entire release
profile. For porous hydrogels, when pore sizes are much larger than the molecular
dimensions of the drug, the diffusion coefficient can be related to the porosity and the
tortuosity of the hydrogels [91]. However, for nonporous hydrogels and for porous gels with
pore sizes comparable to the drug molecular size, drug diffusion coefficients are decreased
due to steric hindrance provided by polymer chains within the crosslinked networks [13, 91,
92]. In these cases, the average free volume per molecule available to the drug is decreased
and the hydrodynamic drag experienced by the drug is increased, leading to increased drug
diffusion path length compared to porous hydrogels with pore sizes much larger than the
encapsulated drug [93-95]. Due to the usually high permeabilities of hydrogel networks and
the advantages of in situ fabrication, most research efforts are focused on understanding
diffusion-controlled release of encapsulated drugs from three-dimensional hydrogel matrices.
Drug diffusion within highly swollen hydrogels is best described by Fick’s law of
diffusion or Stefan-Maxwell equations [8]. Diffusion-controlled hydrogel delivery systems
can be either reservoir or matrix systems [96]. For a reservoir system where the drug depot is
surrounded by a polymeric hydrogel membrane, Fick’s first law of diffusion can be used to
describe drug release through the membrane:
J A = −D

dC A
dx

(6)

Here, JA is the flux of the drug, D is the drug diffusion coefficient, and CA is drug
concentration. In many cases, the drug diffusion coefficient is assumed constant to simplify
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the modeling. However, in the general case it is a function of drug concentration and a
special correlation incorporating the concentration-dependent drug diffusivity must be
utilized to accurately predict drug flux. Another assumption of this expression is that JA is
the drug flux corresponding to the mass average velocity of the system.
For a matrix system where the drug is uniformly dispersed throughout the matrix,
unsteady-state drug diffusion in a one-dimensional slap-shaped matrix can be described
using Fick’s second law of diffusion:

dC A
d 2C A
=D
dt
dx 2

(7)

Here, the drug diffusion coefficient is again assumed as a constant. Other assumptions
include sink condition and a thin planar geometry where the release through slab edges is
neglected. When diffusivity is concentration-dependent the following equation is used:
∂C A
∂C 
∂ 
=  D (C A ) A 
∂t
∂x 
∂x 

(8)

Many previous attempts to model diffusion-controlled drug delivery from hydrogels
rely largely on empirically determined diffusion coefficients. Once the diffusion coefficient is
determined, Eqs. (6) to (8) can be solved, together with proper initial and boundary
conditions, to yield drug concentration profiles that dictate the release kinetics. For example,
an exact analytical solution to Eq. (7) can be obtained using separation of variable
technique. The ratio of the amount of molecule released up to any time t (Mt) to the final
amount of molecule release ( M ∞ ) can be expressed as:
∞
 − (2n + 1)2 π 2 D 
Mt
8
= 1− ∑
⋅ exp 
t
2
2 2
M∞
(
)
L
+
π
2
n
1


n =0
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(9)

This equation can be used to predict the diffusion of a broad range of molecules
including small molecular weight drugs and biomacromolecules like proteins and DNA once
an appropriate diffusion coefficient is obtained. Although this simple solution applies to
many diffusion-controlled drug release systems, model complexity will increase as other
mechanisms, polymer-drug interactions, and when non-spherical drugs are used [15].
Another empirical equation developed by Peppas et al. assumes a time-dependent
power law function [6, 50]:

Mt
= k ⋅tn
M∞

(10)

Here, k is a structural/geometric constant for a particular system and n is designated as
release exponent representing the release mechanism. Table 2.3 lists the n values for delivery
matrices with different geometries and release mechanisms [50].
Table 2.3. Release exponent values (n) in the empirical power law model. Adapted from
[50].
Matrix Geometry
Slab
Cylinder
Sphere

Diffusion-controlled delivery
system (Case I)
n = 0.5
n = 0.45
n = 0.43

Swelling-controlled delivery
system (Case II)
n=1
n = 0.89
n = 85

It is noteworthy that in a purely swelling-controlled slab-based delivery system, the
drug fractional release (Mt/M∞) appears to be zero-order as the release exponent equals
unity. The power law is easy to use and can be applied to most diffusion-controlled release
systems. However, it is too simple to offer a robust prediction for complicated release
phenomena. For example, in diffusion-controlled systems where n = 0.5, the power law is
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only valid for the first 60% of the release profile. These empirical models can only predict
the release profile after certain release experiments are conducted and have limited capability
to predict how the release profiles will change as the chemical or network properties of the
system are varied.
Analytical solutions to Fick’s law are not available when more complex geometries or
non-constant drug diffusivities are incorporated into the model descriptions. Except in
extremely dilute systems, drug diffusion coefficients will be a function of drug concentration.
Additionally for hydrogel systems diffusivities of encapsulated molecules will depend on the
degree of swelling and crosslinking density of the gels. Therefore the diffusion coefficient
used to describe drug release will be sensitive to environmental changes or degradation of
the polymer network and may vary over the timescale of release. Several theoretical models
have been developed to relate molecule diffusion coefficients to fundamental hydrogel
characteristics and have been reviewed elsewhere [6, 13]. Generally, theoretical models for
predicting molecule diffusion coefficients have the following general form:
Dg
Do

= f (rs , v 2 ,s ,ξ )

(11)

Here, Dg and Do are the drug diffusion coefficients in the swollen hydrogel network and in
pure solvent, respectively. rs is the size of the drug to be delivered. This general expression
takes into account factors affecting drug release such as the structure of the gel, the polymer
composition, the water content, and the size of the molecules. For a degradable hydrogel, Dg
changes as the network degrades due to an increase in gel mesh size and a decrease in
polymer volume fraction over time.

31

Several theories have been developed to correlate the relationship between drug
diffusivity in the gels and in the solution [13]. For example, the following equation using a
free-volume approach proposed by Lustig and Peppas can be used to describe the
relationship between drug diffusivity and network structure [15]:
r

=  1 − s
Do 
ξ

Dg

  v 2 ,s

 exp − Y 
  1 − v 2 ,s

 






(12)

Here, Y is defined as the ratio of the critical volume required for a translational movement of
the encapsulated drug molecule and the average free volume per molecule of solvent. A
good approximation for Y is unity. For highly swollen (Q>10) hydrogels with degradable
crosslinks the diffusivity correlation shown in Eq. (12) can be simplified during the initial
stages of degradation to [10, 97]:
1−

Dg
Do

'
r
= s ~ e −7 / 5 jk E t

ξ

(13)

Here, the lumped parameter jkE’ is the pseudo-first-order reaction rate constant for the
hydrolysis of a labile crosslink. From this expression one can realize that mesh size is timedependent due to network degradation. It is clear that Dg increases as degradation proceeds
and approaches Do. The rate of increase in drug diffusivity depends on network structure and
bond cleavage kinetics [10, 98].
2.3.2 Swelling-controlled delivery systems
Another mechanism for drug delivery is swelling-controlled delivery. As shown in
Figure 2.3, hydrogels may undergo a swelling-driven phase transition from a glassy state
where entrapped molecules remain immobile to a rubbery state where molecules rapidly
diffuse. In these systems, the rate of molecule release depends on the rate of gel swelling.
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One example of swelling-controlled drug delivery systems is hydroxypropyl methylcellulose
(HPMC). Drug loaded HPMC tablets are three dimensional, hydrophilic matrices that are
usually stored in a dry, glassy state. After oral administration, HPMC polymer absorbs liquid
and a rapid glassy-to-rubbery phase-transition occurs once the glass transition temperature
(Tg) is reached, causing the systematic release of loaded drugs. The drug release rates are
modulated by the rate of water transport and the thickness of the gel layer.
z

r
Glassy (dried) state

Rubbery (swollen) state

Figure 2.3. Schematic of HPMC hydrogel tablet in the glassy (left) and rubbery (right) state.
Drug diffusion time and polymer chain relaxation time are two key parameters
determining drug delivery from polymeric matrices. In diffusion-controlled delivery systems,
the time-scale of drug diffusion, t, (where t=δ(t)2/D and δ(t) is the time-dependent thickness
of the swollen phase) is the rate-limiting step while in swelling-controlled delivery systems
the time-scale for polymer relaxation (λ) is the rate-limiting step. The Deborah number (De)
is used to compare these two time-scales [99, 100]:
De =

λ
t

=

λD
δ ( t )2

(14)

In diffusion-controlled delivery systems (De << 1), Fickian diffusion dominates the
molecule release process and diffusion equations described in the previous section can be

33

used to predict molecule release. In swelling-controlled delivery systems (De >> 1), the rate
of molecule release depends on the swelling rate of polymer networks.
The empirical power law (Eq. (9)) used to describe diffusion-controlled drug release
from hydrogel matrices can also be used comprehensively in swelling-controlled delivery
systems. A modification of Eq. (9) takes into account both the drug diffusion and polymer
relaxation [101]:

Mt
= k1t m + k 2 t 2 m
M∞

(15)

where k1, k2, and m are constants. The two terms on the right side represent the diffusion
and polymer relaxation contribution to the release profile, respectively.
The above empirical relationship does not account for “moving-boundary”
conditions in which the gel expands heterogeneously as water penetrates and swells the
gels. For this more rigorous description, Korsmeyer and Peppas introduced a
dimensionless swelling interface number, Sw, to correlate the moving boundary
phenomena to hydrogel swelling [102-104]:
Sw =

Vδ (t )
D

(16)

Here, V is the velocity of the hydrogel swelling front and D the drug diffusion coefficient in
the swollen phase. For a slab system when Sw <<1, drug diffusion is much faster than the
movement of glassy-rubbery interface and thus a zero-order release profile is expected.
Building on several modeling iterations [11, 15, 105-107], a more rigorous method for
predicting molecule release from swelling-controlled systems is provided by a sequential layer
model developed by Siepmann and Peppas [50, 108-112]. In this model, drug diffusion,
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polymer relaxation and dissolution are all taken into account. Drug transport in both radial
and axial directions is accounted for using Fick’s second law of diffusion in a cylindrical
geometry with concentration-dependent diffusion coefficients as shown below [110, 111]:
∂C k 
∂C k
∂C k  Dk ∂C k
∂ 
∂ 
+  Dk
=  Dk

+
∂z 
∂z 
r ∂r
∂t
∂r 
∂r 

(17)

Here, Ck and Dk are the concentration and diffusivity of the diffusible species (1: water; 2:
drug), respectively. Concentration-dependent diffusivities derived by a “Fujita-like” freevolume model can be expressed as [113]:



C
D1 = D1eq exp − β 1  1 − 1


C1eq








(18)



C
D2 = D2eq exp − β 2  1 − 1


C1eq








(19)

where β1 and β2 are dimensionless constants and “eq” represents the equilibrium drug
concentration at the water/matrix interface where polymer disentanglement occurs.
Due to the concentration-dependent diffusion coefficients, Eqs. (17) to (19) can only
be solved numerically. Siepmann et al. demonstrated that these numerical solutions agreed
well with experimental results [50, 108]. This model is therefore useful in predicting the
shape and dimensions of HPMC tablets needed to acquire desired release profiles [109].
Stemming from the work of Siepmann and Peppas, Wu and coworkers [114] recently
developed a mathematical model to describe swelling-controlled release. They introduced
additional boundary conditions derived from a volume balance and accounted for twodimensional movement of the swelling front in the radial or axial directions. This model
assumes a homogeneous mixture of drug and polymer at t = 0, perfect sink conditions, and
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geometrical symmetry of the tablet. Model predictions were verified using compressed
poly(ethylene oxide) (PEO) hydrogel tablets with different molecular weights. The results of
water uptake, swelling and dissolution of PEO matrices as well as drug release are shown to
agree well with the mathematical model [114].
2.3.3 Chemically-controlled delivery systems
In addition to diffusion and swelling-controlled delivery systems discussed previously,
a third type of molecule release mechanism is chemically-controlled delivery. The latter can
be further classified as (1) purely kinetic-controlled release where polymer degradation
(bond-cleavage) is the rate-determining step and diffusion term is assumed to be negligible;
and (2) reaction-diffusion controlled release in which both reaction (e.g. polymer
degradation, protein-drug interaction) and diffusion terms must be included in the model to
accurately predict drug release. The reaction-diffusion controlled release is particularly
intriguing as more synthetic hydrogel systems designed with drug-binding capacity are
utilized in drug delivery [87, 88, 115] and tissue engineering [89].
2.3.3.1 Kinetic-controlled release – Pendant chain systems
There are two types of kinetic-controlled release systems: pendant chain (prodrugs)
and surface-eroding systems. In pendant chain systems, drugs are covalently linked to the
hydrogel network via cleavable spacers and drug release is controlled by the rate of spacerbond cleavage. In surface-eroding systems, drug release is mediated by the rate of surface
erosion. Drug diffusion does not determine the rate of drug release in either system.
Prodrugs or polymer-drug conjugates are designed to enhance the therapeutic efficacy
of the drug. This strategy is especially useful when growth factors are to be delivered as most
of them are susceptible to rapid proteolytic degradation. The design of prodrugs has
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attracted much attention and extensive reviews on the design and therapeutic application of
these systems can be found elsewhere [116, 117].
Generally, the release of covalently tethered prodrugs is determined by the
degradation rate of the polymer-drug linkage [118-121]. Most of these linkages have been
designed to be hydrolytically degradable allowing degradation and release rates to be
characterized by fairly simple first-order kinetic relationships [59]. However, in particular
applications, for example where a more targeted delivery profile is desired, it is advantageous
to design enzymatically cleavable spacer bonds [122]. These chemistries lead to more
complex release kinetics.

Furthermore, in cases where the prodrugs are tethered to

degradable hydrogel matrices, the kinetics of gel degradation may also play a significant role
in determining overall drug release profiles. [118-123].
Ehrbar et al. recently developed fibrin matrices tethered with pendant vascular
endothelial growth factor (VEGF) variants linked by plasmin-sensitive peptidyl substrates
[122]. These covalently bound VEGF variants can only be liberated from the insoluble
matrix through plasmin-mediated cleavage of the engineered peptide substrates. First-order
cleavage kinetics were used to model the time-dependent VEGF release. Accurate prediction
of VEGF release profiles also required a description of VEGF-release via matrix-mediated
degradation. Two adjustable parameters were therefore used to accurately predict complete
VEGF release profiles. The first parameter was the pseudo first-order degradation rate
constant, k. The degradation of bonds within the fibrin network and the plasmin-sensitive
substrates used to link VEGF to the fibrin were assumed to follow the same first-order
kinetics. The second adjustable parameter, N, represented the number of fibrin repeat units
between two crosslinks and was an indication of fibrin network structure. As shown in
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Figure 2.4, the developed model accurately predicted release of cleavable and non-cleavable
VEGF variants from both low and high-density fibrin matrices by accounting for both
network structure and kinetics of individual bond cleavage.

Figure 2.4 Mathematical modeling predicts experimental observations of proteolysismediated release of fibrin-bound VEGF121 variants from low- or high-density fibrin gel
networks. Reproduced from [122], Copyright (2005), with permission from Elsevier.
Unique release profiles unattainable with diffusion-controlled release mechanisms
have also been demonstrated from hydrolytically degradable hydrogels with tethered agents.
Dubose et al. covalently incorporated fluorescently labeled probe molecules within the threedimensional network structure of PEG-based hydrogels formed via step-growth
polymerizations [123]. As shown in Figure 2.5, they demonstrated that hydrolytic
degradation of covalent bonds within the step-crosslinked PEG network as well as the
cleavage of immobilized probe molecules resulted in a biphasic release profile in which a
constant molecular release profile is obtained prior to gel dissolution and an almost
instantaneous burst release following gel dissolution. The authors demonstrated that the
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slope of the approximate zero-order delivery regime as well as the extent of the latent burst
could be controlled by crosslinker functionality (tetra-functional versus octa-functional PEG,
Figure 2.5a) and degradation kinetics (varying temperature, pH, or chemistry of the
degradable bond, Figure 2.5b).
2.3.3.2 Kinetic-controlled release – Surface-eroding systems
Other kinetic-controlled systems occur when drug release is mediated by surface
erosion of the polymer matrix. For hydrophobic polymer networks, surface erosion occurs
when the rate of water transport into the polymer is much slower than the rate of bond
hydrolysis. However, due to the inherently high water content of hydrogels, surface erosion
only occurs in enzymatic-degrading systems where the transport of enzyme into the gel is
slower than the rate of enzymatic degradation. While no hydrogels have been specifically
designed to degrade in this fashion, surface erosion of enzymatically degradable
poly(ethylene glycol)-polycaprolactone (PCL-b-PEG-b-PCL) block copolymer hydrogels has
been observed in vitro by Rice et al. when exposed to relatively high concentrations of lipase
[61].

Figure 2.5 Fractional probe release from degradable PEG-acrylate/dithiol gels formed via
step-growth polymerization (a) Gels fabricated from 30 wt % eight-armed PEGacrylate/DTT precursor solutions and degraded at varying temperatures: 37°C (▲), 46°C
(), and 57°C (). (b) Gels fabricated with either four-arm/10-kDa () or eight-arm/20kDa () PEG were measured and compared with model predictions (– – –). Reproduced
with permission from [123]. Copyright 2005, John Wiley and Sons.
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Most of the models focusing on surface-eroding polymers are based on hydrolyticdegrading polymers. These relationships, however, can also be applied to enzymatically
degradable, surface-eroding hydrogel systems. Surface-eroding matrices are advantageous for
drug delivery applications as the structural integrity of the carrier device is maintained during
delivery and zero-order release of the encapsulated molecules can be readily obtained by
appropriate choice of device geometry [7].
Hopfenberg initially developed a drug delivery model where the release only depends
on matrix erosion rates. Eq. 22 describes the release from surface-eroding devices with an
initial dimension a0 (radius for a spherical or cylindrical geometry and half-thickness for slab
geometry) and drug concentration C0 [124]:

Mt
k t
= 1 −  1 − a
M∞
C0 a0






n

(20)

In this equation, n is a geometrical factor and a number of 1, 2, or 3 is used for a slab,
cylinder, or sphere, respectively. It is clear that when a slab-shaped device is used (n = 1),
drug release appears to be a zero-order profile.
Following Hopfenberg’s work, Katzhendler, Hoffman, and coworkers further
developed a general mathematical model for heterogeneous eroding networks accounting for
different radial and vertical erosion rate constants for a flat tablet (ka and kb for radial and
vertical degradation constant, respectively) [125]:
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k t
= 1 −  1 − a
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 C0 a0
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(21)

Here, a0 is the initial radius of the tablet and b0 is the thickness of the tablet. By changing the
radius to thickness ratio of the device, one can easily obtain various drug release rates. It is
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noteworthy that in these models, swelling of the matrices is either not considered or is
assumed to occur prior to erosion and drug release. Stemming from these initial efforts,
several additional models have been developed to predict molecule release via surfaceerosion [108, 126, 127].
2.3.3.3 Reaction-diffusion controlled release – Bulk-degrading systems
Many of the approaches for modeling drug release from hydrogel networks assume
only one mechanism, either diffusion, swelling, or degradation, dominates the release
process. Although not realistic for many cases, this is one way to simplify the model and, in
many cases, obtain a reasonable fit to experimental results. As more complicated drug
delivery systems are designed to fulfill the ever-increasing needs for advanced drug delivery
and tissue engineering, the assumption of a single dominant release mechanism will no
longer be suitable. Overlooking the coupled effects of diffusion and matrix degradation
within hydrogel matrices will result in significant deviations when comparing modeling and
experimental results.
The coupling of reaction and diffusion phenomena is already notable in bulk
degrading networks where drug release profiles are governed by both network degradation
and molecule diffusion. Macroscopically, this degradation-diffusion coupling phenomena can
be observed through the swelling characteristics and mechanical properties. The degradation
behavior of chain-polymerized hydrogels with hydrolytically or enzymatically labile bonds
can be tailored through a variety of parameters. Sawhney’s pioneering work incorporated
degradable PLA moieties within hydrophilic PEG macromers [128]. The resulting PLAPEG-PLA block copolymers can be polymerized to form hydrolytically degradable
hydrogels. Metters et al. further described the release of encapsulated macromolecules from
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bulk-degrading, covalently crosslinked PLA-PEG-PLA hydrogels considering network
structure as well as degradation kinetics [55, 56]. Generally, molecule diffusivity decreases as
crosslinking density increases ( M c decreases), as the molecular size (rs) increases, and as the
polymer volume fraction of the gel (v2,s) increases [91, 129, 130]. In PLA-PEG-PLA hydrogel
systems, molecule diffusivity can be correlated to gel degradation kinetics and can be used to
predict drug release corresponding to gel degradation as shown in Figure 2.6 [10, 97]. The
diffusion coefficient of a solute from the degrading network with time-dependent mesh size
can then be obtained using Eq. (13) described in the previous section. As shown in Figure
2.6, the scaling model agreed well with the volumetric swelling ratio of the degrading gels
while for solute release only a qualitative agreement was obtained.
The degradation behaviors described above are only valid for hydrogels made from divinyl macromers. For hydrogels formed via chain-polymerization of multifunctional
macromers such as acrylated poly(vinyl alcohol) (PVA), Martens et al. developed a
generalized statistical-co-kinetic model to predict their degradation behaviors [131-133]. In
this model, a statistical approach was used to predict the different configurations of the
crosslinking molecules and kinetic chains. It also accounts for the probability of an intact
degradable linkage. The model was verified by experimental observation of gel swelling,
mass loss and compressive modulus [133]. Combining the degradation kinetics provided by
this model and the diffusivity estimated by Eq. (13), the release of a model protein, bovine
serum albumin (BSA), was verified [97].
For hydrogels formed via step-growth polymerization, Metters and Hubbell have
shown that the degradation rates of networks depend on molecular weight, hydrophilicity,
and degree of functionality of the starting monomers [134].
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Figure 2.6 (A) Volumetric swelling ratio and (B) fractional release of BSA as a function of
degradation time from a series of PLA-b-PEG-b-PLA hydrogels polymerized from
increasing concentrations of macromer: (●) 25 wt%, (■) 35 wt%, and (♦) 50 wt%. Lines
represent exponential fits to the swelling data (A) and solute release predictions based on
scaling equations (B). D0 = 1.0×10-5 mm2/s for all curves. Reproduced with permission from
[10]. Copyright 2001 American Chemical Society.
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In addition to the statistical modeling approaches assuming homogeneous changes in
gel properties, Monte Carlo simulations have also been used to predict protein release from
degradable polymer networks at the microscopic level. Gopferich and Langer developed
Monte Carlo simulations to predict polymer erosion and monomer release. Although this
work was not for hydrogel systems, it allowed the calculation of porosity distributions within
the polymer and was useful in predicting drug and degraded monomer release [135-138].
Monte Carlo simulation is good for describing network morphological changes, however it
dose not provide any information regarding molecule release. Diffusion equations (Fick’s
law) must be incorporated in order to link the network degradation to molecule diffusion
[138]. The following modified diffusion equation can be used to describe one-dimensional
diffusion in porous polymers:
∂
∂
∂C (x ,t )
Deff (C )ε ( x ,t )
C (x ,t )ε ( x ,t ) =
∂x
∂x
∂t

(22)

Here, C(x,t) is the concentration of diffusing monomer, ε(x,t) is the porosity along the
diffusion path, and Deff(C) is the effective concentration-dependent diffusion coefficient.
Recently, Vlugt-Wensink et al. developed kinetic Monte Carlo simulations to predict
protein release from crosslinked dextran microspheres [57]. Although this approach,
reasonably predicts protein release from degrading networks and incorporates spatial
variations in the network microstructure that are not accounted for in the previously
described macroscopic models of network degradation, some predictive limitations still exist.
Most importantly, swelling of the hydrophilic microspheres and changes in swelling with
matrix degradation were not accounted for in the described model.
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The macroscopic models used to correlate solute release (diffusion) with gel
degradation (reaction) provide a powerful tool for predicting protein release with changing
network structure. However, macroscopic observations in gel swelling and mass erosion are
not sufficient to obtain precise predictions due to the averaging of microscopic events. On
the other hand, models describing network changes at a microscopic level may provide more
accurate release predictions. However, gel swelling, a very important characteristic of
hydrogel drug carriers, must be included during the simulation since solute diffusivity is
tightly coupled to water content.
2.3.3.4 Reaction-diffusion controlled release – Affinity hydrogel systems
Inspired by the reversible sequestering of proteins to the extracellular matrix (ECM),
researchers have developed biomimetic hydrogel carriers bearing reversible binding
capacities to decrease release rates of target protein therapeutics. These so-called ‘affinity’
hydrogels can also be classified as reaction-diffusion controlled hydrogel delivery systems.
The release kinetics of a molecule from affinity gels can be depicted by a model developed
by Crank [139] where protein-ligand (P-L) binding equilibrium is described using simple
binding kinetics:
kf

P + L⇔ P⋅ L

(23)

kr

Here, kf and kr are association and dissociation rate constants, respectively. In this model,
binding of proteins to immobilized elements is considered reversible and a time-independent
equilibrium constant Kb = CPL/CP is used to represent the concentration equilibrium between
bound (PL) and free (P) proteins. Kb can be therefore also described as a ratio of freereceptor concentration to dissociation constant (Kb = [L]/Kd). Assuming that the reaction is
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fast compared to protein diffusion, the following equation can be obtained for the transport
of reversibly bound protein within an affinity hydrogel [140]:
∂C P
D
∇ 2C P =
Kb + 1
∂t

(24)

Compared to the standard form of Fick’s law of diffusion (Eq. 7) the above equation
illustrates that the presence of rapid and reversible protein-ligand binding retards the release
of free protein by decreasing the apparent protein diffusivity by a factor of (Kb+1).
From this simple reaction-diffusion model described above, one can easily obtain the
concentration profile of free proteins in the affinity gels available for diffusion. However,
due to the fact that this model assumes a time-independent equilibrium constant (Kb) and a
rapid binding equilibrium, the model is limited to describing systems with simple yet rapid
binding mechanisms with high ratios of ligand to protein. These assumptions may not be
valid in the hydrogel matrix where the mobility of therapeutic macromolecules and therefore
the intrinsic reaction constants are retarded by their size and limited free volume.
Heparin, a highly sulfated glycosaminoglycan (GAG), is known to serve as a growth
factor depot in vivo owing to its electrostatic affinity to various basic growth factors including
NGF, bFGF, VEGF, etc. Matrices containing heparin have been used as delivery depots to
modulate the release rates of these growth factors through affinity binding [141, 142]. For
example, Sakiyama-Elbert and Hubbell have developed affinity hydrogels composed of fibrin
gels copolymerized with peptides that bind to heparin [87, 88, 115]. This system has been
applied to deliver several growth factors including NGF [87], basic fibroblast growth factor
(bFGF) [88], and neurotrophin-3 (NT-3) [89]. In order to incorporate heparin into the fibrin
network and modulate growth factor release, a group of short peptide sequences with
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different affinities for heparin have been identified and copolymerized into the fibrin gel
networks. To model growth factor release from this tri-component delivery system, six
partial differential equations based on diffusion-reaction kinetics were solved simultaneously
[88]:
∂C G
∂ 2 CG
− k F C G C H + k R C GH − k F C G C HP + k R C GHP
= DG
∂t
∂x 2
∂C H
∂ 2C H
− k F CG C H + k R CGH − κ F C H C P + κ R C HP
= DH
∂t
∂x 2
∂C P
= −κ F C H C P + κ R C HP − κ F CGH C P + κ R CGHP
∂t
∂CGH
∂ 2 CGH
+ k F CG C H − k R CGH − κ F CGH C P + κ R CGHP
= DGH
∂t
∂x 2
∂C HP
= κ F C H C P − κ R C HP − k F CG C HP + k R CGHP
∂t
∂CGHP
= k F CG C HP − k R CGHP + κ F CGH C P − κ R CGHP
∂t

(25)
(26)
(27)
(28)
(29)
(30)

In these equations CG, CH, and CP represent the concentrations of growth factor (G), heparin
(H), and heparin-binding peptide (P), respectively. Similarly CGH, CHP, and CGHP represent the
concentrations of the possible biomolecule complexes.
Assuming the system is in equilibrium between the species initially, these equations, in
conjunction with proper initial and boundary conditions, can be solved numerically and used
to predict the fraction of growth factor present in its freely diffusible and bound state
(Figure 2.7 [89]) and the ratio of heparin to growth factor needed to obtain sustained
growth factor release (Figure 2.8. [88]). As can be seen from the above equations, there are
four kinetic constants (kF, kR, κF, κR) and three diffusion coefficients (DG, DH, DGH) required
to solve the equations which largely complicate this modeling approach. Furthermore, while
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experimental results and model predictions agree qualitatively, these results were never
directly compared to the theoretical predictions obtained from this model [87-89].

Figure 2.7 Predicted initial equilibrium fractions of NT-3-containing species versus initial
heparin to NT-3 ratio. Reproduced from [89], Copyright (2004), with permission from
Elsevier.
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Figure 2.8 Theoretical concentration of matrix-bound bFGF as a function of distance from
the midline of a model tubular nerve growth guide, 6 mm long and open at both ends.
Concentration is shown as percentage of the initial bound concentration, which was 5.7 ×
10-8 M. The ratio of heparin to growth factor modeled was ~500. The decreasing
concentration profile propagates inward over time, as one would expect. Reproduced from
[88], Copyright (2000), with permission from Elsevier.

2. 4 Emerging Systems and Remaining Challenges
Although mathematical simulations have been performed extensively to predict and
design better hydrogel systems, there are still many challenges associated with the modeling
of drug delivery phenomena and accurate prediction of release profiles from complex
hydrogel systems. Creating a fundamental understanding of drug transport processes is the
first step towards developing a suitable mathematical model. Mass transport governs the
translocation of drug from the interior of hydrogels to the surrounding environments.
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Multiple factors affect the mass transport of encapsulated molecules including the network
crosslinking density, extent of swelling, gel degradation, the size and charge of the
encapsulated molecules, and the physical interactions these molecules exhibit for themselves
and for the polymer matrix. If specific drug-binding motifs are present within the hydrogels,
then the kinetics and/or thermodynamics of drug-ligand binding must also be understood
and quantified to predict the controlled release of the encapsulated molecules. In this final
section, the network design and mathematical modeling of several emerging hydrogel-based
delivery systems as well as the challenges associated with these systems are discussed.
2.4.1 Dynamic hydrogel delivery systems
2.4.1.1 Degradable hydrogels
Previous sections have detailed the fabrication, degradation, and molecule release
from degradable hydrogels. Understanding degradation mechanisms is critical in designing
hydrogels for drug delivery applications since the rates of matrix swelling and degradation
govern the diffusion of encapsulated or tethered molecules. Via appropriate design of
polymer chemistries and network structure, degradable hydrogel matrices can be engineered
with proper degradation profiles for achieving previously unattainable molecule release
regimes.
Mathematical modeling of molecule release has provided much information to
facilitate the design of degradable hydrogels and identify key parameters dictating molecule
release profiles. However, to accurately predict the unique molecule release profiles that
occur with many degradable hydrogels, additional parameters not commonly found in
previous release models must be included. For example, as discussed in the previous section,
enzymatically degradable hydrogels are becoming more important in controlled release
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applications. One challenge for this novel class of hydrogel is how to model the rate of
enzyme (e.g. MMPs) production by invading cells. As discussed before, enzyme
concentration determines whether gel degradation occurs via surface-erosion (rate of
enzyme/substrate reaction greater than rate of enzyme transport) or bulk-degradation (rate
of enzyme transport greater than rate of enzyme/substrate reaction). Therefore, the accuracy
of predicting gel degradation and molecule release from enzymatically degradable hydrogels
largely depends on correctly understanding cellular physiology and cell-material interactions
and properly incorporating these phenomena in a quantitative model along with molecule
transport and enzyme-substrate kinetics.
2.4.1.2 Stimuli-sensitive hydrogels
Stimuli-sensitive hydrogels represent another advanced hydrogel system that, under
intelligent design, can sense changes in complex in vivo environments and utilize these
triggers to modify drug release rates. Since the swelling or deswelling of these hydrogels is
controlled by external stimuli, it is critical to model the dynamic swelling response in order to
predict solute release. Several review articles have been published detailing the fabrication
and application of stimuli-sensitive hydrogels [18, 62, 143]. Ionic or pH-sensitive hydrogels
are probably the most studied stimuli-sensitive gels. At a fixed pH and salt concentration, the
swelling of ionic hydrogels is balanced by the osmotic pressure and the relaxation of the
polymer chains. Thermodynamically, the total free energy can be expressed as:

∆GT = ∆Ge + ∆Gm + ∆Go

(31)

Here, ∆GT is the total Gibbs free energy, ∆Ge is the free energy contributed by elastic force
of the polymer chains, ∆G m is the free energy of mixing, and ∆Go is the free energy due to
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osmotic pressure. When the swelling of an ionic hydrogel is in equilibrium (∆GT = 0 ) , the
decreased elastic free energy is balanced by the free energy of mixing and osmotic pressure.
Based on this concept, the simulations of ionic hydrogel swelling have been derived in many
reports [66, 144-146]. Grimshaw et al. developed a continuum model to describe the
macroscopic behaviors of pH-responsive poly(methacrylic acid) (PMAA) hydrogel
membranes accounting for charge density, ionic strength, stress, strain, and electric field
[144]. The simulation results were used to compare experimentally determined PMAA
swelling and shrinking. It was found that the membrane swelling was slower than shrinking.
Following Grimshaw’s work, De et al. derived an equilibrium model to predict the degree of
hydrogel swelling at given pH and ionic strength and a kinetic model to predict the rate of
swelling under changing pH. Their simulation results agreed well with experimental
observations. The equilibrium swelling of anionic pH-responsive hydrogels appears to be
proportional to the pH with a sharp increase around the pKa of the charge group.
For molecule release from pH-sensitive hydrogels, Peppas and coworkers developed a
series of models focusing on ionic hydrogel swelling, water transport, and molecule release
[106, 107, 147, 148]. For example, a concentration-dependent solute diffusion coefficient Di
was used to predict cationic hydrogel swelling and solute release upon pH changes induced
by the production of gluconic acids [148]:
Di = Di ,0 exp(α d υ 1 )

(32)

where Di,0 is the solute diffusion coefficient in the dry state. From this expression, it is clear
that the diffusion coefficient changes exponentially with the water volume fraction ν1 and
experimentally determined water-polymer interaction parameter αd. The modeling of cationic
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hydrogel swelling agreed well with experimental data. For insulin release, however, no
experimental results were compared to model predictions [148] indicating that verification of
this modeling approach is still required.
While the benefits of using thermo-sensitive hydrogels are widely acknowledged,
mathematical simulation of molecular release from these “smart” hydrogels is still very
limited. A strategy correlating gel swelling and diffusion-controlled molecule release can be
readily constructed using equations for estimating molecule diffusivity.

Amsden [13]

reviewed a variety of hydrogel diffusivity models related to fundamental characteristics such
as hydrogel water content and molecule free volume. Andersson et al. applied one such
expression for assessing glucose and insulin diffusivities in n-isopropylacrylamide gels [26]:
De (1 − Φ )3
=
D0 (1 + Φ )2

(33)

where De and D0 are the effective molecule diffusivities in the gel and in pure solvent,
respectively. Φ is the polymer volume fraction of the gel. Since the swelling of thermosensitive hydrogels depends on temperature changes, one can readily obtain the polymer
volume fraction at the tested temperature. Using this equation, the effective diffusivities of
molecules encapsulated within thermo-sensitive hydrogels can be estimated as a function of
temperature. Once the molecule diffusivity is determined, a release profile can then be
predicted using Fick’s law of diffusion [26]. Figure 2.9 shows one comparison of simulated
and experimental results [26].
Finally, several groups have devoted significant efforts to the fabrication and
characterization of dual-stimuli responsive hydrogels that respond to changes in pH and
temperature [79-82]. Although the unique drug release profiles observed from these novel
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carriers have revealed the usefulness of this exciting new strategy of hydrogel design,
mathematical modeling of drug release from these dual-responsive networks has yet to be
developed.

Figure 2.9 Experimental and simulated concentration profiles for one of the glucose
diffusion experiments at 10°C. Reproduced from [26], Copyright (1997), with permission
from Elsevier.

2.4.2 Composite hydrogel delivery systems
Modeling drug release from composite hydrogel systems has proven to be challenging
due to the fact that their material and molecule transport properties change dramatically with
spatial location within the device. Two primary types of composite hydrogel delivery systems
have been investigated, multilayer and multiphase systems. These composite systems have
great potential in delivering multiple protein therapeutics for tissue engineering applications
where temporal and spatial control over drug delivery is desirable. The simultaneous delivery
of multiple proteins is known to occur in vivo during angiogenesis, bone remodeling, and
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nerve regeneration. For example, several angiogenic proteins including vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor
beta (TGF-β), platelet-derived growth factor (PDGF), and matrix metalloproteinases
(MMPs) are involved in the angiogenesis process. Marui et al. discovered that the dual
delivery of bFGF and hepatocyte growth factor (HGF) from collagen microspheres greatly
increased blood vessel formation in an animal model [149]. Peattie et al. utilized crosslinked
hyaluronan (HA) hydrogels to simultaneous deliver VEGF and keratinocyte growth factor
(KGF) to enhance angiogenesis [150]. Simmons et al. used alginate hydrogels to deliver bone
morphogenetic protein-2 (BMP2) and transforming growth factor-β (TGF-β3) and showed
enhanced bone formation compared to delivery of either single protein [49]. Although in vivo
tissue growth was improved in animal models using these dual-protein delivery systems, it is
not clear whether tissue growth would be further enhanced if the proteins were delivered at
optimized rates since no independent control over the release profiles has been shown in
these studies. Therefore, the development of models that can relate drug transport and
release in these composite systems to their fundamental properties would prove valuable and
possibly lead to the engineering of devices capable of independently tunable delivery of
multiple proteins for modulating cell behavior and tissue growth.
2.4.2.1 Multi-layer hydrogel delivery systems
In multi-layer systems, a basal polymer layer is fabricated, followed by lamination of
subsequent layers. Different proteins can be encapsulated into each layer during fabrication
and tunable multiple-protein release or unique single-protein release profiles are made
possible by independently adjusting the crosslinking density of each layer. Many models have
been developed for predicting drug release from multi-layer hydrogel composites. For
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example, Streubel et al. developed a multi-layer system to achieve bimodal drug release [151].
Fick’s second law of diffusion was used to predict drug release profiles. They derived
diffusion equations accounting for constant or non-constant diffusivities, as well as
stationary or moving boundary conditions. Grassi et al. fit their experimental data into a
semi-empirical model accounting for the resistance the drug experienced when diffusing
through the multi-layer system [152]. They started the modeling with an equation governing
the dissolution of solid drug and accounted for the gel layer resistance (R) and drug
dissolution resistance (1/K):
ϕ A CS − C
dC
=− d
dt
V (1 / K ) + R

(34)

where C is the drug concentration, t is the dissolution time, CS is the solubility of the drug in
the dissolution medium, ϕ d is the drug volume fraction, A is the surface area at the
solid/liquid interface, and V is the volume of the medium. The release of some small
molecular weight drugs from partially coated matrices containing different drug to polymer
fraction can be fit into the analytical solution of this model.
Sohier and colleagues developed a porous scaffold containing three hydrogel layers
with different porosities to simultaneously deliver lysozyme and myoglobin [153]. The
governing equations used to model this system were again based on Fick’s second law with a
time-dependent diffusion coefficient related to the rate of polymer degradation. Although
this model successfully predicted the release of lysozyme from a multi-layer polymer
construct, it did not provide an accurate description of dual-protein delivery.
In addition to multiple-protein delivery, multilayer matrices can also be used to
decrease the problematic burst release, a common challenge facing drug delivery. For
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example, Lu and Anseth developed a multi-laminated hydrogel system prepared by
photopolymerization. A desirable, zero-order release profile was obtained through nonuniform initial drug loading in multi-laminated hydrogels and the results were verified by a
diffusion model [154-156]. Their model was based on the well-known diffusion model first
developed by Crank [139]. Assuming a constant diffusion coefficient and one-dimensional
release under sink conditions, the fractional passive release of drug (Mt/M∞) from these
composite hydrogels can be analytically derived from Fick’s second law of diffusion and
expressed as the following equation:
∞

Mt
= 1−
M∞

( −1 )n + 1 − λ 2n Dt  L
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∫

(35)
In this expression, f(x) is the initial concentration profile, D is the molecule diffusion
coefficient, and L is the thickness of the gel. As shown in Figure 2.10, experimental results
verified the accuracy of this model and indicate that the initial burst was nearly eliminated.
2.4.2.2 Multi-phase hydrogel delivery systems
Another strategy for multiple-protein delivery is multi-phase systems. In this
approach, prefabricated microspheres containing one or more proteins are uniformly
embedded within a hydrogel containing a second protein [157-159]. The release of the
microsphere-encapsulated protein is delayed due to the combined diffusional resistances of
the microsphere polymer and surrounding gel. Richardson and colleagues prepared a
composite polymeric scaffold containing PLGA microspheres embedded in porous PLGA
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matrices with different intrinsic viscosities to simultaneous deliver VEGF and PDGF. The in
vitro and in vivo results using this approach have shown promising results in an animal
model to enhance the maturation of vasculatures [48]. Although this multi-phase
formulation is not considered to be a hydrogel system, it was the first heterogeneous
polymeric system for delivering two proteins with distinct release profiles. Holland et al. also
fabricated degradable oligo(poly(ethylene glycol) fumarate) hydrogels containing gelatin
microspheres to independently control the delivery of insulin-like growth factor-1 (IGF-1)
and transforming growth factor-β1 (TGF-β1). Release profiles can be adjusted by varying the
protein loading in each polymer phase [157]. These multi-phase dual delivery systems have
achieved substantial success, however, to date no rigorous mathematical models for
predicting molecule release from these composite networks have been developed.

Figure 2.10 Comparison of theoretical and experimental solute release. The initial
concentration profile used, from center outward, was: 1.2 wt%, 0.55 wt%, 0.2 wt%, and 0
wt%, respectively. Model results (——), experimental results (–●–). Reproduced from [154],
Copyright (1999), with permission from Elsevier.
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2.4.2.3 Challenges facing composite hydrogel delivery systems
The design and application of composite hydrogel delivery systems have attracted
much attention due to their multifaceted roles in advanced drug delivery and tissue
engineering. However, many challenges facing the design and modeling of these novel
systems remain largely unattended and need to be addressed to optimize their application as
drug carriers. First, these systems have complex network geometries and phase
morphologies that must be properly parameterized to quantify diffusion length scales in each
phase. The individually tailored physicochemical properties of each layer, which results in
heterogeneous transport properties within a single matrix, must also be evaluated in the
context of the overall device. For example, as shown by Sohier et al. the swelling, and
therefore permeability, of a highly hydrophilic layer can be limited by its attachment to layers
exhibiting a lower degree of swelling [153]. Once identified, the positional dependence of
drug diffusion coefficients as well as drug-polymer interaction parameters must be taken into
account during the development of any rigorous mathematical model describing these
composite systems.
2.4.3 Micro/Nano-scaled hydrogel delivery systems
Over the past few decades, polymeric microspheres and, more recently, nanoparticles
have been widely used for sustained or targeted drug delivery [160] as well as cell
encapsulation [161-163]. Numerous studies have been conducted using PLGA as a matrix
for encapsulating proteins, peptides, DNA, and small molecular weight drugs. However, the
hydrophobicity, acidic degradation products, and harsh fabrication/encapsulation processes
of PLGA micro/nanoparticles make them unfavorable as carriers for biomacromolecules
such as protein and DNA [164]. Alternatively, micro/nanoparticles made from hydrophilic
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hydrogels are more suitable for encapsulating these fragile biomacromolecules. These
miniaturized drug-containing vehicles can be fabricated in vitro and then administered via
oral [165, 166] or nasal route [167, 168] or injected into the patients in a minimally invasive
manner to increase patient compliance. Protein-containing microparticles can also be
fabricated and loaded into a bulk gel containing a second protein for dual-protein delivery as
discussed in the previous section. It is beyond the scope of this review to thoroughly discuss
the fabrication and application of micro/nanoparticles and readers are advised to look to the
cited references for more information [169, 170].
Two types of mathematical approaches have been used to predict molecule release
from hydrogel microspheres: macroscopic diffusion models and microscopic Monte Carlo
simulations. For macroscopic modeling, the most applicable models are still based on Fick’s
second law of diffusion. Particle size and geometry are the most important parameters in this
type of modeling as well as surface area since this appears to correlate to observed burst
effects. Additionally molecule diffusivities must be accurately determined. As with other
diffusion-controlled delivery systems, simple empirical relationships have been used to
estimate molecule diffusivity [171]. Other more rigorous expressions for molecule diffusivity
such as those discussed in Section 3.1 for degradable gels, can also be applied to these
systems. The accuracy of any diffusion model to predict molecule release from hydrogelbased microparticle systems will directly depend on the accuracy of the diffusivity estimation.
Another technique to model molecule release from hydrogel microspheres is Monte
Carlo simulation. This method has proven itself valuable for describing the transport
behavior of molecules within degradable microsphere systems and has been widely applied
to hydrophobic polymer networks such as PLGA [172, 173]. As mentioned earlier, Vlugt-
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Wensink et al. recently utilized Monte Carlo simulations to predict protein release from
degradable dextran microspheres [57]. Unfortunately, the accuracy of the model is highly
protein specific. For example, for larger proteins such as IgG, model predictions only agreed
with experiments qualitatively in most cases. This may be due to the fact that swelling of the
dextran gels was not accounted for in the Monte Carlo description of the degrading hydrogel
network.
One of the unique challenges facing micro-scaled matrix delivery systems is burst
release due to the high surface-to-volume ratio of these particulate systems [174, 175]. Burst
release may cause a “dose-dumping“ effect and is potentially harmful to patients in clinical
applications. Several possible causes of burst release have been identified including
material/drug interactions, fabrication conditions, and sample geometry and/or morphology
[174]. Although not completely understood, burst release has been taken into consideration
during the design of delivery matrices as well as in modeling approaches [154-156, 176, 177].
Several methodologies have been developed in an attempt to decrease the degree of burst
release. These include increasing crosslinking density of the matrix surface [178, 179],
coating additional drug-free layers [152, 177, 180], embedding the drug-containing particles
within a bulk polymeric matrix [157-159, 181], and loading drug unevenly with higher
concentrations toward the center of the matrix [182, 183].
The prediction of burst release is problematic as the exact mechanism has not been
elucidated. Typically, diffusion-controlled release can be divided into two phases: a rapid
burst phase and a prolonged diffusion-controlled phase. The later can be modeled by
conventional diffusion theories while the prediction of initial burst release is not readily
attainable. Models in this area are therefore very limited. Several attempts have been made to
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predict burst release in polymeric delivery matrices. For example, the simplest model
employed to describe the impact of burst release on drug delivery profiles is to add an extra
parameter, namely α, into the well-known fractional release equation [174]:

Mt
= kt n + α
M∞

(36)

In previous applications of this expression, the experimental release data were simply
shifted a certain fraction to fit the model prediction. If no burst release exists, α equals zero
and the equation is reduced to the original fractional release equation. However, this
empirical model fails to relate the extent of burst release to quantifiable system parameters.
Thus, this simple model is not practical for extrapolating results between different device
designs or optimizing delivery profiles.
2.4.4 In-situ forming hydrogels
Recent advances in polymer chemistry and hydrogel engineering have promoted the
development of in-situ forming hydrogels for drug delivery applications. Through intelligent
design of monomers/macromers with desired functionalities, hydrogel precursor solutions
can be injected and subsequently polymerized in situ. This in situ sol-gel transition enables
the surgery or implantation procedure to be performed in a minimally invasive manner.
Several physical or chemical crosslinking mechanisms have been used for in-situ network
formation. Physically, in-situ forming gels are formed by one of the following mechanisms:
hydrogen bonding, hydrophobic-hydrophobic interactions, or electrostatic interactions.
Sodium alginate hydrogels, for example, can be physically crosslinked through the addition
of calcium ions [160]. The common disadvantage of physical crosslinking, however, is that
the gels thus formed are unstable and may disintegrate rapidly and unpredictably.
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For long-term drug delivery applications, covalent crosslinking methods performed
under physiological conditions, such as photopolymerization of multi-vinyl macromers, are
more favorable compared to physical crosslinking methods as they produce relatively stable
hydrogel networks with predictable degradation behaviors. The photocuring process, for
example, is fast, usually taking only seconds to minutes to complete, and can be conducted at
room temperature without organic solvents [53]. Photopolymerization of degradable
hydrogels has been applied in protein [71, 184, 185] and gene delivery [186-188] and permits
in situ encapsulation of these species during network fabrication. These advantages
overcomes the complexities and limitations associated with post-loading techniques and
provides a convenient and efficient way of loading high concentrations of proteins and other
releasable solutes for subsequent long-term delivery.
When in-situ forming hydrogels are used to deliver macromolecules such as DNA and
protein, reduced or incomplete release of these biomolecules is commonly observed [185188]. Incomplete protein release decreases the bioavailability of the therapeutic agent and
alters the overall delivery profile. In addition, the protein trapped within the gel is generally
modified or denatured, which can lead to undesirable antigenic responses when applied in
vivo. The factors influencing incomplete biomolecule release from these hydrogel carriers
has commonly been attributed to the fabrication processes. For example, several researchers
have studied the effect of drug-polymer interactions on molecule release using thermally
responsive poly(N-isopropylacrylamide) hydrogels [189, 190] and alginate microparticles
[191]. Although these studies observed and verified the incomplete release phenomena, no
mathematical model was derived for predicting molecular release.
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When in-situ forming gels are used to deliver proteins, irreversible interactions
between the encapsulated proteins and polymerizing polymer chains decrease the efficacy of
the therapeutic agent. van de Wetering et al. identified the modification of hGH by reactive
thiol macromers in a PEG-based hydrogel system prepared via Michael-type addition
reaction [192]. Additionally, Quick and Anseth specified free radicals as the major source of
incomplete DNA release when photopolymerization was used to fabricate DNA-containing
hydrogels [186-188]. According to the authors, free radicals produced from the
photoinitiation process attacked DNA molecules during UV irradiation, leading to DNA
damage. Based on similar observations during protein encapsulation, Lin and Metters
utilized a metal-ion-chelating molecule, iminodiacetic acid (IDA), to block undesirable
protein-polymer conjugation reactions mediated by free radicals.

This protective agent

increased the fractional release of target proteins such as bovine serum albumin (BSA) from
40% to 100% following in situ photocuring of PEG-diacrylate hydrogels [185]. A
mathematical model accounting for reversible protein-IDA binding directly correlated the
extent of BSA release to the degree of protein-IDA binding.
Modeling drug release from in-situ forming hydrogels is challenging due to several
reasons. First, the effects of reduced/incomplete protein release discussed above can only be
taken into account after identifying the sources of protein destabilization and quantifying the
extent of interaction. These interactions will greatly depend on the selected polymer and
drug chemistries as well as the method of gel fabrication. Secondly, in-situ forming gels
assume irregular geometries at the implant site which are difficult to predict prior to
injection. This irregular geometry will increase model complexity and may also contribute to
non-uniform drug distribution within the gels, which further increases the difficulty to
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accurately represent the real system in a mathematical construct. Finally, experimental
measurement of release profiles is usually accomplished through in vitro release studies.
These in vitro systems must be designed to include as many complexities of the in vivo
environment as possible if these experiments are to accurately represent what will occur
during clinical application.
2.5 Conclusion
Hydrogels have played a very important role in biomedical applications. With
increasing efforts devoted to controlled molecule release, the applications of hydrogels will
continue to grow in the future. Proper network design and accurate mathematical modeling
are keys to tuning the drug release rates as well as to modulating tissue regeneration.
Although many fundamental studies have revealed the basic molecule release mechanisms
from hydrogel-based controlled release devices, many parameters in the current models are
unknown and/or change with time or position and need to be identified in order to
accurately predict drug release profiles. Reduced release efficiency, burst effects, complex
geometries, and unknown correlations between in vitro and in vivo release further
complicate our understanding of these materials as delivery devices and present difficult
challenges to developing mathematical models that accurately describe the transport and
release of molecules from these systems. Furthermore, as more advanced release devices are
developed such as affinity hydrogels, microparticle systems, and in-situ forming gels, more
rigorous mathematical modeling approaches are needed to describe the coupled mechanisms
governing molecule release from these systems.
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CHAPTER THREE
FREE RADICAL-MEDIATED PROTEIN INACTIVATION AND RECOVERY
DURING PROTEIN PHOTOPOLYMERIZATION
Abstract
Photoencapsulation is very attractive for preparing biomolecule-loaded hydrogels for a
variety of biomedical applications. However, detrimental effects of highly active radical
species generated during photoencapsulation must be carefully evaluated to maintain
efficient hydrogel crosslinking while preserving the stability of encapsulated biomolecules.
Here, we examine free radical-mediated inactivation and incomplete release of proteins from
photocurable hydrogels utilizing lysozyme as a conservative model system.

Various

photoencapsulation conditions were tested to determine the factors affecting lysozyme
structural stability and bioactivity. It was found that a portion of the lysozyme becomes
conjugated to polymer chains at high photoinitiator concentrations and long polymerization
times. We also found that the more hydrophilic photoinitiator Irgacure-2959 (2-hydroxy-1[4-(hydroxyethoxy)phenyl]-2-methyl-1-propanone I-2959) causes more damage to lysozyme,
compared

to

the

hydrophobic

photoinitiator

Irgacure-651

(2,2-dimethoxy-2-

phenylacetophenone or I-651), even though I-2959 has been previously shown to be more
cytocompatible. Furthermore, while non-acrylated PEG provides only limited protection
from the denaturing free-radicals that are present during hydrogel curing, acrylated PEG
macromers effectively preserve lysozyme stability in the presence of either photoinitiator.
Overall, these findings indicate how hotopolymerization conditions must be optimized to
obtain a functional hydrogel device that can preserve protein bioactivity and provide
maximal protein release.
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3.1 Introduction
Photopolymerization has emerged as a favorable method for preparing hydrogels [1-3],
membranes/films [4-9], surface coatings [10-12] and other functional materials.
Photopolymerization possesses many advantages including its facile spatial and temporal
control over reaction kinetics and its rapid and mild reaction conditions that are feasible
under ambient environments. Beginning with an aqueous prepolymer solution containing
monomers, biomolecules, and photoinitiator, photopolymerization is completed in a single,
rapid-step process and therefore has achieved substantial success in fabricating drug delivery
carriers and tissue engineering scaffolds. Depending on the type of photoinitiator used, the
prepolymer solution is irradiated with ultraviolet or visible light for photo-curing over the
timescale of a few seconds to several minutes. These favorable properties of
photopolymerization not only make it a simple method for preparing a variety of polymeric
devices but also allow it to uniformly encapsulate biomolecules in a single processing step.
Although some photoinitiator-free reaction schemes have been recently proposed [13-18],
the use of biocompatible photoinitiator to rapidly initiate polymerization reactions is still the
most popular method for simultaneous network polymerization and crosslinking.
Biomaterials prepared via in situ photopolymerization with encapsulated biomolecules have
been used extensively for controlled protein/gene delivery [19-22], cell encapsulation [3, 8,
23, 24], and tissue engineering applications [2, 3, 23].
Although most therapeutic proteins and other bioactive agents are not destabilized by
short exposure to low-energy UV or visible light, encapsulation of these materials via
photopolymerization still causes problems due to the use of light-sensitive photoinitiators.
Photolysis of photoinitiators generates free radicals, which enable network formation by
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initiating chain polymerization. High-energy free radicals react with not only polymerizable
monomers but also attack the co-encapsulated biomolecules, leading to DNA fragmentation,
protein denaturation, protein-polymer conjugation, or cell damage. Efforts have therefore
been devoted to investigate the effects of photoencapsulation on the stability and bioactivity
of these biomolecules. For example, Bryant et al. examined and compared the
cytocompatibility of several photoinitiators during in situ cell encapsulation [25]. Williams et
al. performed similar studies and revealed parallel results as Bryant et al. that photoinitiator
Irgacure-2959 (2-hydroxy-1-[4-(hydroxyethoxy)phenyl]-2-methyl-1-propanone), when used
under optimal conditions, is more cytocompatible than Irgacure-651 (2,2-dimethoxy-2phenylacetophenone). As our results will demonstrate, the conclusions from these previous
studies are not necessarily indicative of photoencapsulation systems where photoinitiators,
acrylated macromers and protein or DNA/RNA therapeutics are all present during UV
exposure.
With the objective of improving the delivery of various macromolecular therapeutics,
Quick and Anseth studied the effects of photoinitiators on the structural integrity of plasmid
DNA during in-situ photoencapsulation. Their results show that the detrimental effects of
photoinitiators and free radicals can be decreased by adding free-radical scavengers [21, 22].
However, this method decreases the total radical concentration and rate of polymerization,
necessitating longer reaction times or incomplete network formation.
To preserve high polymerization rates while minimizing detrimental interactions of
encapsulated species with photo-initiated free-radicals, Lin and Metters recently proposed a
protection mechanism using metal-ion chelators [20]. They demonstrated that for select
proteins exhibiting a moderate affinity for various metal ions, such a mechanism could be
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used to effectively prevent the significant amount of protein-polymer conjugation that
routinely occurs during photoencapsulation. More recently, Gu et al. discussed the damaging
effects of I-651 on the bioactivity of vascular endothelial growth factor (VEGF) and bovine
serum albumin (BSA) [26]. They concluded that while free radicals generated from I-651
damage protein structure and bioactivity in the absence of reactive monomer, the presence
of acrylated macromers effectively preserves protein stability during photopolymerization.
Proteins have long been considered major biological targets for free-radical induced
oxidative damage. In biological systems, the major sources of free radicals include the
primary hydroxyl radicals (•OH) and nitric oxide (•NO), as well as other secondary radicals.
These radicals generate oxidative stress to proteins through modification of amino acid
residues such as lysine, arginine, tryptophan, tyrosine, proline, cysteine, threonine, leucine,
and histidine [27-29]. These modifications, in turn, result in peptide bond cleavage, sitespecific oxidation, and protein-protein crosslinking. Several reaction routes have been
suggested for free radical-mediated oxidative modifications in which the abstraction of
hydrogen atoms from the α-carbon of amino acids or protein polypeptide backbone is the
initial site of free-radical attack [28]. Although protein damage resulting from carbon radicals
generated by ultraviolet and visible-light photoinitiators has not been extensively studied, it is
reasonable to hypothesize a mechanism similar to the reaction generated by hydroxyl radicals
and nitric oxide. Among the several possible reaction pathways, carbon-centered radicals
transferred to proteins during photoencapsulation can react with propagating carbon radicals
on growing polymer chains, resulting in covalent conjugation of the encapsulated proteins to
the polymer matrix.
Although the importance and advantages of photopolymerization are wellrecognized
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[1-3, 19, 23, 24], the potential for adverse effects on encapsulated species limit the
advantageous use of photopolymerization for simultaneous network formation and
biomolecule encapsulation. We aim to discover photoinitiator-induced proteinpolymer
interactions leading to protein inactivation and to provide generalized protection strategies
for enhancing protein bioactivity and bioavailability [20]. Here, we design a series of protein
photoencapsulation experiments to investigate protein stability and bioactivity under various
reaction conditions, including the type and concentration of photoinitiator, UV-irradiation
time, and the presence of acrylated versus non-acrylated polyethylene glycol (PEG). The
often overlooked phenomenon of protein-polymer conjugation induced by free-radicals is
also discussed.
3.2 Materials and Methods
3.2.1 Materials
Photoinitiators

2-hydroxy-1-[4-(2-hydroxyethoxy)

phenyl]-2-methyl-1-propanone

(Irgacure 2959 or I-2959) and 2,2-dimethoxy-2-phenylacetophenone (Irgacure 651 or I-651)
were obtained from Ciba Specialty Chemicals. Chicken Egg White Lysozyme, Micrococcus
lysodeicticus, and hydroxyl-terminated poly(ethylene glycol) (MW. 8000) were obtained from
Sigma-Aldrich. Poly(ethylene glycol) monoacrylate (PEGMA, MW. 3000) was supplied by
Monomer-Polymer & Dajac Labs Inc. All other chemicals were obtained from SigmaAldrich unless otherwise specified.
3.2.2 Protein photoencapsulation
Protein photoencapsulation reactions were performed in 50mM, pH 7.4 phosphatebuffer solution (PBS) at room temperature. Photoinitiator stock solutions (I-2959 or I-651)
were dissolved in ethanol at a concentration of 10 wt% and diluted in PBS to obtain required
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concentrations. Lysozyme stock solution at 40 mg/mL was prepared in PBS and a final
concentration of 2 mg/mL (with or without the presence of polymer) was used for UV
irradiation. A low-energy ultraviolet light (BLACK-RAY®, intensity 8mW/cm2 at 365nm)
was used as source of UV irradiation.
3.2.3 Fluorescence spectroscopy
Fluorescence spectroscopy has been widely used as a facile method of detecting
alterations in intrinsic protein fluorescence.

The later characterizes changes in protein

tertiary structure due to protein-ligand interaction as well as protein aggregation or
denaturation.

Lysozyme fluorescence measurements were carried out in a GeminiEM

Spectramax plate reader (Molecular Devices, CA). The excitation wavelength was set at
295nm and the emission spectra recorded in the range of 300 to 400nm.

Accurate

measurements of lysozyme intrinsic fluorescence spectra are not possible in the presence of
different concentrations of photoinitiators and PEGMA due to the high molar extinction
coefficients of photoinitiators and auto-fluorescence of PEGMA.

3.2.4 Lysozyme bioactivity assay
Following photopolymerization, a portion of the reacted polymer-protein mixture was
diluted 100-fold to obtain a solution with 0.02 mg/mL lysozyme for assaying bioactivity.
Micrococcus lysodeicticus at a concentration of 0.4 mg/mL was used as lysozyme substrate. The
lysozyme bioactivity assay was performed in a 96-well microplate where 20 µL lysozyme
sample solution was added to 200 µL Micrococcus lysodeicticus solution. The turbidity of the
combined solution was monitored kinetically using a UV-Vis spectrophotometer (µQuant,
Biotek Instruments, Inc.) at a wavelength of 450 nm. The slope obtained from the linear
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portion of the decreasing optical density (OD450) due to enzymatic degradation of the
bacterial cell wall was used to represent lysozyme bioactivity. Native lysozyme solution was
used as positive control for all samples and the ratio of the two slopes (sample lysozyme to
native lysozyme) was calculated as relative bioactivity.
3.2.5 Circular dichroism (CD) spectroscopy
CD measurements were carried out in quartz cuvettes using a Jasco 810 CD
spectrophotometer (Jasco Inc., Bethesda, MD). All measurements were carried out at room
temperature and in double-distilled water. Lysozyme solutions at a concentration of 10
µg/mL were used for CD measurements. To decrease the influence of polymer chains
(PEGMA) on CD measurements, samples were further diluted to 5 µg/mL lysozyme when
PEGMA was present. CD spectra were recorded over a wavelength range of 190 to 240 nm.
3.2.6 Non-reduced SDS-PAGE
Non-reduced SDS-PAGE has been successfully used to determine protein molecular
weight changes due to protein-polymer conjugation [20, 28]. Briefly, lysozyme (2 mg/mL),
10 wt% linear poly(ethylene glycol) monoacrylate (PEGMA), and required amount of
photoinitiator I-2959 were mixed and subjected to a prescribed does of low-energy UV
irradiation.

Following exposure, protein-polymer solutions were analyzed according to

standard SDS-PAGE procedure with the exception that lysozyme was not heat-denatured.
Protein samples in the gel were visualized using Coomassie Blue staining.
3.2.7 Hydrogel fabrication, characterization, and protein release
Polyethylene glycol diacrylate monomers (PEGDA, M.W. 3400) were synthesized
following an established protocol [7].

PEG hydrogels were prepared from solution

photopolymerization of 10 wt% PEGDA monomers and required amount of photoinitiator.
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The photopolymerization was carried out between glass slides separated by 0.55 mm Teflon
spacers. The photopolymerized hydrogels were cut into rectangular shape (~0.8 × 0.8 cm).
0.3 wt% photoinitiator (I-2959 or I-651) was used to fabricate hydrogels for comparison of
gelation efficiency through direct measurements of equilibrium swelling ratios (Q) and gel
fractions (fgel).
Equilibrium swelling ratio measurements: PEG hydrogels were washed, after gelation,
in deionized water for 24 hours to remove any unreacted monomers, followed by drying in
air (24-hr) and then in vacuum (24-hr). The dried gel weights were measured gravimetrically,
after which the dried gels were placed in deionized water for 48 hours to obtained
equilibrium swollen weight. Equilibrium swollen ratio (Q) was then determined by:
Q=

Equilibrium swollen weight
Dried gel weight

Gel fraction measurements: the photo-cured gels were dried directly after gelation
without the washing step. The obtained dried gel weight represents crosslinked gel and
unreacted monomers. The gels were then swelled in deionized water for 48 hours and then
dried again to obtain dried gel weight containing only crosslinked polymer. Gel fraction (fgel)
was determined using the following equation:
f gel =

Dried gel wt. after swelling
× 100%
Dried gel wt. before swelling

3.2.8 Lysozyme release from in situ photopolymerized PEG hydrogels
Lysozyme at a final concentration of 1 wt% was mixed with 10 wt% PEGDA
crosslinker solution. The lysozyme was then encapsulated in situ by exposing the precursor
mixture with 0.1, 0.2, or 0.3 wt% I-2959 for 10-min to low-energy UV-irradiation to form

87

partially swollen hydrogels.

This strategy permitted the effect of photoinitiator

concentration on the released lysozyme structure and bioactivity to be investigated.
Furthermore, hydrogels with 1 wt% lysozyme cured with 0.2 wt% I-2959 for 10 or 20-min
gelation time were used to evaluate the effect of gelation time on lysozyme structure and
bioactivity. Release studies were conducted in 3 mL, 50mM PBS (pH 7.4) at 37˚C. Total
lysozyme release was characterized using a fluorescamine assay (3 mg/mL in acetone).
Bioactivity assay and fluorescence spectroscopy were performed on released lysozyme
samples with diluted concentrations (bioactivity assay: 0.02mg/mL; fluorescence
spectroscopy: 0.1mg/mL).
3.3 Results and Discussion
3.3.1 Effect of photoinitiator and UV irradiation on lysozyme bioactivity
Based on prior experimental observations [20], we hypothesized that incomplete
release of encapsulated proteins from photopolymerized hydrogels results, at least in part,
from free-radical induced protein-polymer conjugation during protein photoencapsulation.
Mechanistically, this is a consequence of radical species generated by photoinitiators and
propagated by (meth)acrylated monomers that irreversibly conjugate proteins in the
precursor solution to growing polymer chains. To examine the effects of photoinitiator
chemistry and concentration on protein bioactivity during protein photoencapsulation,
lysozyme was utilized as a representative protein due to its well-understood structurefunction relationships. Prior to assessing protein inactivation during photoencapsulation, it
was necessary to examine the effect of low-energy UV irradiation on protein structure and
bioactivity. To achieve this, lysozyme solutions at 2 mg/mL were exposed to low-energy
UV for up to 20 minutes.

Figure 3.1 shows the intrinsic fluorescence (Excitation
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wavelength: 295 nm) of lysozyme following increasing UV exposure time. Clearly, no
substantial differences were found, suggesting the tertiary structure of lysozyme is unaffected
by the low-energy UV irradiation commonly used to cure the hydrogel networks. The
bioactivity of the UV-irradiated lysozyme samples is also comparable to that of native
lysozyme. It is important to note that, although the low intensity UV used throughout this
study does not cause any apparent protein damage, protein denaturation does occur at higher
intensities, shorter wavelengths or with significantly prolonged exposure times [27, 29].
We next examined the effect of photoinitiator chemistry on lysozyme bioactivity at
different UV exposure times. I-2959 and I-651 are two photoinitiators widely used to
prepare hydrogel scaffolds for encapsulating cells, proteins, and other biologically active
agents [19, 25, 27]. As shown in Figure 3.2, it is clear that, regardless of the type of
photoinitiator used (0.05 wt% I-2959 or I-651), lysozyme activity decreases rapidly with
increasing UV exposure time.

For example, after 7 minutes of UV irradiation in the

presence of 0.05 wt% I-2959 or I-651, lysozyme bioactivity decreases rapidly to only 5% or
12%, respectively. During UV irradiation, the presence of photoinitiator leads to protein
inactivity and denaturation due to the generation of high-energy free radicals. Free-radical
mediated protein denaturation is substantiated by observing increased turbidity of the
protein solution with increasing UV exposure time (data not shown).
When comparing the photo-inactivation effects of I-651 and I-2959 on lysozyme, it is
interesting to note that I-651 causes less damage to lysozyme (except at 1-min UV
irradiation). This is an interesting result as prior studies by Bryant et al. [25] and Williams et
al. [26] suggested that photoinitiator I-2959, when used at optimal conditions, is more
cytocompatible than I-651 for mammalian cells.
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However, for in situ lysozyme

encapsulation, I-651 is at least as protein-friendly as I-2959. We hypothesize that this may
be due to the increased phase separation of the hydrophobic, less water-soluble I-651 in
aqueous solutions compared to I-2959. Therefore I-651 will not contact the exposed,
hydrophilic residues of lysozyme (e.g. lysine or arginine) as extensively as I-2959 during UV
exposure. Future studies, however, are needed to verify this hypothesis and to elucidate the
underlying mechanisms.

Nevertheless, the results presented in Figure 3.1 and 3.2

demonstrate that, although low-energy UV irradiation is harmless to protein structure and
bioactivity, it can trigger serious protein inactivation during photoencapsulation by
generating high-energy free radicals through photolysis of photoinitiators.
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Figure 3.1 Fluorescence spectra (Excitation wavelength: 295 nm; emission wavelength: 310 400 nm) of lysozyme subjected to low-energy UV irradiation (BLACK-RAY®, intensity
8mW/cm2 at 365 nm) without the presence of photoinitiator for up to 20 min (Lysozyme
concentration: 2 mg/mL for UV exposure; 0.2 mg/mL for fluorescence spectra detection).
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Figure 3.2 Effect of exposure time of low-energy UV (BLACK-RAY®, intensity 8 mW/cm2
at 365 nm) on lysozyme bioactivity. Bioactivity of native lysozyme (no UV or photoinitiator
exposure) was used as positive control (100%). Photoinitiator: 0.05 wt% I-2959 (□) and 0.05
wt% I-651 (■). No PEGMA monomer was present.
3.3.2 Effect of PEG on lysozyme bioactivity during protein photoencapsulation
It is well-known that PEG is a hydrophilic molecule that stabilizes proteins owing to
its “stealth” effect [30-32]. Because of its volume-exclusion effect, PEG has also been used
to precipitate proteins prior to encapsulation and hence can increase protein bioavailability
[28].

Taken together, adding hydroxyl-terminated PEG (PEG-OH) into UV-irradiated

protein-photoinitiator precursor solutions can presumably decrease free-radical mediated
inactivation of proteins.

To verify this hypothesis, we systematically increased the

concentration of 8 kDa linear PEG-OH from 5 wt% to 20 wt% in lysozyme solutions
containing 0.05 wt% I-2959 or I-651 and irradiated the mixture with UV light for 7-min.
Table 3.1 reveals that a significant (PEG-OH)-induced protection effect (i.e., retention of
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protein bioactivity) was found only in the most concentrated PEG-OH solutions (20 wt%
PEG-OH). (PEG-OH)-induced inhibition of protein photo-inactivation can be attributed
to: (1) increased solution viscosity that restricts the diffusion of free radicals, and (2) (PEGOH)-induced precipitation of lysozyme that decreases the protein’s exposure to free radicals
in the aqueous phase. In support of these proposed protection mechanisms, we also found
that the addition of linear PEG-OH with molecular weight 3.4 kDa or 4.6 kDa did not
provide significant retention of protein bioactivity at similar mass concentrations (5-20 wt%)
and UV irradiation conditions (data not shown). Overall, these results indicate that addition
of non-reactive PEG, even at relatively high concentrations, can only provide encapsulated
proteins with limited protection from attack by free-radicals.
It has been previously shown that protein bioactivity can be retained during
photocuring in the presence of acrylated macromers in organic solvent [27]. For example,
Gu et al showed that the addition of acrylated star(ε-caprolactone-co-D,L-lactide) preserves
the bioactivity of the photoencapsulated proteins (VEGF and BSA) initiated by high-energy
UV (50-1000mW/cm2). We confirmed this general result by investigating the effect of
PEGMA on the inhibition of lysozyme photo-inactivation in aqueous solutions. As shown
in Figure 3.3(a), the addition of 10wt% PEG monoacrylate (PEGMA, 3kDa) effectively
eliminates the previously discussed photo-inactivation of lysozyme and increases its
bioactivity to over 100% at all UV exposure times (up to 20-min) regardless of which
photoinitator is used.
To further elucidate the effect of PEGMA on inhibiting photoinitiator-induced
protein inactivation and to examine whether I-651 indeed causes less damage to lysozyme,
we varied the concentration of I-2959 or I-651 while keeping a constant UV exposure time
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of 10-min.

Surprisingly, the addition of 10 wt% PEGMA effectively inhibits photo-

inactivation of lysozyme induced by I-651 at all concentrations (up to 0.3 wt%) while
lysozyme bioactivity decreases when corresponding concentrations of I-2959 were used
(Figure 3.3b). In fact, the addition of PEGMA increases lysozyme bioactivity to 130%
when 0.3 wt% I-651 is used while at the same conditions with I-2959, PEGMA can only
preserve lysozyme bioactivity to about 80%.

Table 3.1 Effect of PEG macromer (8 kDa) on lysozyme bioactivity after 7-min UV
irradiation.
[PEG] (8 kDa)
0%

Relative lysozyme activity (%)
0.05 wt% I-2959
0.05 wt% I-651
6.15 ± 0.97
10.5 ± 1.71

5%

14.7 ± 1.42

17.1 ± 1.81

10%

22.9 ± 0.82

15.5 ± 1.49

15%

29.1 ± 1.44

25.7 ± 1.79

20%

48.0 ± 2.79

50.0 ± 3.85
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Figure 3.3 Addition of 10 wt% PEG-monoacrylate (PEGMA, 3 kDa) on lysozyme
bioactivity. Effect of: (a) UV exposure time (photoinitiator: 0.05 wt% I-2959 (□) and 0.05
wt% I-651 (■)), and (b) photoinitiator concentration (I-2959 (□) and I-651 (■) for 10-min
UV exposure). Bioactivity of native lysozyme was used as positive control (100%).
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Comparing the two photoinitiators used in this study, I-651 has higher molar
extinction coefficient (94.6 and 6.7 lmol-1cm-1 for I-651 and I-2959, respectively [25]) and
quantum yield (ranging from 0.1 to 0.7 for I-651 [33, 34] and 0.05 for I-2959 [35]) that make
it more efficient in initiating photopolymerization. Thus at the same concentration and
irradiation dose, I-651 generates more free radicals than I-2959. To indirectly verify this, we
fabricated PEG hydrogels using PEGDA with either 0.3 wt% I-2959 or I-651 as
photoinitiator (10-min low-energy UV exposure, 8 mW/cm2 at 365 nm). As shown in Table
3.2, the equilibrium swelling ratio of gels cured with 0.3 wt% I-651 is significantly lower than
those of gels cured with 0.3 wt% I-2959 (8.78 ± 0.61 and 9.86 ± 0.12, respectively, p<0.04)
while their gel fractions are relatively identical (95.34 ± 5.63 and 93.88 ± 4.68 % for I-2959
and I-651, respectively). This suggests that I-651 results in gels with higher crosslinking
densities and is at least as efficient as I-2959 in initiating polymerization under the given
conditions. Although I-651 is considered more efficient than I-2959 in generating free
radicals, it does not decrease protein bioactivity as significantly as I-2959 in the presence of
PEGMA.

Table 3.2 Equilibrium swelling ratio and gel fraction of PEGDA hydrogels prepared from
different photoinitiators.
Photoinitiator

Q [a]

Gel fraction (%)

0.3wt% I-2959

9.86 ± 0.12 [b]

95.34 ± 5.63

0.3wt% I-651
8.78 ± 0.61 [b]
93.88 ± 4.68
[a] Q: equilibrium mass swelling ratio of hydrogels
[b] Statistically significant. (Student’s T-test, n=3, p<0.04)
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3.3.3 Lysozyme structural integrity
In order to gain more insights into the structural changes of lysozyme caused by
photoinitiators and UV-irradiation, we examined lysozyme secondary structure by circular
dichroism (CD) spectroscopy. Far-UV CD spectra shown in Figure 3.4a illustrate the
secondary structure of lysozyme in its native form (curve a), incubated with 0.2 wt% I-2959
without (curve b), and with (curve c) 10-min UV-irradiation. Solely incubating lysozyme
with 0.2 wt% I-2959 without UV-irradiation slightly decreases CD spectra intensity in the
region between 190nm and 200nm, indicating moderate changes in lysozyme secondary
structure (β-sheet). No differences were found in the two spectra above 200nm. However,
the CD spectrum for lysozyme was altered dramatically after 10-min UV irradiation (curve
c), suggesting significant modification of lysozyme secondary structure (both in α-helix and
β-sheet).

These results are in line with lysozyme bioactivity assays where moderate

bioactivity decrease (to 69.4 ± 1.57%) was found for lysozyme incubated with 0.2 wt% I2959 without UV-irradiation while no lysozyme activity was detected after 10-min UV.
Figure 3.4b shows that when 10 wt% PEGMA is added into 0.2 wt% I-2959containing lysozyme solution, the secondary structure of lysozyme is not significantly altered
(compared to native lysozyme, curve a) even after 20-min UV exposure (curve b),
supporting the earlier argument that PEGMA provides some degree of protection from freeradical exposure during photopolymerization. Note that the differences in absolute CD
signal occurring between Figures 3.4a and 3.4b were due to the use of different lysozyme
concentrations (Figure 3.4a: 10 µg/ml; Figure 3.4b: 5 µg/ml).
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Figure 3.4 Effect of photopolymerization conditions on lysozyme structure examined by
circular dichroism spectroscopy. (a) In the absence of PEGMA. Curve a: native lysozyme;
Curve b: lysozyme + 0.2 wt% I-2959 without UV exposure; Curve c: lysozyme + 0.2 wt% I2959 with 10-min UV exposure (BLACK-RAY®, intensity 8mW/cm2 at 365nm). (b) In the
presence of 10 wt% PEGMA. Curve a: native lysozyme; Curve b: lysozyme + 0.2 wt% I2959 + 20-min UV exposure.
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While CD spectra reveal the alteration in protein secondary structure due to the
presence of photoinitiators and UV irradiation, they do not provide information regarding
whether protein is conjugated onto polymer chains [31, 36, 37].

Protein-polymer

conjugation can be beneficial and lead to enhanced bioactivity via so-called PEGylation in
cases where the site of conjugation is precisely controlled [38, 39]. However, the freeradicals present during photopolymerization can react with a number of sites on the protein
backbone in an uncontrollable manner. Random protein-polymer conjugations have been
shown to take place on the active sites of protein surfaces and results in reduced bioactivity
[40]. In addition, protein-polymer conjugation within a crosslinked hydrogel network will
result in incomplete protein release [20]. We have previously used non-reduced SDS-PAGE
to display protein molecular weight changes due to protein-polymer conjugation [20]. This
technique was used here to detect the molecular weight changes of lysozyme due to free
radical-mediated protein-polymer conjugation. As shown in Figure 3.5a, solely irradiating
lysozyme solution with low-energy UV for 10-min (Figure 3.5a, lane 2) or solely incubating
lysozyme with 0.2 wt% I-2959 (Figure 3.5a, lane 3) does not induce any lysozyme molecular
weight change. However, when combining these two conditions to generate free-radicals
(Figure 3.5a, lane 4), the total amount of monomeric lysozyme decreases significantly, most
likely due to the formation of large protein inactive aggregates at these conditions preventing
its elution on the acrylamide gel. When PEGMA was added at 10 wt% without free-radicals
present, some lysozyme can be seen at higher molecular weight positions (Figure 3.5a, lane
5 and 6), presumably due to non-specific adsorption of PEGMA monomers on lysozyme.
These complexes are replaced by higher molecular weight products, however, upon the
introduction of propagating free-radicals (i.e., UV, I-2959, and PEGMA). The amount of
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Figure 3.5 Protein-polymer conjugation-induced lysozyme molecular weight changes examined by non-reduced
SDS-PAGE. (a) Effects of I-2959 and PEGMA. (b) Effect of UV exposure time.
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higher molecular weight species increases with increasing I-2959 concentration in
conjunction with UV-irradiation. It can be seen that an almost uniform band of higher
molecular weight protein products forms at higher photoinitiator concentration (Figure
3.5a, lane 9), suggesting the formation of polydispersed protein-polymer conjugates at this
photopolymerization condition (0.3 wt% I-2959, 10 wt% PEGMA, and 10-min UV
exposure).
In addition to photoinitiator concentration, another important parameter that determines the
extent of protein-polymer conjugation is UV exposure time. As show in Figure 3.5b, nonreduced SDS-PAGE results reveal that higher molecular weight protein products increase
dramatically with UV exposure time in the presence of 10 wt% PEGMA (0.2 wt% I-2959),
indicating increased conjugation between the encapsulated proteins and the in-situ
polymerized polymer chains. Although the SDS-PAGE results presented in Figure 3.5
substantiates the formation of protein-polymer conjugates in certain photopolymerization
conditions, it is important to note that these conjugates may still remain protein bioactivity.
However, these covalent irreversible conjugates wll result in permanant immobilization in a
crosslinked and non-degradable hydrogel network.

The consequence of this is the

incomplete protein release as disscused earlier.
The occurrence of protein-polymer conjugation during photocuring is also supported
by fluorescence spectroscopy data which quantify the extent of protein tertiary structure
changes compared to native protein. As shown in Figure 3.6, a decreasing lysozyme
intrinsic fluorescence was observed at increasing UV exposure time in the presence of 0.2
wt% I-2959 and 10 wt% PEGMA, confirming changes in protein tertiary structure
consistent with protein-polymer conjugation. Although conjugation of PEG onto protein
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has been shown to enhance protein structural and functional stability [30, 41], nonspecific
protein-PEG conjugations occurring during in-situ polymerization are not desirable in the
cases where crosslinked hydrogels are to be used for controlled protein delivery. These
results are important in that, although the conjugation of PEGMA chains to lysozyme does
not necessarily decrease protein bioactivity (Figure 3.3), it does result in decreased protein
bioavailability or incomplete protein release from in situ photo-cured hydrogels. The nonspecific conjugation of encapsulated proteins to the polymer chains will result in decreased
bioavailability or incomplete release if the gels are non-degradable (See Section 3.3.4 and
Figure 3.7). Even if degradable gels can be used, the release of these protein-polymer
conjugates may not be as active as native proteins and may induce unpredictable
physiological reactions including inflammation and immune response. Therefore, careful
optimization

of

photopolymerization

conditions

is

especially

critical

when

photopolymerization is used to encapsulate protein therapeutics for controlled release
applications.
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Figure 3.6 Influence of photopolymerization time on lysozyme structural change in the
presence of 0.2 wt% I-2959 and 10 wt% PEGMA examined by fluorescence spectroscopy.
Increasing photopolymerization time (5-min incremental) results in decreased lysozyme
intrinsic fluorescence.
3.3.4 In situ photo-cured hydrogels for protein delivery
Even though the changes in tertiary protein structure generated by protein-polymer
conjugation during free-radical polymerization may, for proteins such as lysozyme, not elicit
functional damage to encapsulated agents, covalent immobilization of the proteins onto a
crosslinked polymer scaffold will inevitably cause incomplete protein release from the
photopolymerized controlled delivery matrices. SDS-PAGE results from Figures 3.5, as
well as previous reports in the literature, demonstrate that free-radical species generated by
photoinitiators immobilize some fraction of encapsulated proteins to the growing polymer
chains [20]. This phenomenon is likely to be universal for protein therapeutics and therefore
precautions must be taken when encapsulating therapeutic agents within photopolymerized
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delivery vehicles. As shown in Figure 3.7 and Table 3.3, we prepared 10 wt% PEGDA
hydrogels by exposing the precursor solutions to UV light for 10-min with 0.1, 0.2 or 0.3
wt% I-2959, respectively. We found that the release kinetics and total release of lysozyme
after 24 hours remain unaffected in all cases (Figure 3.7a) while the bioactivity of the
released lysozyme decreases dramatically when higher concentrations of I-2959 were used to
fabricate the hydrogels (Table 3.3). When examining the tertiary structure of the released
lysozyme using fluorescence spectroscopy (Figure 3.7b, curve a, b, and c), it was found that
the intrinsic fluorescence of released lysozyme decreases with increasing I-2959
concentration. These results reveal that although the release rates and total amount of
released protein is not affected by the range of hydrogel fabrication conditions used in this
study, the released protein may not be as active as native protein due to modifications caused
by photoinitiator-generated radical species.

Table 3.3 Characteristics of lysozyme releasing from hydrogels with different fabrication
conditions
[I-2959]

Gelation time

Total release (%) [a]

Activity (%) [b]

Q

0.1wt%

10-min

70.2 ± 1.07

92.0 ± 1.38

8.27 ± 0.04

0.2wt%

10-min

72.0 ± 7.00

76.5 ± 4.80

8.29 ± 0.05

0.3wt%

10-min

66.8 ± 4.29

73.2 ± 3.88

8.33 ± 0.09

0.2wt%

20-min

54.9 ± 5.19

69.2 ± 3.00

8.76 ± 0.08

[a] Total release: obtained after releasing 24-hr, no significant increase was found afterward.
[b] Activity of 24-hr release samples.
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Figure 3.7 (a) Effects of I-2959 concentration and gelation time on lysozyme release from
10 wt% PEGDA hydrogels. (b) Representative intrinsic fluorescence spectra of lysozyme
(24-hr released samples) released from PEGDA hydrogels cured from: 0.1 wt% I-2959, 10min gelation (curve a); 0.2 wt% I-2959, 10-min gelation (curve b); 0.3 wt% I-2959, 10-min
gelation (curve c); 0.2 wt% I-2959, 20-min gelation (curve d).
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To strengthen the argument that protein-polymer conjugation decreases total protein
release, we prepared non-degradable PEG hydrogels with in situ loaded lysozyme by
photocuring for 10-min or 20-min. The results shown in Figure 3.7a demonstrate that the
total amount of lysozyme released after 24 hours decreases from 72% (10-min exposure) to
55% (20-min exposure) but the bioactivity of the released lysozyme shows no significant
changes (Table 3.3). Fluorescence spectroscopy of the released protein shown in Figure
3.7b reveals parallel results to the bioactivity assay and indicates no substantial differences in
tertiary protein structure were found (curve b and d). These results suggest that while the
gelation time does not sabotage the bioactivity of released lysozyme, a larger fraction of
encapsulated lysozyme becomes permanently immobilized within hydrogel networks
photocured for longer periods due to protein-polymer conjugation. Note that the hydrogels
prepared for this study were non-degradable and exhibited identical crosslinking densities,
irregardless of exposure time (Table 3.3).
3.3.5 Proposed protein inactivation mechanisms
Several studies, including the present one, have examined the detrimental effects of
photoinitiators on protein denaturation, DNA fragmentation, and cell death during in situ
photoencapsulation. One common and important feature of the photo-curable systems
studied is the presence of highly reactive free-radical species, including primary radicals
produced directly from photoinitiator fragments and propagating radicals located at the ends
of actively growing polymer chains. These radical species either directly or indirectly damage
the encapsulated biomolecules.

Stemming from our previous work as well as studies

established by others, the present study further reveals that the use of I-651 is not necessarily
harmful to the in situ encapsulated proteins when applied in a suitable environment. This
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interesting finding leads us to consider the supramolecular structure of an aqueous precursor
solution consisting of PEGMA or PEGDA, a photoinitiator, and the therapeutic protein of
interest. Figure 3.8 illustrates our hypothesis regarding the differential protein inactivation
phenomena caused by I-2959 and I-651. Given that linear PEGMA is an amphiphilic
molecule with a hydrophilic PEG tail and relatively hydrophobic acrylate head-group, at
sufficiently high concentrations these functional macromers may form a micellar structure
with a PEG shell and acrylate core. Since I-651 is more hydrophobic compared to I-2959,
we hypothesize that I-651 will selectively partition into the acrylate core in PEGMA
solutions to a greater extent than I-2959 (Figure 3.8a). This partitioning decreases I-651
exposure to predominantly hydrophilic proteins such as lysozyme while also facilitating
polymerization due to the co-localization of initiator and reactive units.

Overall this

proposed architecture should lead to less protein inactivation as well as protein-polymer
conjugation during UV irradiation. In contrast, the more hydrophilic I-2959 partitions to a
greater extent into the protein-rich phase, increasing its exposure to encapsulated proteins
leading to more significant protein inactivation (Figure 3.8b).
3.4 Conclusion
In summary, we have investigated the role of two photoinitiators, I-2959 and I-651,
on the inactivation of lysozyme during photoencapsulation and hydrogel formation using
fluorescence spectroscopy, circular dichrosim, non-reduced SDS-PAGE, and a bioactivity
assay. We found that I-651, compared to I-2959, causes less functional damage to the
photoencapsulated lysozyme. Furthermore, while linear, non-acrylated PEG-OH provides
only moderate protection against free- radical induced protein inactivation, the presence of
acrylated PEG macromers (PEGMA) effectively retains lysozyme bioactivity following

106

(a)

I-651

+ PEGMA

+ UV

Less I-651 in contact
with protein, less
protein inactivation

(b)

I-2959

+ UV

+ PEGMA

More I-2959 in contact
with protein, more
protein inactivation

Figure 3.8 Proposed mechanisms of (a) I-651 and (d) I-2959 induced protein inactivation in
the presence of PEGMA and UV irradiation.
exposure to photoinitiator-generated free radicals. We hypothesize that the addition of
reactive acrylate monomers such as PEGMA do not lower the total radical concentration as
radical scavengers have been shown to do, but rather convert the primary radical chemistry
into a propagating species that is either less reactive or less damaging to encapsulated
proteins. Furthermore, the degree to which PEGMA helps maintain protein bioactivity was
shown to be dependent on the type of photoinitiator present with I-651 providing a greater
level of lysozyme bioactivity compared to I-2959.

These results are contrary to

cytocompatibility trends published by previous researchers [25, 26]. It was also shown that
extensive protein-polymer conjugates resulting in incomplete protein release will form at
high photoinitiator concentrations (0.3 wt% I-2959) and/or long UV exposure times (20
minutes). Understanding the interactions that occur between polymers, free-radicals, and
proteins during photoencapsulation of proteins and the effects of these interactions on
protein bioactivity and bioavailability are critical to rationally optimizing protein
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encapsulation conditions and successfully implementing photocurable hydrogels as protein
delivery devices.
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CHAPTER FOUR
ENHANCED PROTEIN DELIVERY FROM PHOTOPOLYMERIZED HYDROGELS
USING A PSEUDOSPECIFIC METAL CHELATING LIGAND
(As appearing in Pharmaceutical Research 2006(23):614-622)
Abstract
Purpose. This study was conducted to investigate the cause of incomplete protein release
from photopolymerized poly(ethylene glycol) (PEG) hydrogels and verify the proteinprotection mechanism provided by iminodiacetic acid (IDA). Methods. The in vitro release
of bovine serum albumin (BSA) from PEG hydrogels prepared under different conditions
was studied. Photoinitiator and initial protein concentrations were varied as well as the
addition of IDA and metal ions. Protein immobilization within the nondegradable networks
via freeradical reaction was demonstrated by gel electrophoresis. Results. Protein release
efficiency was shown to be dependent on photoinitiator and initial protein concentration.
Gel electrophoresis results revealed immobilization of protein to the polymer network and
further indicated the detrimental role of free radicals in lowering protein-release efficiency.
Adding IDA to the prepolymer solution enhanced total protein release from the
subsequently photopolymerized network in a dose-dependent manner. The addition of metal
ions including Cu2+, Zn2+, and Ni2+ further increased BSA release efficiency. Agreement
between the protein release data and theoretical model predictions accounting for reversible
protein-IDA binding further validated the protection effect provided by IDA and IDAtransition metal complexes. Conclusions. The protection effect described in this study
offers a novel strategy for increasing the delivery efficiencies of many therapeutically valuable
proteins.
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4.1 Introduction
Controlled release of bioactive proteins is becoming attractive for disease treatments
requiring extended therapeutic effects. Injectable depots of human growth hormone (hGH),
for example, are administered in both adults and children to treat chronic growth hormone
deficiency [1], whereas slow-acting formulations of insulin are used to prevent hyperglycemia
in patients suffering from type I or type II diabetes. Differing from synthetic drugs with
small molecular weights, proteins have complex three-dimensional structures and
characteristics that provide added challenges for their effective delivery. The correct
structural folding determines the bioactivity of a protein and its therapeutic efficiency [2] and
therefore must be maintained. Furthermore, environmental factors such as pH, temperature,
and solvent composition can have profound effects on the physical stability of a protein [3].
Poly(ethylene glycol) (PEG) hydrogels are excellent carriers for protein delivery
because of their high hydrophilicity and aqueous gel-forming environments that help to
retain protein stability and bioactivity [4]. Furthermore, by altering the composition and the
degree of cross-linking, one can readily control the release rate of protein drugs from PEG
hydrogels [5]. Another advantage of PEG hydrogels is that protein encapsulation and
network formation can be achieved simultaneously via in situ photopolymerization [6]. This
provides a convenient and efficient method for loading high concentrations of proteins for
subsequent controlled release. The photocuring process is fast, mild, and can be performed
under room temperature in aqueous solution. Moreover, spatial and temporal control of the
photopolymerization enables hydrogels fulfilling specific physicochemical requirements to be
fabricated. Photopolymerization of hydrogels has been applied in tissue engineering [7-11] as
well as protein [12-14] and gene delivery [15-17].
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The main disadvantage of photopolymerizations comes from the necessary
production of highly reactive free radicals that facilitate network polymerization and crosslinking. These free radicals can also induce side reactions between encapsulated protein or
DNA and polymer chains during network formation. Quick et al. [15-17] used
photopolymerized hydrogels for DNA encapsulation and delivery. They showed that
without the presence of monomer, free radicals attack and damage DNA molecules.
Through the use of vitamin C, a radical scavenger, and protamine sulfate, a transfection
agent, they were able to preserve the structural integrity of encapsulated DNA [15]. These
studies suggest that free radicals are responsible for the reduced amount of DNA delivery.
Similar to the DNA damage caused by free radicals, proteins are susceptible to
undesirable reactions during polymer network formation that limit protein bioavailability.
Research has been conducted in the development of suitable polymeric matrices for protein
delivery based on several chemistries including poly(lactide-co-glycolide) (PLGA) [18,19],
poly(anhydride) [20], and poly(ethylene glycol) [4]. However, proteins may still be unstable in
these synthetic polymeric matrices because of physical or chemical interactions with the
encapsulating network or because of physical or chemical stresses experienced by the protein
during matrix fabrication and protein encapsulation. Previous studies focused on PLGA
delivery systems show that proper protein stabilization strategies are needed to increase the
delivery efficiency and bioactivity of encapsulated proteins [21-28]. However, a protein
stabilization strategy to overcome free-radical-induced protein-polymer reactions has not
been discovered. Reactions with free radicals can reduce the bioactivity and bioavailability of
the encapsulated protein. The decreased total protein delivery is attributable to protein
denaturation, aggregation, or conjugation to the polymer network.
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It is well known that recombinant proteins with polyhistidine tags on their N- or Cterminals can be easily purified by using immobilized metal ion chelating affinity
chromatography (IMAC) [29-31]. It has been shown that histidine residues offer the
strongest interaction with chelators such as nitrolotriacetic acid (NTA) [32-35] or
iminodiacetic acid (IDA) [36-38] in the presence of divalent transition metal ions including
Cu2+ and Ni2+. In particular, the three-amino-acid sequence Asp-Ala-His on the N terminus
of bovine serum albumin (BSA) is the strongest binding site for copper ions [39-42]. The
strong binding between BSA and the chelator-metal ion complex is associated with the
deprotonated Asp-Ala [43]. We hypothesize that the same mechanism is responsible for the
reaction between protein and the monomeric or polymeric free radicals during
photopolymerization. Therefore, when highly reactive free radicals are generated from
photoinitiators, reactions with the deprotonated amide on BSA may occur and form proteinpolymer conjugates, which result in permanent, irreversible changes to the protein chemistry,
structure, and bioavailability.
To increase the delivery efficiency of BSA from photopolymerized networks, the
factors affecting total protein release from nondegradable PEG hydrogels are evaluated as
part of this study. A strategy for protecting BSA from freeradical reaction during polymer
network formation and protein encapsulation is proposed by adding a known proteinbinding ligand, IDA, to the prepolymer solution. BSA-IDA binding should minimize the
exposure of highly reactive N-terminal residues of BSA to the free radicals generated during
hydrogel formation. BSA was chosen because of its known affinity to both IDA and IDAmetal ion complexes. Nondegradable PEG hydrogels are used to eliminate any release due to
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gel degradation. A theoretical model for estimating total protein release efficiency is derived
based on the equilibrium dissociation constant (Kd) of the protein-IDA complex.
4.2 Materials and Methods
4.2.1 Formation of protein-loaded PEG hydrogel
PEG diacrylates (PEGDA) were synthesized by reacting linear 3.4 kDa PEG (SigmaAldrich) with acryloyl chloride (Sigma-Aldrich) as described elsewhere [44]. PEG hydrogels
were formed via solution photopolymerization of PEGDA monomers. Briefly, PEGDA
macromer was dissolved in 50mM, pH 7.4 phosphate buffered solution (PBS) to a
concentration of 10 wt%. Required stoichiometric amounts of BSA (Sigma-Aldrich), IDA
(Fisher Scientific), and metal ions including cupric sulfate pentahydrate, zinc sulfate
heptahydrate, or nickel sulfate hexahydrate (Fisher Scientific) were mixed with PEGDA
precursor solutions. Prior to photopolymerization, Irgacure 2959 (I-2959), a photoinitiator,
was also added at the desired concentration. 50µl of the mixed precursor solution was
injected between glass slides separated by 0.8mm Teflon spacers and was exposed to a 100W UV lamp (BLACK-RAY®) with a maximum intensity of 8.4 mW/cm2 at 365nm for a
total of 20 minutes.
4.2.2 In vitro protein release
PEG hydrogels (weighted ~50mg) loaded with BSA, with or without chelating ligands,
were placed into a 5mL of pH 7.4 PBS for in vitro protein release at 37°C. At specified time
intervals, 200 µl supernatant solutions were sampled and replaced with an equal amount of
fresh PBS. The cumulative percent of protein released was quantified by a fluorescamine
assay.

Briefly, fluorescamine (Sigma-Aldrich) was dissolved in acetone to a final

concentration of 3 mg/ml. 150 µl of sample solution was mixed with 50 µl of fluorescamine
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solution for fluorescence quantification at an excitation wavelength of 395 nm and an
emission wavelength of 475 nm using a micro-plate reader (Spectramax GeminiEM,
Molecular Devices). Protein concentrations in measured samples were quantified using the
linear portion of a standard fluorescence curve constructed from solutions of known
concentrations.
4.2.3 Non-Reducing SDS-PAGE experiments
The effect of free-radical induced BSA immobilization to PEG monomers was
examined by SDS-PAGE. Linear 3.0 kDa PEG monoacrylate (PEGMA) was used to
replace PEG3400 diacrylate to prevent photocrosslinking and gel formation during
photopolymerization of samples. The amount of PEGMA used in these experiments was
calculated based on the same concentration of acrylate bonds present during hydrogel
formation and protein encapsulation. Varying amounts of IDA or IDA-Cu2+ complex were
added.

The samples prepared for SDS-PAGE were loaded without any denaturation

treatments so that any changes in the molecular weight or conformation of the BSA
molecules can be detected.
4.2.4 Swelling ratio measurements
The swelling ratios of PEG hydrogels were measured to characterize the gel crosslinking density. After photopolymerization, gels were placed into an excess amount of pH
7.4 PBS for swelling. Gels were allowed to swell for 2 days to reach equilibrium and then
dried completely under reduced pressure at room temperature. Gel weights before and after
drying were taken and the mass swelling ratios (Q) were determined by the following
equation:
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Swelling Ratio (Q) =

Swollen Weight
Dried Weight

4.2.5 Theoretical model of protein release efficiency
The affinity between BSA and metal-ion charged ligands such as iminodiacetic acid is
well documented [36]. The binding of IDA to BSA is believed to reduce the proteinpolymer conjugation caused by free radicals produced during network formation and thus
increase the total amount of protein released from PEG hydrogels.

In the model

development, two assumptions were made: (1) BSA has only a single binding site for IDACu2+, and (2) BSA is released in a non-aggregated state. The shielding effects provided by
IDA and various IDA-metal ion complexes were modeled by assuming a reversible
association between the two components given by:
Kd
Protein + Ligand ←→
Protein ⋅ Ligand Complex

(1)

The dissociation constant (Kd) of the protein-ligand interaction can be expressed as the
following equation:
Kd =

[ P ][ L] ([ P ]0 − x)([ L]0 − x )
=
[ P ⋅ L]
x

(2)

Where [P]0 and [L]0 are the initial concentrations of protein and ligand in the precursor
solution and x is the concentration of associated protein, ligand or protein-ligand complex.
The dissociation constants for BSA-IDA and BSA-IDA-Cu2+ are 0.4 and 0.0082 mM
[43], respectively. By knowing Kd, Equation (2) can be used to determine x / [P]0, the
fraction of protein bound to the ligand at equilibrium, for any combination of [P]0 and [L]0.
Increasing the ligand-protein ratio or decreasing Kd shifts the equilibrium such that a greater
fraction of protein is present in the bound or “protected” form.
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Furthermore, total release (TR) is defined as the percentage of protein released after an
infinite amount of time compared to the amount initially present in the gel and can be
expressed as:

TR =



[ P ]0 − i ([ P]0 − x)
ixK d
[ P]
× 100% =
× 100% = 1 −
 × 100%
[ P] 0
[ P]0
 ([ L]0 − x)[ P ]0 

(3)

Where i is the fraction of immobilized protein obtained when no ligand is present during gel
formation. i is obtained by experimentally measuring total protein release (TR) when [L]0 = 0
and is equivalent to (100% - TR) under these conditions. Therefore i accounts for any nonspecific adsorption of protein to the polymer network as well as the presence of any
aggregated protein that cannot be released. All other parameters needed to solve Equation
(3) are determined a priori based on ligand selection and composition of the gel precursor
solution.
4.3 Results and Discussion
4.3.1 Photoinitiator effects on BSA total release
Several critical factors lead to incomplete release of proteins encapsulated during
hydrogel photocuring. These factors can be either directly or indirectly related to the freeradical induced crosslinking in the hydrogels. Under UV exposure, free radicals generated
from photoinitiators propagate through the vinyl bonds on di-acrylated PEG molecules and
form cross-linked hydrogels. However, if other reactive sites on protein surfaces are present
during photopolymerization, free radicals will also propagate through these sites. Although
the exact mechanisms of interaction between these free radicals and encapsulated proteins
remains unresolved and most likely varies dramatically with protein surface chemistry, we
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hypothesize that these interactions lead to the irreversible immobilization of proteins within
the hydrogel networks.
The most apparent variable affecting free radical concentration is the photoinitiator
concentration. Excessive amounts of free radicals generated from photoinitiators play a
critical role in limiting the bioactivity and bioavailability of encapsulated objects such as
DNA, proteins and cells.

As shown in Figure 4.1, incomplete release of BSA from

photocured gels is observed at every photoinitiator (I-2959) concentration.

As higher

photoinitiator concentrations produce higher concentrations of free radicals during UV
irradiation, a greater number of undesirable proteinYradical interactions and a lower total
release of BSA is expected as I-2959 concentration increases. This trend is confirmed by the
experimental results in Figure 4.1, which show total release of BSA decreases from 42 % to
21 % after 24 hours as the concentration of I-2959 is increased from 0.2 wt% to 1.0 wt%.
The decrease in BSA release with an increase in photoinitiator concentration cannot
entirely be attributed to changes in gel crosslinking density. The hydrogel mass swelling ratio
decreases slightly and reaches a plateau with increasing initiator concentration (7.43 ± 0.16,
6.64 ± 0.28, and 6.75 ± 0.34 respectively for hydrogels cured with 0.2 %, 0.5 %, and 1 %
photoinitiator). Furthermore, based on the release profiles, the diffusivities of releasable
BSA within the gels of varying initiator concentration were found to be identical (~1.0×10-7
cm2/sec). These results suggest that the decrease in the total release of BSA with initiator
concentration is due to increased protein-polymer coupling rather than changes in gel
swelling.
To further investigate the cause of incomplete release, the total release of BSA from
photopolymerized PEG hydrogels loaded with different concentrations of BSA was studied.
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The results in Figure 4.2 indicate that total release of BSA is also a function of initial protein
concentration. When BSA is initially loaded at 15 wt%, over 80% of the protein is released
within 24 hours. However, less than 50% of the protein is released when BSA is loaded at 5
wt%. Therefore, the absolute amount of released protein increases with initial protein
concentration. It is interesting to note, however, that the amount of unreleased protein
within each of these networks remains relatively constant as can be seen in Table 4.1. This
observation is attributed to the fact that all of these networks were photopolymerized under
identical conditions (photoinitiator concentration, light intensity, etc.) and thus should
present the same concentration of free radicals to encapsulated BSA during hydrogel
formation.

Figure 4.1 The effect of photoinitiator concentration on BSA release. BSA (5 wt %)
released from 10 wt% PEGDA hydrogels polymerized with 0.2 wt % (), 0.5 wt % () and
1.0 wt % (▲) of photoinitiator (I-2959). (n = 3, mean ± SD)
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Figure 4.2 The effect of BSA initial loading concentration on its total release. Different
amounts of BSA (wt %) were loaded into 10 wt% PEGDA gels. (n = 3, mean ± SD.
Concentration of I-2959: 0.2 wt%)
Table 4.1 Total amount of released and unreleased BSA from photopolymerized PEG
networks as a function of protein loading. (n = 3, mean ± SD)
Concentration of
Loading BSA (wt %)

Amount of
loaded BSA
(mg)

Total release of
BSA (%)

Amount of
unreleased BSA
(mg)

5

10

51 ± 3.0

4.9 ± 0.3

6

12

55 ± 0.7

5.3 ± 0.1

8

16

73 ± 1.4

4.3 ± 0.2

10

20

80 ± 1.0

4.1 ± 0.2

15

30

85 ± 5.0

4.6 ± 1.5
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4.3.2 BSA-polymer conjugation
The structural integrity of BSA was examined by SDS-PAGE to demonstrate the
coupling of BSA with PEG macromers via free radicals during photopolymerization (Figure
4.3).

The rationale for choosing SDS-PAGE instead of other molecular weight

determination techniques such as MALDI-TOF is that the polymerization process yields
protein-polymer conjugates with a wide distribution of molecular weights due to the
polydispersity of the polymer chains. PEG monoacrylate (PEGMA, MW = 3000 Da) is
used instead of PEGDA to prevent gel formation and allow sample elution on the PAGE
gel.
4.3.2.1 Photoinitiator induced BSA-polymer conjugation
As shown in Figure 4.3a, when BSA and PEGMA are subjected to free-radical
induced photopolymerization, broad distributions of higher molecular weight products were
produced, suggesting that a large portion of the encapsulated BSA is covalently bound to
polymerized oligomers of PEG. This results in higher molecular weight products (Lane 5 –
7) compared to native BSA (Lane 1). When higher concentrations of I-2959 were added to
the protein-polymer mixture and subjected to UV exposure, the fraction of unmodified BSA
monomer was decreased. Assuming any modified protein would not be released from a
crosslinked polymer due to its immobilization onto the network this result agrees with the
release trends of Figure 4.1 that demonstrate decreased BSA release with increasing
photoinitiator concentration.

This phenomenon clearly demonstrates the significant

structural modification of BSA that occurs only in the combined presence of photoinitiator,
monomer, and UV light.
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Figure 4.3 The determination of BSA structural integrity using SDS-PAGE. A significant
amount of higher molecular weight products appear when BSA is mixed with PEG3000MA
and photoinitiator (I-2959) and exposed to 365nm UV light for 20 minutes. (a) Lanes: (1)
Native BSA; (2) 5 wt% BSA, 0.2 wt% I-2959 and PEG3000MA without UV exposure; (3) 5
wt% BSA and 0.2 wt% I-2959 subjected to UV exposure; (4) 5 wt% BSA and PEG3000MA
subjected to UV exposure; (5) 5 wt% BSA, PEG3000MA and 0.2 wt% I-2959 subjected to
UV exposure; (6) BSA, PEG3000MA and 1.0 wt% I-2959 subjected to UV exposure; (7)
BSA, PEG3000MA and 4.0 wt% I-2959 subjected to UV exposure. (b) Lanes: (1) Native
BSA; (2) 5 wt% BSA, PEG3000MA and 0.2 wt% I-2959 subjected to UV exposure; (3) 5
wt% BSA and molar equivalent of IDA, PEG3000MA, and 0.2 wt% I-2959 subjected to UV
exposure; (4) 5 wt% BSA and molar equivalent of IDA-Cu2+, PEG3000MA, and 0.2 wt% I2959 subjected to UV exposure.
4.3.2.2 Polydispersity of BSA-polymer conjugates
The broad distributions of BSA molecular weight products that occur during freeradical photopolymerization (Lanes 5-7 in Figure 4.3a) are due to the high polydispersity
(PDI) of the conjugated PEG chains.

BSA was conjugated onto uncrosslinked PEG

molecules that polymerize with a high polydispersity, leading to a broad distribution of high
molecular weight products.

Therefore, no specific bands at molecular weights above
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monomeric BSA (MW ~60kD) are seen. Without UV exposure, BSA remains unmodified
with the presence of I-2959 and PEGMA (Lane 2). Also, when BSA and I-2959 (Lane 3) or
BSA and PEGMA (Lane 4) were subjected to UV exposure, no molecular weight
modification was found in either case. This suggests that all three components are required
for free-radical induced protein-polymer conjugation to occur.
4.3.2.3 BSA aggregates
As shown in Lane 1, an extremely small amount of BSA dimers, trimers, and
aggregates appear above monomeric BSA (120kD, 180kD, etc). Furthermore, Figure 2
indicates that the total BSA release increases with initial BSA concentration. Combining
these results with Figure 4.3a suggest that aggregates do not contribute to the fraction of
unreleased BSA in the hydrogel systems studied. The results in Lanes 5-7 reveal that even
relatively stable proteins such as BSA are modified under standard photopolymerization
reaction conditions. Therefore, proper protein stabilization strategies are needed when
encapsulating proteins into photopolymerized hydrogels.
4.3.2.4 Ligand-mediated protein protection
The ligand-mediated protection effect of BSA protein is directly demonstrated in
Figure 4.3b. The addition of IDA (Lane 3) or IDA-Cu2+ complex (Lane 4) prevents the
polymerization of BSA molecules with PEG3000MA macromers as indicated by the absence
of any significant molecular weight modification. This result qualitatively supports our
hypothesis of IDA-mediated protein protection.
4.3.3 Effects of metal chelating-ligand on BSA total release
Enhanced protein delivery is achieved by adding IDA to the prepolymer solution
prior to photopolymerization. As shown in Figure 4.4, the total release of BSA is increased

125

from about 40% to 60% when IDA is added in a molar ratio of 0.5 (to BSA). Total BSA
release is further increased to almost 70% when the IDA to BSA molar ratio is increased to
1.0.

Figure 4.4 The effect of IDA concentration on BSA total release. BSA (5 wt %) was mixed
with PEGDA (10 wt %) and IDA in molar ratios (IDA:BSA) of 1 (▲), 0.5 (), and 0 () in
the prepolymer solution and released from PEGDA hydrogels. (n = 3, mean ± SD.
Concentration of I-2959: 0.2 wt%)
Adding transition metal ions such as Cu2+ can further increase the affinity between
BSA and IDA. The coupling of Cu2+ to metal-ion chelators like IDA has been well studied
in the field of immobilized metal ion chelating affinity chromatography (IMAC).

The

dissociation constant of IDA-Cu2+ and BSA coupling is 0.0082mM [45] compared to a value
of 0.4mM for the coupling of IDA and BSA. In another words, IDA-Cu2+ has a greater
affinity for BSA than IDA alone. As shown in Figure 4.5, while the BSA to IDA molar
ratio is held constant at 1, total BSA release increases as more Cu2+ ions are added. When
Cu2+ is added in a molar ratio of one, the total release of BSA is increased to almost 100 %.
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No significant increase in total release is observed when Cu2+ is added to the prepolymer
solution without IDA present (data not shown).

Figure 4.5 The effect of Cu2+ concentration on BSA total release. BSA (5 wt %) was mixed
with PEGDA (10 wt %), IDA and different amounts of Cu2+ ions. Molar ratio of IDA to
BSA is held at 1. Molar ratios of Cu2+ ions to BSA are 1 (), 0.5 (), and 0 (▲). (n = 3,
mean ± SD. Concentration of I-2959: 0.2 wt%)

4.3.4 Metal-ion effects on BSA total release
From IMAC studies it is well known that the affinity between protein and ligand can
be varied by using different transition-metal ions [46-48]. For example, Cu2+ provides the
strongest binding affinity to BSA, followed by Ni2+ and Zn2+ [48]. Ideally, at the same IDA
concentration, BSA release efficiency should increase with protein-ligand binding strength.
As shown in Figure 4.6, the total release of BSA increases when Zn2+ or Ni2+ are added
along with IDA, compared to adding IDA alone. Furthermore, total release is even higher
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when Cu2+ ions are added and approaches 100%. Total release of BSA from all ligandcontaining systems is significantly higher than when no ligand is present.
Figure 4.6 also shows the mass swelling ratio of the ligand-containing gels. The
swelling ratio of all gels remains relatively constant and suggests that the crosslinking density
of the hydrogel is not affected by the addition of IDA or any metal ions. Thus the observed,
enhanced release of BSA is solely due to the association of BSA with IDA and not changes
in gel crosslinking density and protein diffusivity.

Figure 4.6 The effect of different metal ions on total BSA release and hydrogel swelling.
BSA (5 wt %) was mixed with equal moles of IDA and metal ions in 10 wt % PEGDA
prepolymer solutions. The swelling ratios of each nondegradable gel were measured after
protein release. (n = 3, mean ± SD. Concentration of I-2959: 0.2 wt%; * and ** indicate
statistical significance with P<0.05)
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The data in Figure 4.6 further demonstrate a direct correlation between the extent of
protein-ligand binding and protein release efficiency. The results presented in Figure 4.3
demonstrate an inverse correlation between the extent of protein-ligand binding and the
extent of protein-polymer coupling. Taken together, the results in Figure 4.3 and 4.6
support the conclusion that BSA is protected from adverse side reactions with free radicals
during gel formation by complexing with the small-molecule IDA ligand. The higher the
fraction of protein bound to the ligand, the greater the observed increase in release efficiency.
Although the addition of metal ions can be beneficial to the therapeutic efficacy when
released in vitro, a potential problem behind this approach is the toxicity of metal ions in vivo.
Nonetheless, the increased amount of protein delivery proved by this research does open an
avenue for enhancing protein stability during hydrogel formation and protein encapsulation.
4.3.5 Prediction of reversible IDA-BSA binding
A theoretical prediction of the extent of BSA-IDA-Cu2+ association based on the
binding equilibrium shown in Equations (1) and (2) is presented in Figure 4.7.

At

equilibrium, binding between BSA and the IDA-Cu2+ complex is considered reversible and is
determined, in part, by the Kd value and total BSA concentration. The degree of association
decreases with Kd and increases with BSA concentration. BSA is far more concentrated in
the prepolymer solution than in the swelled gel or the surrounding media. Therefore,
compared to the protein-rich hydrogel (50 µl), the relatively protein and ligand-free
supernatant solution (5 ml) can be treated as a “sink” where the BSA concentration is
dramatically lower than in the gel. In Figure 4.7, the solid curve represents the theoretical
extent of BSA-IDA-Cu2+ association present in a 5 wt % BSA prepolymer solution at
different BSA-IDA-Cu2+ molar ratios (Kd = 0.0082 mM). The extent of BSA-IDA-Cu2+
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association is approximately 90% when a one to one molar ratio of IDA-Cu2+ to BSA is used.
However, when BSA-IDA-Cu2+ complex is released from the hydrogel, its bulk
concentration rapidly decreases. For example, under these same conditions, a drop in BSA
concentration from 5% (solid curve) to 0.01% (dotted curve) also lowers the degree of
association from 90% to only 13%. In other words, most of the released BSA will dissociate
from the BSA-IDA-Cu2+ complex due to its diluted concentration and make BSA available
to its target in its uncomplexed, native form. The general trends in BSA-(IDA-Cu2+) binding
shown in Figure 4.7 can be readily extrapolated to other protein-ligands pairs.

Figure 4.7 Predicted extent of association between BSA and IDA-Cu2+ complex
(Kd=0.0082mM) as a function of total protein concentration. Solid curve: 5wt% BSA;
Dashed curve: 0.5wt% BSA; Dotted curve: 0.01wt% BSA. The extent of association is
defined as the molar ratio of IDA-Cu2+-BSA complex to unbounded BSA.
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4.3.6 Prediction of BSA total release
To further understand the mechanism of BSA protection provided by IDA-metal ion
complexes during free-radical polymerization, a theoretical model was developed to predict
total BSA release from gels where IDA-based ligands with different protein affinities are
incorporated in the prepolymer solutions at various concentrations. The total release of BSA
can be modeled by using known dissociation constant values and a single experimentally
determined variable, the fraction of protein nonspecifically immobilized in the hydrogel (i).
Figure 4.8 illustrates the ability of this model to predict total BSA release from systems
exhibiting different protein affinities as well as ligand-protein ratios. The agreement between
predictions of this theoretical model and experimental BSA release data shown in Figure 4.8
support the proposed mechanism of BSA immobilization and IDA-mediated protection
within the photopolymerized networks.
Once validated, the developed protein-ligand binding model can be used to explain
experimental observations. As shown in Figure 4.8, the total release of BSA depends upon
the initial BSA loading concentration as well as the ligand-protein ratio. Recall from Figure
4.2, BSA total release increases with the protein loading concentration. Therefore, i values
were obtained from the experimentally determined total BSA release at 10 wt% and 5 wt%
in Figure 4.2 and used to predict release at all ligand-protein ratios (dashed and solid lines)
using Equation (3).
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Figure 4.8 Comparison of experimentally determined total BSA release (symbols) with
predictions of a theoretical model (curves). Release data obtained with various molar ratios
of ligand to protein are used to verify the accuracy of the model. Ligand-protein ratios,
protein loading concentration, and ligand-protein affinity all affect total BSA release. Release
data and predictions from three systems are compared: (a) IDA-Cu2+ with Kd = 0.0082mM,
[BSA]0 = 10 wt% ( and dotted curve); (b) IDA- Cu2+ with Kd = 0.0082mM, [BSA]0 = 5
wt% (▲ and dashed curve); and (c) IDA alone with Kd = 0.4mM and [BSA]0 = 5 wt% (∆
and solid curve). (n = 3, mean ± SD. Concentration of I-2959: 0.2 wt%)
From Equation (3) it can be understood that the relatively weak binding affinity
between BSA and IDA leading to low total BSA release can be countered by increasing IDA
concentration. The increased ligand concentration forces the free protein into the associated
protein-ligand state and therefore increases its degree of protection and total release. As
shown by the solid line (model prediction) and open triangles (experimental data) in Figure
4.8, when the molar ratio of IDA to BSA is increased to a ratio of 4:1, the total release of
BSA is increased to almost 90% compared to only 45% when no IDA is used. As predicted
by the model, further increasing the IDA concentration to a molar ratio of 10 does not
significantly increase the total release of BSA (data not shown).
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Total release of BSA also increases with initial BSA loading concentration. As shown
by the dotted (10 wt% loaded BSA) and dashed (5 wt% loaded BSA) lines in Figure 4.8, the
more BSA loaded into the prepolymer solution, the greater its total fractional release.
Additionally, the model predicts differences in total BSA release when a variety of proteinbinding ligands are utilized. For example, incorporating the IDA-Cu2+ ligand into a 5 wt%
BSA prepolymer solution leads to higher total BSA release values than incorporation of IDA
alone at similar ligand-protein ratios (solid triangles versus open triangles). This increase is
due to the higher affinity of the IDA-Cu2+ complex for BSA compared to IDA. Release data
from systems incorporating high concentrations of IDA-Cu2+ ligand are not obtained due to
the fact that high Cu2+ concentrations prevented gel formation.
Though the exact mechanism in which IDA-Cu2+ complex provides a protection
effect on BSA during polymer network formation remains undetermined, we speculate this
protection effect is due to the fact that the copper-binding site on BSA also acts as a reactive
center for protein-polymer conjugation as discussed previously. Therefore, when IDA-Cu2+
complex is added, immobilization of BSA to the crosslinked polymer network is reduced
which leads to an increased amount of BSA release. An alternative hypothesis is that
binding of the IDA or IDA-Cu2+ complex to BSA leads to a change in protein conformation
that hinders accessibility of free radicals to any number of reactive sites on the BSA surface.
Although the model can accurately predict the total release of BSA in the presence of
IDA or IDA-Cu2+ complex, there are limitations to the model predictions.. The model was
developed under the assumption of a single IDA-Cu2+ binding site per BSA molecule. The
binding equilibrium shown in Equations (1) and (2) is valid only when the single binding site
assumption holds. Some research suggests, however, that a second, weaker copper binding

133

site exists on BSA [43]. It is also assumed that the BSA is present in a non-aggregated state.
If BSA forms aggregates under certain unfavorable conditions, which is not the case in this
study as shown in Figure 4.3, the predicted binding equilibrium based on total protein
concentration will not be valid. In the present model, purely empirical values for the model
parameter i were used to generate the theoretical release curves only applicable to the system
analyzed in this study. The amount of protein nonspecifically immobilized in the polymer
networks will vary with external conditions such as the photopolymerization reaction
parameters as well as inherent biochemical properties such as the extent of protein-polymer
interaction. A method or model is needed to predict the amount of protein immobilized
under specific photopolymerization conditions in the absence of protein-binding ligand.
This is possible only when the exact mechanism of protein-free radical conjugation is
resolved. Nevertheless, the results presented here demonstrate a possible mechanism of
protein-polymer interaction and provide a solution that minimizes this undesired interaction.
4.4 Conclusions
The release efficiency of BSA from photopolymerized PEG hydrogels is increased by
incorporating a soluble transition-metal chelator (iminodiacetic acid) into the prepolymer
solutions. The significance of this strategy is that the protein protection effect is achieved by
simply adding IDA and metal ions while maintaining the advantages provided by in situ
photopolymerization and simultaneous protein encapsulation. The undesired protein-radical
interactions commonly observed during PEG hydrogel formation and the reduction in total
protein release were minimized via ligand incorporation. Specifically, BSA release efficiency
was enhanced by adding IDA and different transition-metal ions to the prepolymer solution.
Although BSA is used in this study, it is hypothesized that similar protection strategies can
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be applied to other therapeutically valuable proteins that display an affinity for IDA. This
includes proteins exhibiting transition-metal binding domains such as hepatocyte growth
factor (HGF) or human growth hormone (hGH) and recombinant proteins engineered with
histidine tags [49]. Furthermore, specialized ligands other than IDA can be engineered to
display affinities for specific proteins of interest and thereby increase their release efficiency
in a manner similar to that seen with BSA.
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CHAPTER FIVE
METAL-CHELATING AFFINITY HYDROGELS FOR SUSTAINED PROTEIN
RELEASE
(As appearing in Journal of Biomedical Materials Research A 2007, in press)
Abstract
Affinity hydrogels based on poly(ethylene glycol) diacrylate (PEGDA) and a metalion-chelating ligand, glycidyl methacrylate-iminodiacetic acid (GMIDA), have been
developed to systematically decrease protein release rates from hydrophilic tissue engineering
scaffolds formed in situ. In the current work, tunable and sustained release of a model
protein, hexa-histidine tagged green fluorescence protein (hisGFP), is accomplished by
judiciously increasing ligand:protein ratio or replacing low-affinity nickel ions with high
affinity copper ions. Agreement between theoretical predictions of a reaction-diffusion
model and experimental measurements confirm metal-ion-mediated sustained protein release
from these affinity hydrogels is governed by equilibrium protein-ligand binding affinity
(dissociation constant, Kd) as well as protein-ligand dissociation kinetics (protein debinding
rate constant, koff). The former dictates the release rate in the early period of protein release
while the latter determines the long-term sustained release effect. While metal-ion affinity
binding has been widely used for various purposes including protein purification and surface
patterning, this is the first report describing its application in systematically controlling
protein release from hydrophilic PEG networks suitable for cell encapsulation. By using
ligands with proper binding kinetic constants (Kd and koff), localized protein delivery can be
sustained over clinically relevant timescales while maintaining a favorable environment for
cell encapsulation and viability.
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5.1 Introduction
The development of affinity hydrogels is becoming increasingly important due to the
emerging field of tissue engineering.

Spatially and temporally controlled delivery of

biomacromolecules such as growth factors and cytokines from artificial scaffolds is a critical
technique for the successful implementation of tissue engineering strategies as these
biomolecules are known to stimulate cell growth and tissue regeneration after injury [1-3].
Synthetic hydrogels are excellent candidates for delivering proteins and peptides due to
highly controllable and relatively mild network fabrication conditions compared to
hydrophobic polymers [4]. However, one of the limitations facing hydrogel-based protein
delivery systems is their rapid release rate due to high water content and gel permeability.
Protein release rates can be decreased by substantially increasing the hydrogel crosslinking
density [5, 6].

However, this results in decreased amounts of loaded protein as well as

decreased matrix hydrophilicity.

Therefore, efforts have been directed towards the

development of affinity hydrogels to systematically decrease release rates of therapeutically
relevant proteins via mild and reversible protein-matrix binding.

This unique strategy

maintains hydrogel properties that are advantageous for tissue engineering and protein
delivery applications.
Inspired by the reversible sequestering of proteins to the extracellular matrix (ECM),
researchers have previously developed biomimetic hydrogel carriers bearing reversible
binding capacities to decrease release rates of target protein therapeutics [7-9]. ECM is full
of anionic polysaccharides including hyaluronic acid and proteoglycans. The abundance of
negative charges on the native matrix modulates release of cationic growth factors and also
protects them from proteolytic degradation. For example, heparin, a highly sulfated
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glycosaminoglycan (GAG), serves as a growth factor depot in vivo owing to its electrostatic
affinity to various cationic growth factors such as nerve growth factor (NGF) and basic
fibroblast growth factor (bFGF) [10, 11]. Matrices containing passively adsorbed heparin
have been used as delivery depots to modulate release rates of these growth factors [12-16].
In addition to the physical adsorption of heparin, Sakiyama-Elbert and Hubbell developed
fibrin-based hydrogels containing affinity peptides for reversibly immobilizing heparin [7, 8].
The transiently-immobilized heparin acts as an intermediate component that binds to growth
factors and covalently-immobilized affinity peptides. These researchers showed that growth
factor release rates could be adjusted by incorporating peptides with different heparin
affinities. This system has been applied to the delivery of several growth factors including
NGF [7], basic fibroblast growth factor (bFGF) [8], and neurotrophin-3 (NT-3) [9].
Heparin can also be covalently immobilized within the gel network. Yamaguchi and
Kiick conjugated low molecular weight heparin (LMWH) onto multifunctional PEG
hydrogel network to bind and release bFGF in a sustained manner [17, 18]. Benoit and
Anseth copolymerized methacrylated heparin with dimethacrylated poly(ethylene glycol)
(PEGDMA) to form heparin-containing PEG hydrogels [19] for releasing bFGF and
stimulating hMSC adhesion, proliferation, and differentiation. Tae et al. also fabricated
heparin-containing affinity hydrogels [20] to deliver VEGF for several weeks with low initial
burst release.
While the development of heparin-based matrices for controlled protein release has
been substantial, there is considerable room for improvement in regards to material selection
and network fabrication. First, the electrostatic binding of growth factors to artificial
heparin-containing hydrogels can be weak and unstable in complex biological environments.
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In addition, to obtain significantly delayed growth factor release, an extremely excessive
amount of heparin is required to maintain effective growth factor binding [8, 9]. Multiple
releasable species further complicate growth factor release profiles and theoretical
predictions. Finally, physiological complications associated with the use of heparin include
serious side effects such as heparin-induced thrombocytopenia (HIT syndrome) [21].
In the current work we describe the development and characterization of an affinity
hydrogel system based on the well-established mechanism of metal-ion-chelation and
binding of histidine-tagged proteins [22, 23]. This binding mechanism is highly specific and
stable under a broad range of physiologically relevant conditions. In addition to their
widespread use in protein purification, matrix-immobilized metal-chelating moieties have
been used to fabricate stimuli-sensitive hydrogels [24], and functionalize organic and
inorganic surfaces [25, 26]. They have also been used to increase protein bioavailability
during photoencapsulation [27]. Although several hydrogel systems with metal-ion-chelating
capability have been developed and characterized previously [28-32], these systems were
primarily used for enhancing metal-ion uptake [28-30, 32, 33], protein absorption [30, 31], or
enzyme immobilization [34, 35]. Only a few studies have utilized these hydrogels to release
small molecular weight drugs based on the non-specific electrostatic interactions and pHresponsiveness of the hydrogels [36-39].
In this study, methacrylated iminodiacetic acid (GMIDA) was synthesized and
copolymerized with PEG-diacrylate (PEGDA) macromer to yield PEG-co-GMIDA
hydrogels. The affinity binding of GMIDA functionalities to a model recombinant protein,
hexa-histidine tagged green fluorescent protein (hisGFP), was mediated by divalent metal
ions such as nickel and copper. We demonstrate that hisGFP release rates can be readily
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controlled by judiciously adjusting GMIDA concentration or type of chelated metal ion.
Finally, a mathematical model accounting for protein diffusion and protein-ligand binding
kinetics is developed and shown to accurately predict protein release from these affinity
matrices. This is the first such model to successfully predict quantitative protein release
from affinity hydrogels.
5.2 Materials and Methods
5.2.1 Materials
Irgacure 2959 (2-Hydroxy-1-[4-(2-hydroxyethoxy) phenyl]-2-methyl-1-propanone; I2959) obtained from Ciba Specialty Chemicals was used as a photoinitiator. All other
chemicals were obtained from Sigma-Aldrich unless otherwise specified. pGFPuv6His
plasmid was a generous gift from Professor Marcus Textor and Eva Kuennemann from
ETH Zurich.
5.2.2 Synthesis of poly(ethylene glycol)-diacrylate (PEGDA)
PEG-diacrylate (PEGDA) was synthesized as previously described by Cruise et al. by
reacting PEG macromer with an average molecular weight of 3400 Da with acryloyl chloride
[40]. Briefly, measured amount of PEG was dried in toluene under N2 atmosphere then
reacted with 8 molar excess of acryloyl chloride for 4 hours at room temperature in dark.
The acrylated PEG was filtered through alumina to remove triethylamine-HCl complex.
Toluene was then removed from the product mixture under vacuum using a rotovap. To
obtain pure PEGDA, the crude product was dissolved in dichloromethane and precipitated
in chilled diethyl ether. The purified PEGDA was then filtered and dried under vacuum at
room temperature. A degree of acrylation above 95% was determined using 1H NMR.
5.2.3 Synthesis and characterization of methacrylated iminodiacetic acid
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Methacrylated iminodiacetic acid (GMIDA) was synthesized as shown in Scheme 5.1
following a previously established protocol [32]. Iminodiacetic acid (obtained from Fisher
Scientific) was dissolved in double distilled water and neutralized with two molar excess of
NaOH to keep acetic acid moieties from reacting with epoxy ring of glycidyl methacrylate.
With powerful stirring, an equimolar amount of GMA was added drop-wise to the IDA
disodium salt solution and allowed to react for one hour at 65°C. The product was then
purified by precipitating in acetone and dissolving in double-distilled H2O repeatedly. The
final product was obtained by drying under vacuum at 65°C. A 90% degree of IDA
methacrylation was determined by 1H NMR (Bruker 300MHz). The ability of GMIDA to
bind nickel ions was quantified by scanning the absorbance of GMIDA-nickel complex
solution with different molar ratios of GMIDA to nickel using a UV-Vis spectrophotometer
(µQuant, Biotek Instruments, Inc., USA).

Scheme 5.1 Reaction scheme of glycidyl methacrylate-iminodiacetic acid (GMIDA).
5.2.4 Expression and purification of hexa-histidine tagged green fluorescent protein
The hisGFP expression and purification process was modified according to a previous
report [26].
electroporation.

The plasmid (1 ng/µL) was transformed into MDS41E E. coli. by
The transformed E. coli. cells were expressed in DYT (double yeast

tryptone: 1% Bacto yeast extract, 1.6% Bacto tryptone, 0.5% NaCl) broth containing
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100µg/mL ampicillin to an optical density of 0.9 at 600nm at 37°C and then induced with
1mM IPTG (isopropyl-beta-D-thiogalactopyranoside). After induction, the temperature was
dropped to 25°C and the cells were allowed to grow for 18 hours. The cells were harvested
by centrifugation and re-suspended in 20mM, pH 8.0 Tris-HCl buffer containing 1mg/mL
lysozyme and 10µg/mL DNase at 4°C. The supernatant was collected by centrifuge at 4°C
(30min, 17000g). The purification of hisGFP was performed with QIAexpressionist® (Qiagen)
according to the manufacturer’s protocol. The hisGFP was obtained by dialysis against
10mM, pH8.0 HEPES buffer overnight and freeze-dried. The maximum excitation and
emission wavelengths (395nm and 510nm, respectively) of hisGFP were determined by a
full-scale scan using a microplate reader (Spectramax GeminiEM, Molecular Devices, CA,
USA).
5.2.5 Fabrication of PEG-co-GMIDA hydrogels
PEG-co-GMIDA affinity hydrogels containing proteins were fabricated in situ via
photopolymerization. Briefly, a 10wt% PEGDA macromer solution was produced by
dissolving the dry macromer in 10mM, pH8.0 HEPES buffer. Required amounts of GMIDA
monomer, metal ions, and hisGFP were added to the macromer solution. The mixed
protein-monomer solution was then incubated at 4°C for at least 30 minutes to allow
binding equilibrium to be obtained between hisGFP and metal ion-GMIDA complexes.
After incubation, photoinitiator (I-2959) was added at a final concentration of 0.2wt%. The
mixed prepolymer solution was then injected between two glass slides separated by 0.55mm
Teflon spacers. The assembled apparatus was then exposed to UV-light (365nm, 8mW/cm2)
for 8 minutes to form affinity hydrogels. The resulting gel was cut into 5mm×5mm
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rectangular pieces. After swelling, the surface area of the gel is approximately 1 cm2. The
selected UV exposure was sufficient for gel formation without affecting hisGFP
fluorescence.
5.2.6 Characterization of hydrogel swelling
The swelling ratios of the PEG-co-GMIDA affinity hydrogels were measured
gravimetrically. After photopolymerization, gels with different concentrations of GMIDA
were placed into an excess amount of PBS buffer solution at pH 7.4 and 37°C. Gels were
allowed to swell for 48 hours to reach equilibrium and then dried completely under reduced
pressure at room temperature. Gel weights before and after drying were taken and the mass
swelling ratios (Q) were determined by the following equation:
Swelling Ratio (Q) =

Swollen Weight
Dried Weight

5.2.7 Mathematical modeling of hisGFP release
A mathematical model was developed to predict hisGFP release and to identify key
parameters controlling protein release rates from affinity hydrogels. In its simplest case, the
reversible protein-ligand binding can be described as the following equation:
k on

Protein + Ligand ↔ Protein • Ligand
k off

(1)

where kon and koff are protein-ligand association and dissociation rate constants, respectively.
The equilibrium dissociation constant Kd is the ratio of koff to kon and is inversely proportional
to the affinity between protein and ligand. The initial protein-ligand binding equilibrium can
be described by the following equation:
Kd =

k off
k on

=
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[P ]eq [L ]eq
[PL ]eq

(2)

Here, [P]eq, [L]eq, and [PL]eq are the equilibrium concentrations of free protein, unbound
ligand, and protein-ligand complex (or bound ligand), respectively. Equation (2) dictates the
initial equilibrium binding of proteins to the immobilized ligands. It was assumed that the
protein-ligand binding reaction achieved equilibrium before protein release. The fraction of
bound and free protein can be readily calculated based on the known value of Kd as well as
the total amounts of protein and ligand initially loaded into the matrix. Mass balances for
each species described in Equation 1 are given as:

[P ]total = [P ]released + [P ] free + [P ]bound

(3)

[L]total = [L]unbound + [L]bound

(4)

[PL]total = [P ]bound = [L]bound

(5)

During the period of protein release, the concentrations of free protein, unbound
ligand and bound ligand within the gel constantly change. It was assumed that sink
conditions are maintained in the release medium and the release is one-dimensional owing to
the use of high aspect-ratio gel slabs in which edge effects are neglected. It is also assumed
that all ligand is immobilized in the network and the only diffusible species in the system is
free protein due to the non-degradable PEG-based hydrogels used. With these assumptions,
the following partial differential equations with proper initial and boundary conditions
describe the concentration changes of free protein [P], unbound ligand [L], and bound
protein-ligand [PL] during the period of protein release from the gel matrix:
∂[P ]
∂ 2 [P ]
= D0
-k on [P ][L ] + k off [PL ]
∂t
∂x

(6)

∂[L ] _
= k on [P ][L ] + k off [PL ]
∂t

(7)
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∂[PL ]
_
= k on [P ][L ] k off [PL ]
∂t

(8)

Initial and boundary conditions:

[P ]=[P ]eq @ t=0

(9)

[L]=[L]eq @ t=0

(10)

[PL ]=[PL ]eq @ t=0

(11)

[P]=0 @ x=δ

(12)

∂[P ]
=0 @ x=0
∂x

(13)

where D0 is the protein diffusivity within the crosslinked, nondegradable gel. δ is the halfthickness of the swollen hydrogel slab, x is the spatial coordinate in the gel perpendicular to
the gel surface (assuming one-dimensional release) and t is time. Equation 6 describes the
change in free protein concentration within the hydrogel due to both diffusion and reversible
ligand binding. When inert hydrogels are used (no ligand binding), Equation 6 can be
simplified to the well-known Fick’s second law of diffusion.
Equations (6) to (8) can be solved numerically using a finite-difference method
(Polymath 5.0 Software, Willimantic, CT) to obtain the time-dependent distributions of [P],
[L], and [PL] within the swollen hydrogel. After solving for these concentration distributions,
the fractional release of protein at any time can be obtained by the following equation:
x =δ

A
f release = 1 - 2 ×
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∫ [P]dx

x =0

P0

(14)

Here, frelease is the cumulative fraction of protein released from the hydrogel slab after a given
time, A is the surface area of the gel, and P0 is the initial amount of loaded protein. The
factor of 2 is due to the symmetry of the gel slab.
5.2.8 In vitro release of hisGFP
For in vitro protein release, PEG-co-GMIDA affinity hydrogels (~40 mg/gel)
containing 0.25 wt% hisGFP were placed in 10 mM, pH 8.0 HEPES buffer (3 mL) at 37°C
with constant stirring. 200 µL samples of the supernatant were taken at specified time points
and an equal amount of fresh buffer was added after sampling to maintain constant solution
volume. Total hisGFP release was quantified by fluorescence (Ex: 395 nm, Em: 510 nm)
using a microplate reader and interpolated to a standard curve. Fractional protein release was
obtained by dividing the total amount of hisGFP released up to a given time with the
maximum amount released. For release studies with different ligand to protein ratios,
different concentrations of GMIDA(Ni) ligand were added accordingly. GMIDA(Cu)
complex was used as the higher affinity ligand.
5.3 Results and Discussion
5.3.1 Synthesis and Characterization of GMIDA monomer
To fabricate affinity hydrogels, methacrylated iminodiacetic acid (GMIDA) was first
synthesized by reacting glycidyl methacrylate with iminodiacetic acid in basic aqueous
solution. The methacrylate bond of GMIDA facilitates its copolymerization into the
hydrogel network while the pendant iminodiacetic acid group acts as a metal-ion chelator
that binds to hexa-histidine tagged proteins with high and stable affinity [22, 23]. The
reaction between the epoxy ring on GMA and the secondary amine on IDA was confirmed
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by visual inspection of the disappearance of the oil (GMA) – aqueous (IDA) interface during
reaction. The structure of the purified monomer (Scheme 5.1) was then confirmed by 1H
NMR with the presence of both methacrylate bond and iminodiacetic acid group.
After reaction and purification, GMIDA monomer retains its ability to chelate
divalent metal ions such as nickel as shown in Figure 5.1. The wavelength at which
maximum absorbance of Ni2+ occurs shifts from 720nm (Ni2+ only) to 639nm (GMIDA:Ni2+
molar ratio of 0.5) to 626nm (GMIDA:Ni2+ molar ratio of 1) as more GMIDA is added to
the Ni2+ solution. The ligand-metal bonding can also be substantiated by the color change of
GMIDA-Ni2+ complex solutions from light green (Ni2+ only) to light blue (GMIDA molar
ratio of 1). The chelation of transition metal ions to ionic ligands as well as the color spectra
shift has been reported [32]. In this study, the wavelength shift of the Ni2+ absorption
maxima upon GMIDA addition demonstrates the metal-ion-chelating ability of GMIDA
monomer.
5.3.2 Fabrication and characterization of photopolymerized affinity hydrogels
Photopolymerization is one of the most favorable methods for in situ hydrogel
fabrication and protein loading [4]. Photopolymerized PEG-based hydrogels for controlled
release applications can be formed under mild, physiological conditions which protects
fragile biomolecules such as proteins. Furthermore, hydrogels formed via this route usually
have readily tailorable physicochemical properties through adjustment of parameters such as
macromer concentration or functionality.

Several acrylate and methacrylate monomers

including acrylic acid (AA) and methacrylic acid (MAA) have been used to expand the
functionality of otherwise inert PEG hydrogels. For example, Peppas and coworkers have
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extensively investigated PEG-g-MAA hydrogels for oral insulin delivery. The grafted MAA
pendant chains enable pH-responsiveness in otherwise inert PEG hydrogels through
hydrogen bonding between the PEG and anionic repeat groups [41].

Figure 5.1 UV-vis spectra of (A) pure nickel solution (λmax = 721nm), (B) GMIDA-Ni
mixture solution with a molar ratio of 0.5 (λmax = 639nm), and (C) GMIDA-Ni mixture
solution with a molar ratio of 1 (λmax = 625nm).
Here, we copolymerized PEGDA macromers with GMIDA monomers to form
metal-ion-chelating hydrogels for controlled protein release. The resulting PEG-co-GMIDA
affinity hydrogels were first characterized by gel swelling. Figure 5.2 shows the equilibrium
mass swelling ratio of 10wt% PEG-co-GMIDA hydrogels as a function of copolymer
composition.

The swelling behaviors of similar anionic hydrogels have been well-

characterized and reported in the literature [42-46]. GMIDA is a diprotic acid with two
carboxylic acids and therefore the swelling of PEG-co-GMIDA hydrogels increases as the
concentration of GMIDA increases due to electrostatic repulsion between anionic pendent
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groups (Figure 5.2). However, it is noteworthy that the effects of GMIDA on increasing
equilibrium gel swelling were only observed at high GMIDA concentrations ([GMIDA]
>10mM). At relatively low GMIDA concentrations there is no significant difference in gel
swelling (Figure 5.2 inset). This can be explained by the following equation showing the
total free energy balance of the hydrogel system [45].
∆G = ∆Gmix + ∆Ggel + ∆Gion

(15)

The three terms on the right hand side of the above equation represent the free energy
change of polymer mixing, elastic-retractive force of the gel, and ionic force caused by
GMIDA, respectively. For non-ionic PEG hydrogels or in the presence of relatively low
concentrations of GMIDA, ∆Gion can be ignored and hence it does not contribute to
increased gel swelling.

Figure 5.2 Mass swelling ratio of 10wt% PEG hydrogels copolymerized with different
concentration of GMIDA monomers with () or without (▲) nickel ions.

153

In addition, while the swelling of PEG-co-GMIDA hydrogels increases with GMIDA
concentration, this trend is not as significant when transient metal ions such as nickel are
added to the prepolymer solutions (Figure 5.2). This can be explained by the fact that the
chelation of metal ions to GMIDA decreases the electrostatic repulsion between the charged
groups.
5.3.3 Model prediction – Effects of binding kinetics on protein release
The design of affinity hydrogel networks and systematic control of protein release
from these networks can be laborious without the help of mathematical modeling. To
identify the values of various system parameters needed to achieve desired protein release
profiles, a reaction-diffusion model is used to describe hisGFP release from PEG-coGMIDA affinity hydrogels. In our system, initial protein-ligand binding equilibrium was
achieved by incubating the prepolymer-protein mixture solution for a sufficient time (30
min) prior to photopolymerization and subsequent placement into the release medium. At
this stage, the percentage of bound protein can be calculated from the simple concentration
equilibrium dictated by the dissociation constant as shown in Equation (2).
Figure 5.3 shows that the theoretical fraction of protein bound to matriximmobilized ligand is determined not only by the affinity to the ligand (Kd), but also by the
ligand to protein ratio (R). For example, at a fixed total protein concentration (1.82×10-4 M
or 0.25 wt%) about 50% of the protein is bound to the immobilized ligand when R=1 and Kd
= 10-4 M while over 95% of the total protein is bound to ligand when R is increased to 10 at
the same affinity. The equilbrium fraction of bound protein is important as it determines the
initial protein release rate. It is critical to note that protein-ligand binding equilibrium was
only assumed prior to release. During the period of protein release, Equations (6) to (8)
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were used to describe the time and position-dependent free protein and unbound ligand
concentrations considering both protein diffusion and protein-ligand binding.

Figure 5.3 Fraction of ligand-bound protein at equilibrium. The percentage of bound
protein increases as (1) higher affinity (lower Kd) ligands and (2) higher ligand to protein
ratios (R) are used. Total protein concentration: 1.82×10-4M. Solid line: R=1; Dashed line:
R=10; Dotted line: R=100.
To accurately predict protein release, it is crucial to understand the mechanisms
governing protein transport within the affinity hydrogels. Three parameters are important in
describing protein release from these gels, namely protein diffusivity (D0), Kd, and koff. For
inert hydrogels, protein diffusivity is determined by the protein size and the gel mesh size or
gel swelling ratio [47]. As shown in Figure 5.2, the mass swelling ratios of our affinity
hydrogels are not affected by the incorporation of up to 10mM GMIDA monomer. Since
the maximum GMIDA concentration used in all release experiments was 9.4mM (equivalent
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to 100 molar excess of hisGFP), it is therefore reasonable to assume that the diffusivity of
free protein in the affinity hydrogels used in the current studies is independent of GMIDA
concentration.

Therefore, a protein diffusivity value of 10-7 cm2/sec was empirically

obtained by fitting an analytical solution of Fick’s second law of diffusion to the hisGFP
release profile from comparable PEGDA gels without GMIDA. This value agrees with
previous protein diffusivity measurements in the literature6 and was applied to all subsequent
model predictions.
The second system parameter important in determining protein release rates from
affinity networks is the dissociation constant for protein-ligand binding, Kd. As mentioned
earlier, Kd determines the equilibrium free protein concentration. As Kd increases (lower
affinity), a greater fraction of total protein will exist in its freely diffusable, unbound form
which increases the rate of protein release during the initial release period. During release,
protein is constantly removed from the affinity gel through diffusion. If the rates of proteinligand binding and debinding are sufficiently faster than the rate at which protein is lost from
the gel system due to diffusion, then binding equilibrium is maintained during protein
delivery and the concentration of free protein within the gel can be readily predicted by the
reaction equilibrium equation and the value of Kd. However, as free protein diffuses out, the
rate at which bound protein dissociates from the immobilized ligand can affect the overall
protein release rate. Therefore, the ligand-protein dissociation rate constant, (koff), becomes
important for determining protein release kinetics. It is important to note that for the
binding of his-tagged proteins to metal-ion-chelating ligands, koff is usually much lower than
kon [48]. Hence, the rate of ligand-protein dissociation is the rate-determining step.
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Figure 5.4 (A) Kinetics of bound protein concentration as a function of dissociation rate
constant (koff) at a fixed Kd (10-4M). koff = 10-2, 10-3, 10-4, and 10-5 sec-1 for curve 2, 3, 4, and 5,
respectively. (B) Fractional release of hisGFP with different Kd (Curve 1: no ligand; Curve 25, Kd=10-4M; Curve 6, Kd=10-5M) and koff (10-2, 10-3, 10-4, and 10-5 sec-1 for curves 2, 3, 4, and
5, respectively (Kd=10-4M).)
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To illustrate the impact of the dissociation rate constant (koff) on protein release
profiles, we simulated protein binding and release as a function of time at constant Kd (10-4
M) but different dissociation rates (varying koff). It is evident, as showed in Figure 5.4, that
the concentration of bound protein ([PL]) decreases with time at all koff values used. It is
interesting to note that [PL] decreases much slower over time at lower koff values. This can be
explained by comparing the characteristic time for protein diffusion (td) and dissociation (toff)
described by the following equations:
td =

δ2

t off =

(17)

D

1
k off

(18)

where δ is the protein diffusion length (the half-thickness of the gel). For example, for a
protein diffusivity of 10-7 cm2/sec and a gel half-thickness of 0.28mm, the characteristic
diffusion time (td) is 7.8×103 sec. When toff is at least one order of magnitude smaller than td
(koff = 10-2 s-1; Curve 2 in Figure 5.4A), the concentrations of bound protein decrease rapidly
at a rate controlled by protein diffusion. However, when toff is comparable or larger than td
(koff = 10-4 and 10-5 s-1; Curves 4 and 5 in Figure 5.4A), the time needed for protein
dissociation slows the decrease of [PL]. In summary, curves 2 and 3 in Figure 5.4A are
almost identical because, although koff decreases by an order of magnitude, protein release is
diffusion-controlled in both cases. However, the [PL] profile changes significantly with koff
once protein release becomes kinetically controlled (Curves 4 and 5).
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Figure 5.5 In vitro hisGFP release from PEG-co-GMIDA hydrogels as functions of: (A)
Ligand (GMIDA(Ni)) concentration with R=0 (), 1(▲), 10(), and 100 (), and (B)
Ligand affinity. No ligand (), R=1, GMIDA(Ni) (▲) and R=1, GMIDA(Cu) ().
Symbols are experimental data and curves are theoretical predictions as indicated in the
figure. Protein loading concentration: 1.82×10-4M; [PEGDA]: 10wt%.
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Figure 5.6 Effect of metal ions on in vitro hisGFP release from PEG-co-GMIDA
hydrogels. (A) No metal ions added: RG=0 (), RG=1 (▲), and RG=10 (). (B) Excess
amount of EDTA added in the precursor solution together with nickel ions. RG=0 (),
RGNi=10 (▲), and RGNi+EDTA=10 ().
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Figure 5.4B shows the predicted protein release profiles from hydrogels without
ligand (Curve 1) and with lower affinity ligand (Kd = 10-4M; Curves 2-5) or higher affinity
ligand (Kd = 10-5M; Curve 6). Protein release rates are slower when ligand is incorporated.
Generally, higher affinity ligand (smaller Kd) offers stronger protein binding and results in
slower release rates. However, at the same Kd the rate of protein dissociation from ligand
can significantly decrease protein release rates during later stages of release. This trend is
clear when comparing Curves 2 and 5 in Figure 5.4B where they both have same Kd but
different koff. Furthermore, protein release rates can be tuned with higher initial ‘burst’ but
more sustained release afterward by using lower affinity ligands with small koff values (Curve
5). Although the theoretical observations mentioned above have not yet been verified
experimentally, they offer general gel design criteria regarding the selection of proteinbinding ligands with proper affinity characteristics (Kd and koff). In addition, once these
parameters are determined for a given ligand system, release rates for a variety of proteins
can be readily predicted.
5.3.4 In vitro release and verification of model predictions
The effectiveness of obtaining sustained protein release via GMIDA incorporation
was demonstrated by quantifying his-tagged protein (hisGFP) delivery from PEG-coGMIDA hydrogel networks. The impact of two parameters on hisGFP release profiles from
highly permeable PEG networks was evaluated: (1) ligand-protein molar ratio (RG for
GMIDA; RGNi for GMIDA(Ni); RGCu for GMIDA(Cu)) and (2) ligand-protein affinity (Kd).
As shown in Figure 5.5A, when GMIDA(Ni) complex was copolymerized into the
crosslinked PEG networks, the release rate of hisGFP systematically decreased with
increasing ligand concentration.

Specifically, without ligand incorporation, 80% of the
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protein rapidly diffused out of the hydrogel within an hour. However, when 9.4mM
GMIDA(Ni) (corresponding to RGNi = 100) was copolymerized into the network, the time
required to release 80% of the protein was delayed to approximately 24 hours, indicating
over an order of magnitude decrease in the overall rate of protein delivery. The burst-release
behavior commonly observed with traditional hydrogel matrices was also greatly decreased in
the presence of the copolymerized GMIDA(Ni) complex. As RGNi increases, the protein
release rate and burst effect decrease because GMIDA-hisGFP binding equilibrium dictates
that a greater fraction of encapsulated protein is reversibly immobilized to the insoluble
PEG-co-GMIDA network.

This conclusion of reaction-diffusion controlled release is

supported by the fact that the swelling of the described hydrogel formulations does not
decrease upon incorporation of GMIDA (Figure 5.2), indicating that the decreased release
rates are not due to decreases in soluble protein diffusivity.
Predicted release profiles obtained using the reaction-diffusion transport model
developed in this contribution were compared to the experimental hisGFP release data.
Although the exact values of Kd, kon, and koff for our affinity hydrogel system are yet to be
determined, reasonable parameters were obtained from the literature. For example, Kd values
of 10-3 M and 10-4 M were reported for the binding of single histidine residues to IDA(Ni)
and IDA(Cu), respectively [49, 50]. A range of 10-5~10-7 M has also been reported for the
binding of a multi-histidine tag to IDA(Cu) [49]. Therefore, we chose Kd = 10-4 M and koff =
10-2 sec-1 to obtain model predictions of hisGFP release data from hydrogels incorporated
with GMIDA(Ni) affinity ligands. A diffusivity value of 10-7 cm2/sec was also used in the
model as discussed in the previous section. As shown in Figure 5.5A, it is clear that the
resulting theoretical predictions agree with experimental data at low ligand concentrations
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(RGNi=0 and 1). However, the model overpredicts the amount of released protein at high
ligand concentrations (RG,Ni =10 and 100). A primary reason for this selective discrepancy is
that the free-radical mediated hydrogel polymerization efficiency is significantly decreased in
the presence of high concentrations of transition metals such as Ni and Cu as these metal
ions are known to be efficient free radical scavengers [51].
To overcome the limitations presented by high ligand concentrations, model
predictions indicate that low concentrations of high-affinity ligands can be used to achieve
similar sustained release effects. For a given ligand to protein ratio, the fraction of hisGFP
bound to an immobilized ligand should also increase as the hisGFP-GMIDA binding affinity
increases. The binding affinity of PEG-co-GMIDA hydrogels for encapsulated proteins can
be readily tailored through exchange of chelated metal ions. As shown in Figure 5.5B, 80%
of encapsulated hisGFP was released in 4 hours from gels prepared with 0.094mM
GMIDA(Ni) (RGNi = 1); however, this time-point was extended four-fold to approximately
24 hours when the same concentration of GMIDA(Cu) (RGCu = 1) was used. This can be
attributed to the fact that IDA-Cu, compared to IDA-Ni, provides a higher affinity for
6×his-tagged proteins [49, 52].
The developed theoretical model is used to fit the experimental release data when
nickel and copper ions are used with the GMIDA. As shown in Figure 5.5B, a Kd of 10-5 M
and koff=10-3 sec-1 were used to generate the theoretical curve for GMIDA(Cu)-hisGFP
release. The experimental data and theoretical predictions agree very well and indicate how
higher affinity ligands extend the timescale of sustained protein release.
To further support the metal-ion-mediated protein release mechanism, additional
hisGFP release experiments were conducted. Figure 5.6A shows hisGFP release profiles
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obtained from PEG-co-GMIDA hydrogels without metal ions. Fractional hisGFP release
remains unaltered at different GMIDA to protein ratios (RG = 0, 1, 10) indicating the
indispensable role of metal ions in mediating binding of the negatively charged hisGFP.
Additionally, when excess EDTA (REDTA = 10), a strong metal-ion-chelator, was added to the
prepolymer solution together with hisGFP and GMIDA(Ni) (RGNi = 10) during gelation,
Ni2+-mediated hisGFP binding to immobilized GMIDA sites is eliminated via competitive
binding. The subsequent fractional hisGFP release profile is identical to the case where no
ligand was used (Figure 5.6B). Taken together, these release results suggest that binding of
hisGFP to metal-ion-chelating ligands plays a critical role in decreasing protein release rates
from these affinity hydrogels.
5.3.5 Apparent diffusivity calculation
Protein release rates can be expressed in terms of an apparent diffusivity (Dapp), a
coefficient that can be measured experimentally. When the fractional release curves are
plotted versus t1/2, apparent diffusivities can be calculated from the slope of the linear
portion of the curves (fractional release<0.6). Figure 5.7 shows the apparent diffusivities of
hisGFP obtained from gels of various compositions. As can be seen, Dapp of hisGFP in
PEGDA hydrogels (without ligand) is around 1×10-7 cm2/sec and decreases slightly when
GMIDA alone is added (RG=1 and 10). As Ni2+ is used synergistically with GMIDA at RGNi
= 1, Dapp drops to 0.58×10-7 cm2/sec. At RGNi = 10 or RGCu = 1, Dapp further decreases to
0.22×10-7 cm2/sec indicating the effects of using high ligand concentration or affinity as
discussed before. However, further increasing ligand concentration to RGNi = 100 does not
substantially decrease Dapp, contrary to theoretical predictions. As briefly discussed earlier,
this is most likely an artifact due to limited ligand incorporation within the crosslinked
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networks. Furthermore, when EDTA was added to the prepolymer solution, the apparent
diffusivity increases to the level comparable to when no Ni2+ was used. Although Cu2+ has
been shown to greatly decrease Dapp at low concentration (RGCu=1), further decreasing release
rates using higher RGCu was not possible due to that fact that during the preparation of PEGco-GMIDA hydrogels, high concentrations of copper ions hinder gel formation (Cu2+ is
known to be an efficient radical scavenger) [51].

Figure 5.7 Calculated apparent diffusivity of hisGFP.

5.4 Conclusion
PEG-based affinity hydrogels containing immobilized metal-ion-chelating ligands have
been successfully fabricated to deliver his-tagged GFP in a sustained manner. A
mathematical model accounting for protein diffusion and dissociation from the ligandbound state has also been developed to identify important parameters governing protein
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release. The modeling of protein release reveals the importance of Kd on the initial binding
equilibrium and release in the early period while koff dominates the rates and amounts of
protein release in the later period. Experimentally, decreased release rates can be obtained by
utilizing ligands at higher concentrations or with higher affinities. Taken together, the
modeling and experimental studies presented in this contribution broaden the understanding
of the mechanisms governing protein release from affinity hydrogels. With this knowledge,
these systems can be better utilized for wound healing and tissue regeneration applications.
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CHAPTER SIX
CHARACTERIZATION OF PROTEIN LOADING AND RELEASE FROM
PHOTOPOLYMERIZED IONIC POLY(ETHYLENE GLYCOL-COGLYCIDYLMETHACRYLATE IMINODIACETIC ACID) HYDROGELS
Abstract
Ionic hydrogels have been recognized as important biomaterials that are indispensable
in controlled drug delivery applications.

We describe herein the characterization and

controlled protein delivery application of novel pH-responsive hydrogels prepared from
solution photopolymerization. The hydrogels were copolymerized from poly(ethylene glycol)
diacrylate (PEGDA) and anionic glycidyl methacrylate-iminodiacetic acid (GMIDA).
PEGDA was used due to its demonstrated biocompatibility and non-fouling properties. The
incorporation of anionic GMIDA monomers provides the pH-sensitivity of the resulting
PEG-co-GMIDA hydrogels. The presence of anionic GMIDA in the hydrogel network
enhances the post-loading efficiency of cationic protein lysozyme while decreasing its
subsequent release rate due to electrostatic binding. However, the post-loading technique
leads to relatively high rates of protein release. To overcome these disadvantages, we
encapsulated lysozyme via in situ photopolymerization of PEG-co-GMIDA hydrogels.
Results show that in situ-loaded gels deliver lysozyme at a significantly slower rate than postloaded gels. We also utilized the pH-responsiveness of PEG-co-GMIDA hydrogels for
controlled protein delivery - lysozyme is retained within the hydrogels at low pH (pH 5) and
released at higher pH (pH 7.4).
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6.1 Introduction
Hydrogels are crosslinked polymeric networks that absorb and retain a great amount
of water [1, 2]. Because of this, hydrogels are important biomaterials for controlled drug
delivery [1, 2], bioanalytical devices [3-5], and tissue engineering applications [6-9]. The
“tissue-like” property of hydrogels not only contributes largely to device biocompatibility but
also helps to maintain the structural and functional stability of encapsulated proteins.
However, high water contents in hydrogels also result in high permeabilities that make it
difficult to sustain protein delivery. One easy way to overcome this is to increase diffusional
resistance encountered by the encapsulated proteins by increasing the network crosslinking
density [10, 11] or utilizing more hydrophobic polymer precursors [12, 13]. Although these
approaches are commonly used when designing polymeric carriers for controlled delivery,
the decreased water content that results from these methods may destroy the preferential
“tissue-like” properties of the original hydrogels.

Moreover, the bioactivity and

bioavailability of fragile encapsulated protein therapeutics can be significantly limited under
these conditions due to increased chances for unfavorable protein-polymer interactions [14].
To maintain the preferential high water-content of hydrogels while permitting
dynamic control over protein delivery rates and sustained release, research efforts have
focused on the development of hydrogels bearing protein-binding affinity sites [15-22]. Socalled “affinity” hydrogels can be designed to decrease protein release rates due to the
formation of reversible protein-matrix complexes. By tailoring the concentration or affinity
of the protein-binding ligands, protein binding and its release can be systematically
controlled. Since many of the therapeutic proteins, such as basic fibroblast growth factor
(bFGF), platelet-derived growth factor (PDGF), and nerve growth factor (NGF), are
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cationic in biological milieu, it is natural to incorporate anionic components into hydrogel
networks to provide protein-matrix binding and subsequent sustained protein release. The
most commonly used natural anionic ligand is highly sulfated heparin derived from
extracellular matrix [17, 20-22]. Heparin binds to cationic growth factors and synchronizes
their release in vivo. To mimic this controlling mechanism, heparin has been incorporated
into many hydrogel systems for sustaining growth factor release in vitro and in vivo.
Through intelligent design of hydrogel compositions and architectures, stimuliresponsiveness can also be readily tailored into polymeric hydrogel networks [23-28].
Stimuli-responsive hydrogels have been widely used in controlled delivery owing to their
ability to transform hydrogel structure between collapsed and swollen states corresponding
to environmental changes including chemical (pH, ionic strength, glucose), physical
(temperature, mechanical stress, ultrasound), or electrical cues. The encapsulated proteins
are initially retained in the collapsed matrices and the release of loaded proteins is triggered
when the matrices become swollen upon changes in the external stimuli.
Synthetic anionic monomers such as acrylic acid (AA) and methacrylic acid (MAA) are
attractive in a wide variety of hydrogel-based applications due to their well-defined physical
and chemical properties [11, 26, 29-31]. These anionic monomers are deprotonated or
ionized when pH of the surrounding solution is higher then the pKa of the acidic groups.
The deprotonated groups then contribute to the electrostatic protein-binding as well as the
pH-responsive hydrogel swelling. When these anionic moieties are protonated, they are able
to form hydrogen bonds with the hydrogel backbone through ether groups. Utilizing these
protonation-deprotonation transitions, Peppas and colleagues have prepared a series of
complexation PEG-g-MAA hydrogels that shrink in response to acidic environments due to
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extensive hydrogen bonding and swell at neutral to basic environments due to electrostatic
repulsion between deprotonated MAA groups [29-31]. These complexation hydrogels were
used to entrap and protect insulin in acidic environments (stomach) and subsequently release
it in the more neutral environments of the gastrointestinal tract (intestines). However,
similar to less elegant methods for increasing network crosslinking density, this “on-off”
control over protein delivery kinetics still relies on physically entrapping proteins within
dehydrated matrices with mesh sizes smaller than the sizes of the encapsulated proteins and
may cause protein denaturation due to extensive protein-polymer interactions.
Furthermore, the incorporation of ionic groups into neutral polymeric networks
usually requires extended polymerization times or increased monomer concentrations that
can be detrimental to the stability of in situ-encapsulated proteins.

For example, the

photopolymerized PEG-g-MAA hydrogels prepared by Peppas et al. usually take 30-min for
gelation [30-33]. This long period of UV-exposure, together with high monomer content
(40-60 wt%) [32, 33], will result in significant protein-polymer conjugation if protein is
present during the curing process [34]. Therefore, a post-loading technique becomes the
only choice for the incorporation of bioactive protein therapeutics into these anionic
hydrogels.
Previously, we have described the synthesis, characterization, mathematical modeling,
and controlled protein delivery applications of anionic poly(ethylene glycol)-co-(glycidyl
methacrylated iminodiacetate) (PEG-co-GMIDA) hydrogels copolymerized from diacrylated
PEG (or PEGDA) and methacrylated IDA (or GMIDA) [15]. The synthetic ligand GMIDA
is highly water-soluble and can be readily copolymerized into PEG-based hydrogel networks
at high concentrations via photopolymerization. These features permit the rapid fabrication
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of highly swollen (water content: > 90%) ionic hydrogels that allow for in situ encapsulation
and retention of bioactive proteins.
We have detailed in earlier reports the applications of highly swollen PEG-coGMIDA hydrogels for achieving sustained release of hexahistidine-tagged proteins over
timescales suitable for tissue engineering applications [15]. In this work we demonstrate how
these gels can also be used to enhance the loading and pH-responsive delivery of cationic
proteins through straightforward electrostatic interactions. Differing from the PEG-g-MAA
hydrogels developed by Peppas et al., the PEG-co-GMIDA hydrogels maintain high (>
90%) water contents at all pH values. Control over protein delivery kinetics in PEG-coGMIDA gels relies predominantly on protein-matrix binding rather than network volume
transitions. The objectives of this paper are to characterize the stimuli-responsive swelling
of PEG-co-GMIDA hydrogels and to compare the controlled protein delivery performances
from these anionic hydrogels using two protein-loading techniques: post-loading and in situloading.
6.2 Materials and Methods
6.2.1 Materials
Photoinitiator – Irgacure 2959 (or I-2959, 2-Hydroxy-1-[4-(2-hydroxyethoxy) phenyl]2-methyl-1-propanone) was supplied from Ciba Specialty Chemicals. Iminodiacetic acid and
fluorescamine were obtained from Fisher Scientific. All other chemicals were obtained from
Sigma-Aldrich unless otherwise specified.
6.2.2 Monomer and hydrogel synthesis
PEGDA macromer (average molecular weight: 3.4kDa) was synthesized by reacting
toluene-dried PEG macromer with 8 molar excess of acryloyl chloride for 4 hours in the
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dark. The desired PEGDA was purified by dissolving crude products in dichloromethane
followed by precipitation in cold diethyl ether [35]. GMIDA monomer was synthesized by
reacting the amine group of iminodiacetic acid with epoxy ring of glycidyl methacrylate and
purified by precipitation in acetone [15, 36]. The structure and purity of PEGDA (>95%)
and GMIDA (>90%) were determined by 1H NMR (Bruker 300MHz).
To synthesize hydrogels, required amounts of PEGDA macromer (10 – 20 wt%) and
GMIDA monomer (0 – 5 wt%) along with photoinitiator I-2959 at a final concentration of
0.2 wt% were mixed to obtain prepolymer solution. 40

L hydrogel specimens were

photopolymerized using low-energy UV-light (Black-Ray®, intensity: 8 mW/cm2 at 365 nm)
for 10 min from prepolymer solutions injected between two glass slides separated with 0.55
mm-thick Teflon spacers. For post-loading experiments, gels were synthesized without the
presence of lysozyme. For in situ-loading experiments, 1 wt% of lysozyme was mixed with
the prepolymer solution and subsequently photopolymerized to obtain the in gels with
encapsulated protein.
6.2.3 Characterization of hydrogel swelling
PEG-co-GMIDA hydrogels with different GMIDA concentrations were retrieved
from the assembled glass slides after photopolymerization and washed in de-ionized water at
room temperature for 48 hours to remove un-reacted monomers. The gels were then dried
in a vacuum desiccator for 48 hours. The dried gel mass (WD) was measured gravimetrically
and then placed in 50mM phosphate buffer solution (PBS) with different pH values or salt
(NaCl) concentrations for 48 hours to obtain swollen gel mass (WS). The equilibrium mass
swelling ratio (Qm) is defined as:
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Qm =

WS
WD

(1)

6.2.4 Protein loading and in vitro delivery
Hen egg white lysozyme (MW: 14.3kDa, pI: 11) was used as a model cationic protein
for in vitro release studies. Two protein loading techniques were used in this study, namely
in situ-loading and post-loading. For in situ-loading, a known amount of lysozyme was
mixed with prepolymer solutions and exposed to low-energy UV light for in-situ
photopolymerization. For post-loading, PEG-co-GMIDA hydrogels were synthesized from
solution photopolymerization as described in the previous section.

The polymerized

hydrogels were washed in D.I. water for 48 hours to remove unreacted monomers and then
dried in vacuum at room temperature for another 48 hours. The dried gels were weighed
and immersed into concentrated lysozyme solution (500 µL, 10 mg/mL or 20 mg/mL) for
one week or until fully saturated (longer incubation times did not increase protein loading).
Protein loading efficiency was determined via mass balance calculations. After post-loading,
the gel swelling ratio (Qm) was determined with the weight of loaded lysozyme subtracted
from the total swollen weight of the gel Lysozyme-loaded PEG-co-GMIDA hydrogels (40
L) were each placed in 3mL of 50mM PBS at 37°C for in vitro release experiments. At
predetermined time intervals, 200µL of released lysozyme solutions were sampled and stored
at 4°C until quantification of protein concentration. After sampling, an equal amount of
fresh PBS was added into the release buffer to maintain constant solution volume. Total
release of lysozyme was determined using fluorescamine (3mg/mL acetone) assay as
described in earlier publications [14, 15].
6.2.5 Apparent diffusivity calculation
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In highly swollen hydrogels, protein release can be categorized as a diffusioncontrolled mechanism and the time-dependent protein distribution in the gel can be
described by Fick’s second law of diffusion:
∂C
∂ 2C
= Dapp 2
∂t
∂x

(2)

where C is the protein concentration in the gel, Dapp is the apparent protein diffusivity in the
gel, t is time, and x is the diffusion coordinate. In this study, protein apparent diffusivity was
assumed to be concentration-independent and the delivery was considered one-dimensional
due to high aspect ratio (length/thickness ~ 20) of the hydrogel slabs. A sink condition is
also assumed due to the excess volume of the incubating buffer used compared to the size of
the gel (~75-fold excess). Equation (2) can be solved analytically and the apparent protein
diffusivity can be estimated based on the linear portion of the fractional protein release
profiles plotted against the square root of time according to the following equation [37]:
1/ 2

Mt
4  Dapp ⋅ t 

(3)
= 1 / 2 
M ∞ π  δ 2 
where Mt is the amount of protein released at any given time point, M∞ is the amount of

total releasable protein, δ is the half-thickness of the hydrogel slab.
6.3 Results and Discussion
6.3.1 pH-responsive hydrogel swelling
We have previously described the synthesis and characterization of GMIDA
monomers as well as the fabrication of PEG-co-GMIDA hydrogels [15].

Due to the

copolymerization of anionic ligand – GMIDA, the equilibrium swelling of PEG-co-GMIDA
hydrogels increases dramatically at higher GMIDA concentrations due to electrostatic
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repulsion between anionic carboxylic acid groups. Figure 6.1(A) shows the pH-responsive
equilibrium swelling of PEG-co-GMIDA hydrogels (10 wt% PEGDA, 10-min gelation
time). Without the presence of GMIDA, the swelling of 10 wt% PEG hydrogels remains
relatively constant at all pH values tested.

With the copolymerization of GMIDA

monomers, however, the degree of pH-responsive swelling depends largely on GMIDA
concentration in the prepolymer solution. The swelling of PEG-co-GMIDA gels containing
1 wt% GMIDA (mole fraction of GMIDA: 51.4%) show no statistical difference compared
to 10 wt% PEG hydrogels while the swelling of PEG-co-GMIDA hydrogels containing
3wt% (mole fraction of GMIDA: 76.1%) or 5wt% GMIDA (mole fraction of GMIDA:
84.1%) increases gradually with increasing pH in the buffer solutions. GMIDA is a diprotic
acid containing two carboxylic acids with two pKa values, respectively 3.06 and 8.5. When
GMIDA is polymerized into poly(GMIDA), the pKa of these acid groups shift to higher
values of 3.81 and 9.54, respectively [36]. The presence of two different pKa values on a
single GMIDA monomer can have profound influences not only on copolymer hydrogel
swelling but also on the release of encapsulated protein therapeutics. For example, a cationic
protein can be complexed with the anionic GMIDA immobilized within the hydrogel
networks to minimize its release at neutral pH. The retained cationic protein can then be
liberated at a lower pH due to the increased protonation of the anionic GMIDA, or at a
higher pH due to decreased protein-ligand binding (cationic protein is less charged at high
pH) as well as increased hydrogel swelling.
In order to compare the swelling behavior of PEG-co-GMIDA hydrogels to that of
other ionic hydrogels, we also fabricated anionic hydrogels incorporating a commonly used
anionic monomer – methacrylic acid (MAA). Figure 6.1(B) reveals the pH-dependent
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swelling behavior of both PEG-co-MAA and PEG-co-GMIDA hydrogels. As expected, the
increase of swelling of PEG-co-MAA hydrogels occurs at slightly higher pH values due to
the higher established pKa values for pMAA compared to pGMIDA (5.5 [38] vs 3.81 [36]).
The results also demonstrate significantly higher degrees of equilibrium swelling for PEGco-GMIDA hydrogels at all pH values tested, compared to PEG-co-MAA hydrogels with
the same anionic monomer concentration (93.5mM) and gelation time (15-min). It is also
interesting to note that the swelling ratios of PEG-co-MAA hydrogels were lower than
PEGDA hydrogels (monomer content: 10 wt%) at lower pH (2~6), suggesting significant
hydrogen bond formation between protonated carboxylic acid groups on MAA and ether
groups on PEG crosslinks, a phenomenon previously described by Peppas and colleagues
[29, 30].

Furthermore, PEG-co-MAA hydrogels only swell slightly higher than PEG

hydrogels at pH 7.4 and 8.8. However, the potential formation of hydrogen bonds at lower
pH values does not appear to significantly restrict the swelling of PEG-co-GMIDA
hydrogels. The higher degrees of swelling and hence larger mesh sizes of the PEG-coGMIDA hydrogels in acidic and basic environments (Qm>9, see Figure 6.1) allow us to
readily evaluate protein delivery behaviors under the effects of protein-matrix binding
without artifacts due to physical protein entrapment.
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Figure 6.1 (A) pH-responsive swelling of anionic PEG-co-GMIDA hydrogels containing 10
wt% PEGDA and 0wt% (*), 1wt% (), 3wt% (), and 5wt% GMIDA (▲). (n=4, average
± standard deviation, gelation time: 10-min) (B) Comparison of pH-responsive swelling of
PEG-co-GMIDA an PEG-co-MAA hydrogels at the same anionic monomer concentration
(93.5mM, corresponding to 3 wt% of GMIDA). (n=3, average ± standard deviation, gelation
time: 15-min)
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6.3.2 Effect of salt concentration on hydrogel swelling
The swelling of anionic hydrogels can be affected by the salt concentration in the
bathing medium. Figure 6.2 shows the equilibrium swelling of PEG-co-GMIDA (3wt%
GMIDA) and non-ionic PEG hydrogels responding to various salt (NaCl) concentrations at
pH 7.4. Clearly, the salt-induced swelling behavior of anionic PEG-co-GMIDA hydrogels is
different from that of non-ionic PEG hydrogels.

First, the addition of salt at lower

concentrations (<200mM) decreases anionic hydrogel swelling but almost has no effect on
non-ionic PEG hydrogel swelling. On the contrary, addition of higher salt concentrations
(400 - 800mM) decreases the swelling of non-ionic PEG hydrogels but does not further
decrease anionic hydrogel swelling. The fundamental difference in the swelling behavior of
these ionic and non-ionic hydrogels can be explained by the balance of total free energy
(∆G) in the hydrogel system described by:
∆G = ∆Gmix + ∆Ggel + ∆Gion + ∆Gosm
(4)
where ∆Gmix , ∆Ggel , ∆Gion and ∆Gosm are free energy of polymer mixing, elastic-retractive
force of the hydrogel, electrostatic repulsion force caused by GMIDA, and osmotic pressure
caused by salt ions, respectively. For non-ionic PEG hydrogels at fixed compositions (10
wt% PEGDA), no free energy is contributed by electrostatic repulsion force and hence
∆Gosm is the only variable term that affects the energy balance of the non-ionic hydrogel
system. ∆Gosm is almost negligible at lower salt concentrations (>200 mM) and does not
change the equilibrium gel swelling significantly. At elevated salt concentrations (400 – 800
mM), however, the increased osmotic pressure in the surrounding buffer cannot be omitted

182

and this in turn “squeezes” water out of the non-ionic PEG hydrogels and decreases their
equilibrium swelling.
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Figure 6.2 Salt-responsive swelling of non-ionic PEG hydrogels () and anionic PEG-coGMIDA hydrogels containing 10 wt% PEGDA and 3wt% GMIDA (▲). (n=3, average ±
standard deviation)
For anionic hydrogels containing fixed concentrations (3 wt%) of GMIDA, their
equilibrium swelling is determined by the balance of ∆Gion and ∆Gosm. The increase in salt
concentrations decreases anionic hydrogel swelling even at low concentration (<200 mM)
due to the electrostatic shielding effect provided by counterions that partially offset the
charge repulsion between anionic GMIDA. At elevated salt concentrations, one expects to
see a further decrease in hydrogel swelling similar to that of the non-ionic hydrogels, due to
increasing ∆Gosm. However, the swelling of anionic PEG-co-GMIDA hydrogels does not
show a monotonic decrease with increasing salt concentration. Instead, PEG-co-GMIDA
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gel swelling ratio becomes insensitive to salt concentrations at high salinity. In an earlier
study, Ostroha et al. concluded that the degree of anionic gel swelling is not affected by
salinity when pH value of the bathing buffer is far from the transition regions or the pKa of
the charged groups [39]. As can be seen in Figure 6.1, pH 7.4 is indeed away from the
swelling transition regions of the PEG-co-GMIDA hydrogels (the two pKa for
poly(GMIDA) are 3.81 and 9.54, respectively [36]). The fact that the increased ∆Gosm does
not contribute to the decreasing gel swelling at high salinity suggests the important role of
electrostatic interactions even when most of the ionic GMIDA groups are “screened” by
soluble ions [39].
6.3.3 Post-loaded hydrogels: Protein loading characteristics
It is well-known that the incorporation of anionic groups into hydrogel networks will
enhance the loading of cationic proteins via electrostatic binding[19]. The enhanced protein
loading capability of our PEG-co-GMIDA hydrogels was examined by incubating dried gels
in the concentrated lysozyme solution (500 µL, 10 mg/mL) for one week. As shown in
Figure 6.3, very limited amount (26.3 ± 2.5 mg/g polymer) of lysozyme was imbibed into
non-ionic PEG hydrogels, presumably due to the protein-excluding properties of PEG
hydrogels. The incorporation of 1 wt% anionic GMIDA into the hydrogel network only
slightly increases lysozyme loading to 40.8 ± 3.4 mg/g polymer. On the other hand, when
GMIDA was copolymerized into the hydrogel network at 3 wt% and 5 wt%, dramatically
increased lysozyme loadings were observed (178 ± 14.3 and 553 ± 33.9 mg/g polymer,
respectively). Figure 6.3 also shows that the amounts of lysozyme loaded into PEG-coGMIDA hydrogels increase significantly as the concentration of the bathing lysozyme
solution is increased from 10 mg/mL to 20 mg/mL.
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Figure 6.3 Post-loading efficiency of PEG-co-GMIDA hydrogels (10 wt% PEGDA) as a
function of GMIDA concentration. Hydrogels were incubated in 10mg/mL (■) or
20mg/mL (■) lysozyme solution. (n=3, average ± standard deviation)
6.3.4 Post-loaded hydrogels: Controlled lysozyme delivery
Figure 6.4 shows the fractional release of lysozyme from post-loaded hydrogels using
two different loading solutions. Due to the electrostatic binding of anionic GMIDA to
cationic lysozyme, one expects decreased lysozyme release rates from hydrogels with
increasing anionic contents.

As expected, lysozyme release rates decreased as more

GMIDA monomer was copolymerized into the PEG hydrogels, regardless of lysozyme
loading. Lysozyme loading in PEG-co-GMIDA hydrogels increases with the lysozyme
concentration of the bath solution (Figure 6.3). However, the lysozyme fractional release
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profiles (Figure 6.4) and apparent diffusivities (Figure 6.5(A)) show no dependence on the
loading conditions.

Comparing Figures 6.4A and 6.4B, one sees that the sustained release

effect is solely controlled by the hydrogel composition and is independent of the protein
loading buffer. The sustained release effect, however, appears to saturate at higher GMIDA
concentrations as almost identical fractional release profiles were obtained for 3 wt% and 5
wt% GMIDA-incorporated PEG-co-GMIDA hydrogels. One possible explanation for this
is that the sustained release effect provided by increased electrostatic binding at higher
GMIDA concentrations is offset by increases in hydrogel swelling and network mesh size.
These results suggest that the use of hydrogel matrices that induce non-specific electrostatic
binding to achieve sustained protein release may be inherently limited.
6.3.5 In situ-loaded hydrogels: Controlled lysozyme delivery
Although post-loading provides a means of achieving high protein loading into
anionic PEG-co-GMIDA hydrogels (Figure 6.3), the exact dose of payload is difficult to
control and is easily affected by several internal (hydrogel network) and external (bathing
buffer) parameters. The internal parameters include hydrogel crosslinking density, specific
protein-ligand (e.g. GMIDA) interactions, and non-specific protein-matrix interactions. The
external parameters include pH, temperature, ionic strength, and composition of the bathing
buffer. Thus, the appropriate combination of numerous conditions must be identified and
multiple steps following matrix fabrication must be conducted to prepare matrices in this
fashion with therapeutically relevant drug loadings.
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Figure 6.4 Fractional lysozyme release from post-loaded PEG-co-GMIDA hydrogels
containing 10 wt% PEGDA and 0wt% (*), 1wt% ( ), 3wt% ( ), and 5wt% ( ) GMIDA.
(A) Post-loading in 10mg/mL lysozyme solution, and (B) Post-loading in 20mg/mL
lysozyme solution. (n=3, average ± standard deviation)
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Figure 6.5 Apparent diffusivities of lysozyme as a function of GMIDA concentration. (A)
Post-loading: PEG-co-GMIDA hydrogels containing 10 wt% PEGDA were post-loaded in
10mg/mL (■) or 20mg/mL (■) lysozyme solution. (B) In situ-loading: PEG-co-GMIDA
hydrogels containing 10 wt% PEGDA (■), or 20 wt% PEGDA (■). Note that the apparent
diffusivities for hydrogels containing 20wt% PEGDA and 3wt% or 5wt% GMIDA were
calculated from the linear portion of fractional release shown in Figure 6.6 (between 1.5 and
3-hr). (n=3, average ± standard deviation)
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On the other hand, in situ-loading - the encapsulation of protein during network
formation, provides a convenient and efficient way of loading bioactive agents within
crosslinked hydrogels. Not only can the payload doses be readily controlled, but the loaded
protein distributions and swelling properties of the anionic PEG-co-GMIDA hydrogels can
also be well-predicted, which subsequently determine the release rates of the loaded proteins.
The difference in delivery performance between post-loaded and in-situ loaded gels
can be further appreciated by examining the lysozyme release characteristics from in situloaded hydrogels. As shown in Figure 6.6A, lysozyme release rates are again systematically
decreased at higher GMIDA concentrations. Interestingly, PEG-co-GMIDA hydrogels with
5wt% GMIDA also cannot further decrease lysozyme release rate, similar to the release
profiles in post-loaded gels. We have previously hypothesized that this phenomenon is likely
due to either increased gel swelling that leads to increased protein diffusivity or decreased
polymerization efficiency at higher GMIDA concentrations. The release results in Figure
6.6B reveal that, although the use of higher wt% PEG restricts the swelling of PEG-coGMIDA hydrogels at higher GMIDA concentrations, the release rate of lysozyme still
saturates at a lower limit as GMIDA concentration is increased.

These results, in

conjunction with the results presented in Figure 6.4, further solidify our conclusion that the
use of an electrostatic protein-binding mechanism has its inherent limits.

It is also

interesting to note that at higher GMIDA concentrations (3 wt% and 5 wt%), the release of
lysozyme is very limited in the first two hours with increased release rates observed afterward
(Figure 6.6B). This sigmoidal profile is more typically observed during protein release from
moderately crosslinked hydrogels.
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Figure 6.6 Fractional lysozyme release from in situ-loaded PEG-co-GMIDA hydrogels
containing 10 wt% PEGDA and 0 wt% (*), 1 wt% ( ), 3 wt% ( ), and 5 wt% ( )
GMIDA. Hydrogels composed of (A) 10 wt% PEG, and (B) 20 wt% PEG. (n=3, average ±
standard deviation)
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6.3.6 Comparison of lysozyme delivery from in situ and post-loaded hydrogels
Figure 6.5(B) reveals the apparent diffusivity of lysozyme released from in situloaded PEG-co-GMIDA hydrogels. When comparing Figures 6.5(A) and 6.5(B), it is clear
that, at the same GMIDA concentration, the apparent protein diffusivities from in situloaded gels are all smaller than those obtained from post-loaded gels. In order to gain more
insight into lysozyme release using the two different loading techniques and to determine
whether the lower diffusivities from in situ-loaded gels are due to lower amount of lysozyme
loading, we compare the release characteristics from two sets of data with similar lysozyme
loadings. As shown in Table 6.1, similar lysozyme loading is obtained for both post-loaded
and in situ-loaded gels (0.36 ± 0.03 and 0.39 ± 0.01 mg/gel, respectively). However, the
apparent diffusivities obtained from the release data using these gels show a 52% decline
using in situ-loaded gels.
Although the apparent diffusivities of lysozyme released from in situ-loaded gels were
lower than those of post-loaded gels, it is interesting to note that the total percentage of
released lysozyme was also lower from in situ-loaded gels compared to post-loaded gels
(80.2% vs. 98.3%; Table 6.1). This unfavorable phenomenon can be attributed to the
irreversible protein-polymer conjugation that decreases the amount of releasable lysozyme
from photopolymerized, in situ-loaded gels [14, 34]. Decreased protein release rate from in
situ-loaded gels has been previously observed in cationic hydrogel systems where the
measured diffusivities of in situ-loaded insulin were lower than those of post-loaded
insulin.[40] The authors attributed this to (1) the irreversible immobilization of insulin to the
hydrogel network due to protein-polymer interaction and (2) the tighter gel crosslinking that
restricts the diffusivity of in situ-loaded insulin. However, the decreased protein diffusivity
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cannot be reasoned by the irreversible conjugation of protein to the hydrogel network as this
only decreases the total amount of releasable protein but not the diffusivity of the releasable
protein. In earlier reports, we have shown that irreversible protein-matrix conjugation
binding determines the total amount of releasable protein[14] and reversible protein-ligand
interaction determines the rate of protein delivery [15]. It is also unlikely that the decreased
protein diffusivity is due to the entrapment of the in situ-loaded protein in the PEG-coGMIDA hydrogel network, as from the typical swelling ratio values for the gels used in the
current study at all GMIDA concentrations indicate network mesh sizes significantly larger
than the size of lysozyme (26 x 45 Å).

Table 6.1 Comparison of lysozyme release characteristics using two loading techniques.
Lysozyme loading
(mg/gel)

Apparent diffusivity
(×107, cm2/sec)

Total release at 72-hr
(%)

(1) Post-loading

0.36 ± 0.03

1.13 ± 0.18

98.3 ± 4.59

(2) In situ-loading

0.39± 0.01

0.59 ± 0.08

80.2 ± 1.56

Loading technique[a]

[a] PEG-co-GMIDA hydrogels with 10 wt% PEG and 1 wt% GMIDA.
(1) Post-loading in 20 mg/mL lysozyme bathing buffer.
(2) In situ-loading with 1wt% lysozyme.

In contrast to the unsupported reasons given by the previous authors, we suggest that
the increase in protein diffusivities from post-loaded hydrogels observed in this study is due
to the pre-swelling artifact obtained when using the post-loading technique. Post-loaded gels
are fully swollen to their equilibrium values during the protein-loading process. On the
other hand, in situ-loaded gels are only allowed to partially swell (below their equilibrium
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values) after gelation and protein loading. Therefore it is not surprising to observe higher
protein diffusivities for the post-loaded networks compared to identical in-situ loaded gels
when both are placed in the releasing buffer.
6.3.7 pH-responsive controlled protein delivery
Reversible, electrostatic protein-ligand binding not only permits the control of protein
delivery rates, but also allows one to temporally modulate protein delivery. As show in
Figure 6.7, when in situ-loaded PEG-co-GMIDA hydrogels were incubated in buffered
medium at pH 5, a very limited amount (<20%) of lysozyme was released, most likely from
the release of surface-bound protein. The delivery of lysozyme can be triggered by placing
the gels into pH 7.4 buffer. The mechanisms governing this pH-responsive release behavior
can be explained by the swelling of the hydrogels as well as the state of GMIDA and
lysozyme protonation or ionization. At pH 5, the PEG-co-GMIDA hydrogels swell less
than at pH 7.4. In the mean time, considerable amounts of GMIDA are still deprotonated at
pH 5 and can bind electrostatically to cationic lysozyme (which is charged to a greater extent
at pH 5 than pH 7.4). Taken together, a transient retention of lysozyme within the hydrogel
network is obtained. On the other hand, when hydrogels were placed into PBS buffer at pH
7.4, the hydrogel swelling increases and hence results in increased lysozyme release. A
potential advantage for the PEG-co-GMIDA hydrogels compared to other anionic systems
is their dual pH-responsiveness due to GMIDA’s multivalent character and its two pKa
values (3.81 and 9.54, respectively [36]) which could potentially be utilized as two distinct,
triggerable delivery windows. Future studies are needed to explore this added advantage.
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Figure 6.7 pH-responsive lysozyme delivery from in situ-loaded PEG-co-GMIDA
hydrogels containing 10 wt% PEGDA and 5 wt% GMIDA. Lysozyme-loaded hydrogels
were gelled at pH 7.4 PBS and first placed into pH 5 buffer. After 120 hr, gels were
transferred into pH 7.4 buffer. (n=3, average ± standard deviation)
6.4 Conclusions
In conclusion, we have prepared anionic PEG-co-GMIDA hydrogels via
photopolymerization and utilized them as controlled protein delivery devices. The pH- and
salt-dependent swelling of the anionic hydrogels are important characteristics that determine
their protein loading and release properties under a variety of environmental conditions.
From the perspective of anionic monomer selection, GMIDA can be copolymerized into
hydrogel networks at sufficiently high concentrations. This permits fabrication of hydrogels
with increased protein retention over clinically relevant time scales (i.e., less than 10-min).
Enhanced post-loading capability for a cationic protein (lysozyme) is achieved by the
addition of anionic GMIDA monomer compared to non-ionic PEG hydrogels. While post-
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loaded hydrogels produce high protein release rates, significantly lower protein diffusivities
can be obtained from in situ-loaded gels, These enhanced features can be attributed to not
only the protein-loading technique but also the molecular architecture of GMIDA that
allows for multi-valent protein interactions while minimizing dilution of the PEGDA
crosslinks. Overall, the control over protein delivery rate from ionic hydrogels requires
intelligent network design that delicately balances hydrogel swelling and protein-hydrogel
interactions to achieve desired delivery performance.
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CHAPTER SEVEN
BI-FUNCTIONAL MONOLITHIC AFFINITY HYDROGELS FOR DUAL-PROTEIN
DELIVERY
Abstract
Multiple-protein delivery has been proven to be a critical consideration for promoting
tissue regeneration. Many polymeric composite biomaterials have been designed and used
for modulating dual-protein delivery to enhance tissue regeneration in vitro or in vivo.
However, the fabrication conditions and low water contents within the portions of these
composite matrices that determine protein release rates are not optimal for maintaining the
stability of encapsulated macromolecular therapeutics. In this proof-of-concept work, we
aim to improve this deficiency by fabricating bi-functional, monolithic affinity hydrogels
capable of independently delivering two or more proteins. Selective protein-binding sites
were incorporated into poly(ethylene glycol) hydrogels via copolymerization with glycidyl
methacrylate-iminodiacetic acid (GMIDA) ligands to modulate release of two model proteins,
lysozyme and hexa-histidine tagged green fluorescent protein (hisGFP), via two distinct
matrix-binding mechanisms – electrostatic interaction and metal-ion chelation.

Results

indicate that these unique, injectable affinity hydrogels are capable of uniformly
encapsulating multiple therapeutic agents in a single step under mild physiological conditions
and independently controlling their localized delivery. Differing from composite matrices
for dual-protein delivery, the monolithic affinity hydrogels developed in this report can be
fabricated in a single step while retaining high water permeabilities throughout the entire
device – characteristics that are necessary for maintaining the stability and viability of
encapsulated proteins and cells.

199

7.1 Introduction
The simultaneous appearance of multiple growth factors is known to occur in vivo
during wound healing and other tissue regeneration processes [1-3]. Several polymeric
delivery composites capable of releasing two or more proteins with distinct release profiles
have been developed to mimic this physiological event [2, 4-6].

However, these

heterogeneous, composite matrices require multiple fabrication steps and cumbersome
processes to yield non-uniform distributions of loaded proteins.

The use of multiple

emulsion and polymerization processes in the presence of the loaded proteins as well as
contact with the high-energy interfaces within these delivery devices often lead to protein
denaturation and loss of bioactivity [7]. These characteristic deficiencies also hinder in situ
device formation and injectability. Mechanistically, current composite delivery matrices rely
on degradative and diffusional resistances presented in series to modulate molecular
transport and hence fail to provide diverse protein release profiles.
We hypothesize that all the aforementioned limitations can be overcome by coencapsulating and subsequently releasing proteins from a monolithic hydrogel network
presenting distinct affinity sites for each of the co-encapsulated proteins. Here, we present
the first report on bi-functional, monolithic affinity hydrogels designed for tailorable dualprotein delivery.

Two affinity binding mechanisms, namely metal-ion-chelation and

electrostatic interaction, are simultaneously employed within a homogeneous and otherwise
inert poly(ethylene glycol)-diacrylate (PEGDA) hydrogel network to independently modulate
delivery of two proteins without sacrificing the high water content of the hydrogel matrix or
the need for composite polymer layers. Due to their structural simplicity, these affinity gels
are readily fabricated in aqueous solution in a single processing step which, contrary to
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existing composite delivery systems, greatly facilitates in situ encapsulation of bioactive
proteins and living cells [8-12].
While spatially and temporally controlled delivery of multiple proteins is known to
benefit tissue regeneration, the performance of current polymeric hydrogel delivery devices
is far from ideal.

Traditional hydrogel fail to produce versatile delivery profiles for

coencapsulated multiple proteins due to the inherent constrains of size exclusing effect. For
example, one can only significantly delay the release rate of a protein with a dimension
similar or larger to the mesh size of the inert hydrogel. In other words, these inert hydrogels
do not have the capability to (1) distinquish the release rates of two proteins with similar
sizes, or (2) delay the release rate of a smaller protein while keeping the release rate of a
larger protein constant. Prior attempts at controlling dual-protein delivery have relied upon
manipulating protein loading sites [2] (in microspheres or bulk polymer) or implementing
selective matrix degradation to accelerate the release of one protein while keeping the release
rate of the second protein unchanged [4]. One recently developed composite delivery system
is based on degradable gelatin microspheres contained within oligo(poly(ethylene glycol)
fumarate) (OPF) hydrogels [4]. In this portioned three-phase system, insulin-like growth
factor-1 (IGF-1) was loaded in densely crosslinked gelatin microspheres while transforming
growth factor-β1 (TGF-β1) was loaded either in loosely crosslinked gelatin microspheres or
in the bulk OPF gel. The release of TGF-β1 was accelerated by the addition of gelatindegrading collagenase. Although this approach provides a means of tuning TGF-β1 release
by changing its loading site, it requires the incorporation of two types of protein-loaded
microspheres within a third crosslinked polymer phase. There are also concerns regarding
the stability of proteins transported across microsphere-bulk polymer interfaces. From the
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view point of molecular transport, unpredictable discontinuities in protein release profiles
may also arise due to the presence of these interfaces [13-15].
Alternatively, polymers bearing a single type of affinity site for an encapsulated drug
have been extensively studied. These affinity matrices have the capability of retarding the
release of a particular target drug due to reversible drug-matrix binding that lowers the
apparent diffusivity of the therapeutic molecule. Several binding mechanisms, including
electrostatic [16-18], van der Waals, and hydrophobic interactions [19, 20] have been
proposed and exploited to facilitate sustained drug release from affinity matrices. For
example, synthetic monomers with acidic or basic functionalities have been tailored into a
wide variety of polymeric drug carriers to sustain the release of oppositely charged molecules
[16-18]. Natural macromolecules such as heparin and cyclodextrins (CD) have also been
used extensively as drug-binders. Heparin is a highly sulfated glycosaminoglycan (GAG) that
has the demonstrated capability to reduce cationic growth factor release rates when
incorporated, either by physical adsorption or covalent conjugation, into polymer networks
[8, 11, 21-24]. Cyclodextrins are another widely used drug-binder that can accommodate
“guest” molecules by forming drug-CD complexes [25-28]. Although matrices incorporating
these two types of affinity sites have achieved some success in sustaining protein release,
cumbersome chemical modifications are generally required to utilize these macromolecules
in hydrophilic polymer matrices. The mechanical and biological properties of the delivery
matrices made from these affinity agents are also not ideal. For example, heparin is a
polydisperse macromolecule with high molecular weight (ranging from 5,000 to 40,000
Daltons) that greatly limits its incorporation into polymer networks at sufficiently high
concentrations. Administration and handling of heparin-based gels are difficult due to their
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low mechanical strength. In addition, improper release of heparin may also cause serious
physiological complications [29]. The difficulties presented by cyclodextrins, on the other
hand, include their solubility, toxicity, and decreased drug-CD complex formation during
network fabrication [25]. When incorporated into polymeric hydrogels, these properties
make it difficult to systematically control protein release rates, to generate reproducible
release profiles, and to provide distinct release profiles for multiple, co-encapsulated
proteins.
Current research efforts are focused on developing synthetic affinity hydrogels with
alternative ligand chemistries for enhancing protein delivery performance including
enhanced bioavailability [30] and sustained delivery [31]. In an earlier report, we detailed the
synthesis, characterization, as well as mathematical modeling and experimental verification of
controlled protein release using a highly biocompatible and permeable PEG-co-GMIDA
(glycidyl methacrylate-iminodiacetic acid) hydrogel network [31].

The metal-chelating

GMIDA ligands were shown to reversibly bind to a genetically engineered hexahistidinetagged green fluorescent protein (hisGFP). The sustained release of his-tagged proteins
from highly swollen PEG-co-GMIDA hydrogels (water contents ~90%) reveals the
usefulness of this unique and specific binding mechanism for controlling protein delivery
from biocompatible hydrophilic networks. In this proof-of-concept work, we develop a
platform althernative to the existing composite matrices for dual-protein delivery. The goals
of this work are to obtain independently tunable, dual-protein delivery from structurally welldefined, highly permeable affinity hydrogels without sacrificing the preferential
hydrophilicity and permeability of the monolithic hydrogel matrices.
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7.2 Materials and Methods
7.2.1 Materials
All chemicals were obtained from Sigma-Aldrich unless otherwise specificed.
7.2.2 Synthesis of poly(ethylene glycol) diacrylate (PEGDA) macromer
Poly(ethylene glycol) diacrylate (PEGDA) was synthesized as previously described [32].
Briefly, toluene-dried PEG macromer with an average molecular weight of 3400 Da was
reacted with 8 molar excess of acryloyl chloride for 4 hours at room temperature in dark.
The triethylamine-HCl complex was removed from acrylated PEG by filtering the product
through alumina. Toluene was then removed from the product mixture under vacuum. The
crude product was dissolved in dichloromethane and precipitated in chilled diethyl ether to
obtain pure PEGDA. The purified PEGDA was filtered and dried under vacuum at room
temperature.

1

H NMR (Bruker 300MHz) was used to determine the degree of acrylation

(>95%).
7.2.3 Synthesis of methacrylated iminodiacetic acid (GMIDA) monomer
GMIDA monomer was synthesized by reacting glycidyl methacrylate (GMA) with
iminodiacetic acid (IDA) as shown in Scheme 7.1. IDA was dissolved in double distilled
water and neutralized with two molar excess of NaOH to keep carboxylic acids from
reacting with epoxy ring of GMA. Under constant stirring, an equimolar amount of GMA
was added drop-wise to the IDA solution and allowed to react for one hour at 65℃. The
product was then purified by precipitating in acetone and dissolving in double-distilled H2O
repeatedly. The final product was obtained by drying in vacuum oven below 60℃. A degree
of IDA methacrylation of 90% was determined by 1H NMR.
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Scheme 7.1 The synthesis of methacrylated iminodiacetic acid.
7.2.4 Expression and purification of hexahistidine-tagged green fluorescent protein
(hisGFP)
6xhisGFPuv plasmid was a generous gift from Prof. M. Textor at ETH, Zurich. The
expression and purification process was modified according to a previous report [33]. The
6xhisGFPuv plasmid (1ng/µL) was transformed into MDS41E E. coli. by electroporation.
The transformed E. coli. cells were expressed in DYT (Double Yeast Tryptone: 1% Bacto
yeast extract, 1.6% Bacto tryptone, 0.5% NaCl) broth containing 100µg/mL ampicillin to an
optical density of 0.9 at 600nm at 37℃ and then induced with IPTG (final concentration
1mM). After induction, the temperature was dropped to 25℃ and the cells were allowed to
grow for 18 hours. The cells were harvested by centrifugation and re-suspended in 20mM,
pH8.0 Tris-HCl buffer containing 1mg/mL lysozyme and 10µg/mL DNase at 4℃. The
supernatant was collected by ultracentrifuge at 4℃ (30min, 180000g). The purification of
hisGFP was performed with QIAexpressionst® (Qiagen) according to the manufacturer’s
protocol. The hisGFP was obtained by dialysis against 10mM, pH8.0 HEPES buffer
overnight and freeze-dried. The maximum excitation and emission wavelengths (395nm and
510nm, respectively) of hisGFP were determined by a full-scale scan using a microplate
reader (Spectramax GeminiEM, Molecular Devices, CA, USA). The binding of his-tagged
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protein to GMIDA-nickel complex was confirmed by decreased nickel absorbance
(wavelength: 721nm) upon protein-ligand binding using a UV-vis spectrophotometer [31].
7.2.5 PEG-co-GMIDA hydrogel fabrications and characterizations
PEG-co-GMIDA affinity hydrogels containing proteins were fabricated in situ via
photopolymerization. Briefly, a 10 wt% PEGDA macromer solution was produced by
dissolving the dry macromer in 10 mM, pH 8.0 HEPES buffer. Required amounts of
GMIDA monomer, metal ions, hisGFP (5 µg/mL), and lysozyme (10mg/mL) were added to
the macromer solution. The mixed protein-monomer solution was then incubated at 4℃
for at least 30 minutes to allow binding equilibrium to be obtained between hisGFP and
metal ion-GMIDA complexes. After incubation, photoinitiator Irgacure-2959 (I-2959, Ciba
Specialty Chemicals) was added to a final concentration of 0.2 wt%. The mixed prepolymer
solution was then injected between two glass slides separated by 0.55mm Teflon spacers.
The assembled apparatus was then exposed to UV-light (BLACK-RAY®, 8 mW/cm2 at 365
nm) for 8 minutes to form affinity hydrogels. The time for photopolymerization was selected
so that the fluorescence of his-GFP was not affected.

For equilibrium swelling ratio

measurements, the swollen weights of PEG-co-GMIDA hydrogels were measured
gravimetrically to obtain swollen gel weights. After which the gels were dried in vacuum for
48 hours to obtain dried weights. Equilibrium swollen ratio (Q) was then determined by:
Q=

Equilibrium swollen weight
Dried gel weight
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7.2.6 In vitro dual-protein delivery and quantification of released protein
concentrations
In vitro dual-protein release was performed in 3 mL HEPES buffer (10mM, pH 8.0).
At predetermined time intervals, release media were replenished with fresh buffer. hisGFP
and lysozyme concentrations were quantified immediately after sampling. GFP intrinsic
fluorescence was used to quantify its total amount while a fluorescamine (3 mg/mL acetone)
assay was employed to determine lysozyme release. The fluorescamine signal contributed
from hisGFP was subtracted from the total fluorescamine signal of the released protein
mixture, based on a fluorescamine signal – hisGFP fluorescence calibration curve, to
determine the amount of lysozyme release. However, due to the excessive amount of
lysozyme loaded in the gel, released hisGFP contributed to less than 5% of the total
fluorescamine signal. After completing the release studies, the swollen and dried gel weights
were measured gravimetrically and used to determine equilibrium mass swelling ratio (Qm)
and water content.

Equilibrium mass swelling ratio was used for the calculation of

volumetric swelling ratio (Q) and gel mesh size (ξ) according to established equations [34,
35]. Total protein release was converted to fractional release (f=Mt/M∞) and plotted against
the square root of time for apparent diffusivity calculations (see supporting materials). The
slopes of the linear portion of these modified release curves were used to calculate apparent
protein diffusivities [36].

After releasing 240 hours, dual-protein loaded affinity hydrogels

were transferred from 10mM HEPES buffer into 100mM EDTA containing HEPES buffer
to trigger the release of remaining hisGFP. Total protein release was quantified prior to and
24 hours after EDTA addition to determine the stimuli-responsiveness of affinity hydrogels.
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7.3 Results and Discussion
The metal-chelation binding mechanism based on the use of IDA and NTA
(nitrilotriacetic acid) ligand chemistries has been extensively used for protein purification [37]
as well as for hydrogel fabrication [38] and functional surface-patterning [33, 39]. The
common feature for these studies is the utilization of IDA or NTA functionalities to chelate
metal ions for his-tagged-protein immobilization. In the current work we take advantage of
not only the metal-ion chelating ability of IDA but also its anionic nature to fabricate bifunctional monolithic hydrogels capable of simultaneously yet independently tuning delivery
of two representative proteins, hisGFP and lysozyme (Table 7.1).

Our strategy for

controlling dual-protein release is based on selective protein-ligand binding which
significantly decouples protein release rates from matrix crosslinking density and degradation
rate.

Table 7.1 Characteristics of proteins used for dual-delivery.
Molecular weight (kDa)

Isoelectric point (pI)

Stokes radius (Å)

lysozyme

14.1

11

16.0

hisGFP

27.4

5.5

28.2

Protein

Figure 7.1 illustrates the fabrication of dual ligand-protein loaded monolithic affinity
hydrogels.

PEG hydrogels are used due to their demonstrated biocompatibility [40],

nonspecific protein-excluding property [41-43], and well-documented structure-property
relationships [44, 45]. While degradable moieties can be readily incorporated into these
devices, the use of non-degradable PEG hydrogels eliminates protein release resulting from
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network degradation and facilitates the observation of sustained release effects due to
affinity-binding [30, 31]. The use of diacrylated PEG macromers permits rapid network
formation via photopolymerization as well as copolymerization with other (meth)acrylated
monomers such as GMIDA.

The GMIDA ligand monomer is a highly water-soluble

monomer that complexes transition metal ions with high affinity (Kd~10-12M).
GMIDA(Ni2+) complexes copolymerized into the hydrogel network chelate his-tagged
proteins such as hisGFP with moderate affinity (Kd = 10-4 ~10-6 M), providing sufficient
ligand-protein binding while allowing diffusion-driven sustained protein release [31]. In
addition, without metal ions present, anionic GMIDA monomers contribute to the delayed
release of cationic proteins such as lysozyme via electrostatic binding of the diffusible
protein to the insoluble matrix.

Figure 7.1 Schematic representation of the proposed monolithic affinity hydrogel system for
tailorable dual-protein delivery. The affinity hydrogels are prepared from one-step
photopolymerization of PEGDA and methacrylated affinity ligands –GMIDA(Ni2+) and
GMIDA that reversibly complex with hisGFP and lysozyme, respectively.

209

Before demonstrating the ability of our affinity hydrogels on independently
controlling dual-protein delivery, we first fabricated inert PEG hydrogels with different
polymer contents (10 wt% and 20 wt%) in the prepolymer solution and used these inert
hydrogels for simultaneously delivering the co-encapsulated proteins – lysozyme and
hisGFP. Clearly shown in Figure 7.2, it is difficult to independently control dual-protein
delivery by changing gel crosslinking density as the delivery rates of both proteins
simultaneously decrease with increasing polymer content (Figure 7.2C). Furthermore, since
hisGFP is a larger protein compared to lysozyme (Table 7.1), the apparent diffusivity of
hisGFP is affected to a greater extent. An 11-fold decrease in hisGFP apparent diffusivity
(from 0.63 to 0.06 × 108 cm2/sec) is observed when polymer content of the PEG hydrogel is
increased from 10 to 20 wt%. On the other hand, an approximately 3-fold decrease in
lysozyme apparent diffusivity (from 8.43 to 2.83 × 108 cm2/sec) is observed with the same
increase polymer content.
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Figure 7.2 Dual-protein release from inert PEG hydrogels with different PEG content (10
vs. 20 wt%) in the prepolymer solution. (A) hisGFP release and (B) lysozyme release. (C)
Apparent diffusivity of hisGFP and lysozyme is calculated from the initial portion of the
fractional protein release curves according to established method [48]. (Average ± Standard
deviation, n=3, * p<0.05).
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Figure 7.2 reveals that the use of inert hydrogels provides very limited control over
the relative delivery rates of multiple proteins. To promote tissue regeneration that requires
sequential delivery of multiple growth factors, one may wish to deliver a larger protein (e.g.
VEGF: M.W. ~45 kDa) faster than a co-encapsulated smaller protein (e.g. PDGF-BB: ~25
kDa) from a single delivery device. Apparently, it is very difficult to achieve this goal by
using inert hydrogel matrices. By tailoring GMIDA and metal ion concentrations, however,
dual delivery of cationic and his-tagged proteins with independently controllable release rates
can be readily achieved from bifunctional, monolithic PEG-co-GMIDA hydrogels. Figure
7.3 demonstrates that his-tagged protein (hisGFP) release from PEG-co-GMIDA hydrogels
can be independently and systematically controlled without altering the co-encapsulated
cationic protein (lysozyme) release profile. By gradually increasing Ni2+ concentration while
keeping the GMIDA concentration constant during in situ photopolymerization, GMIDAmetal ion complexes are formed which bind strongly and specifically to his-tagged proteins
within the highly hydrophilic PEG-based hydrogel environment. This behavior is similar to
the binding mechanism used in the purification of his-tagged proteins. Since the affinity
binding between his-tagged proteins and GMIDA ligands is mediated by metal ions such as
nickel, one expectedly sees a sharp decrease in hisGFP release (from 75 ± 5.0% for
GMIDA10 gels to 20 ± 5.2% for GMIDA10Ni10 gels at 24-hr) when nickel ions are added
in a stoichiometric ratio to GMIDA (Figure 7.3A). However, the addition of nickel ions
does not significantly affect lysozyme release (Figure 7.3B). The non-responsiveness of
lysozyme to the presence of nickel ions is also observed when lysozyme is solely released
from PEG-co-GMIDA hydrogels containing 10mM GMIDA (data not shown).
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Figure 7.3 Dual-protein release from monolithic PEG-co-GMIDA hydrogels containing
10mM GMIDA only (GMIDA10), 10mM GMIDA and 5mM Ni (GMIDA10Ni5), or 10mM
GMIDA(Ni) (GMIDA10Ni10) ligands demonstrating (A) tailorable hisGFP release and (B)
constant lysozyme release. (C) Apparent protein diffusivity. (Average ± Standard deviation,
n=3, * p<0.02).
When comparing apparent protein diffusivities obtained from PEG-co-GMIDA gels
with and without nickel ions present, one can see that the diffusivities of hisGFP decrease
dramatically from 0.89 ± 0.29×10-8 to 0.15 ± 0.02×10-8 cm2/sec (p<0.02) when nickel ions
are added in a stoichiometric ratio to GMIDA concentration (Figure 7.3C). In contrast, the
diffusivity of the co-encapsulated lysozyme shows no significant change when nickel ions are
added. It is also important to note that the mass swelling ratios of the PEG-co-GMIDA
(10mM GMIDA) gels with and without nickel ions are 10.0±0.14 and 9.41±0.37,
respectively (Table 7.2), implying consistently high gel water contents (90.0±0.14% and
89.4±0.42%). Taken together, these data suggest that the release of his-tagged proteins from
a mixture of co-encapsulated proteins can be independently regulated by simply adjusting the
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concentration or chemistry of copolymerized GMIDA-metal ion complexes without
sacrificing the preferential high water content of these in situ deliverable hydrogels.

Table 7.2 Characteristics of affinity PEG-co-GMIDA hydrogels used in dual-protein
delivery.
Ligand (mM)

Hydrogel
formulation

Mass swelling
ratio

Water content
(%)

Mesh size
(Å)[a]

GMIDA

GMIDA0
GMIDA10

0
10

0
0

9.84±0.13
9.41±0.37

89.8±0.13
89.4±0.42

60.1±0.24
60.2±0.73

GMIDA10-Ni10

10

10

10.0±0.14

90.0±0.14

61.4±0.27

GMIDA15-Ni5

15

5

10.4±0.51

90.4±0.47

61.2±0.91

Ni

2+

[a] Mesh size (ξ) is calculated from measured equilibrium gel swelling ratio. Equations for
mesh size calculation can be found elsewhere [34].
We also performed additional release studies to demonstrate the ability of PEG-coGMIDA affinity hydrogels to independently control the release of a cationic protein –
lysozyme.

As shown in Figure 7.4A, the release profile of hisGFP from PEG-co-

GMIDA15Ni5 gels (15mM GMIDA and 5mM Ni2+) is almost identical to that obtained with
homopolymer PEGDA hydrogels. In hydrogels containing high GMIDA concentrations
(15mM), one would expect to see faster hisGFP release due to electrostatic GMIDA-hisGFP
repulsion (both components are anionic). This trend, however, is offset by adding a small
amount of nickel ions (5mM). Comparing Figures 7.4A and 7.4B, it is clear that the
lysozyme release is independently decreased due to increased electrostatic GMIDA-lysozyme
binding without affecting the release of hisGFP. Further comparison of apparent protein
diffusivities within the inert PEG hydrogels and PEG-co-GMIDA15Ni5 hydrogels (Figure
7.4C and supporting materials), a selective and dramatic decrease in lysozyme diffusivity
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(from 8.43±1.80×10-8 to 0.61±0.07×10-8 cm2/sec, p<0.002) demonstrates the ability of these
bifunctional affinity hydrogels to independently control the release of co-encapsulated
cationic proteins. When examining the release profiles shown in Figures 7.2 to 7.4, one can
clearly see that a significant portion of lysozyme (at least 30%) was retained in the hydrogels.
When the polymer content in the prepolymer solution was increased from 10 wt% to 20
wt% (Figure 7.2B), or when the the anionic GMIDA content was increased to 15mM
(Figure 3B), an even greater portion of lysozyme becomes unreleasable. This incomplete
release phenomenon is most likely due to the following two reasons: (1) The formation of
irreversible protein-polymer conjugates during photopolymerization that prevents their
complete release [30].

This incomplete release phenomenon is rountinely observed in

polymeric protein delivery devices due to unfavorable protein-polymer interactions. (2) The
irreversible electrostatic binding between cationic protein and anionic ligand. Although the
electrostatic binding can be used to significantly decrease protein release rates (Figure 7.3C),
it will gradually produce higher degrees of binding as the local protein concentration within
the anionic gels decreases during the release process.
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Figure 7.4 Dual-protein release from monolithic PEG-co-GMIDA hydrogels containing no
ligand (GMIDA0) or 15mM GMIDA and 5mM Ni2+ (GMIDA15Ni5) ligands demonstrating
(A) constant hisGFP release and (B) tailorable lysozyme release. (C) Apparent protein
diffusivity. (Average±Standard deviation, n=3, * p<0.002)
The facts that the equilibrium water contents of all the described affinity hydrogels
remain at a high level (Table 7.2) and no correlation was found between gel swelling and
diffusivities of either protein suggest that the observed sustained protein delivery effects are
due to the degree of selective protein-GMIDA binding.

Furthermore, from the

characteristic parameters of proteins and hydrogels listed in Table 7.1 and Table 7.2, one
can clearly see that the network mesh sizes calculated for the hydrogels (~60Å [34]) are
much larger than the sizes of either encapsulated protein (16.0Å for lysozyme, 28.2Å for
hisGFP).

Due to its smaller molecular size, lysozyme diffuses rapidly when it is co-

encapsulated and delivered with hisGFP from inert PEGDA hydrogels (Figure 7.4,
GMIDA0 gels). For practical applications, however, one may wish to deliver larger proteins
at comparable or faster rates than smaller proteins. This type of dual-delivery profile is
impossible to accomplish from traditional gel matrices where release rates are controlled by
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size-exclusion effects. As described previously, the only existing method for achieving
selective release of the larger protein is to use complex composite delivery vehicles where
smaller proteins are encapsulated within microspheres or slow-degrading polymers
incorporated within a second polymer matrix. As demonstrated by the data in Figures 7.3
and 7.4, the bifunctional affinity gels described in this work overcome the limitations
presented by composite systems and are capable of successfully delivering proteins at
controlled rates irregardless of their relative sizes.
An additional advantage of the PEG-co-GMIDA affinity hydrogels as dual-delivery
devices is their protein-selective stimuli-responsive behavior. This is achieved by selectively
triggering the release of hisGFP (Figure 7.5A) but not lysozyme (Figure 7.5B) through the
addition of EDTA (ethylenediamine tetraacetic acid), a strong metal-ion chelator, to the
release medium. As can be seen in Figure 7.3A, hisGFP release reaches a plateau after 120
hours.

Prolonged incubation of the hydrogels in the release medium does not yield

significant increase in total hisGFP release, presumably due to exceptionally strong binding
between the GMIDA(Ni2+) ligands and a fraction of the encapsulated hisGFP molecules. As
shown in Figure 7.5A, the complete release of this tightly-bound hisGFP fraction can be
triggered via the addition of EDTA to the release medium. Complete release of hisGFP is
observed within 24 hours of EDTA addition. In contrast, the release of lysozyme is not
affected by the addition of EDTA (Figure 7.5B). Although not intent to work as an actual
triggerable release mechanism in vivo, this unique feature demonstrates that the retained
proteins are recoverable from the hydrogel matrices. The reversible GMIDA(Ni)-hisGFP
binding can be destroyed by applying proper stimuli to fully recover the tightly bound
protein. Most importantly, the retention of these tightly bound proteins is due to the
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reversible protein-ligand binding, but not due to the additional diffusional resistance
imposed by increasing polymer crosslinking density. Therefore, more sustained release
profiles can be designed by incorporating degradable hydrogel chemistry into these affinity
hydrogels without sacrificing the preferencial hydrophilicity of the delivery device.
The current work demonstrates that by preparing the protein-loaded hydrogels with
well-defined hydrogel chemistry and ligand quantities, one can easily and independently
control the delivery of either one protein from the mixture of multiple protein solutions. To
date, there are very limited, if any, reports on the use of affinity hydrogels to deliver multipleprotein independently. The affinity-based dual-protein delivery strategy reported herein
opens new avenue toward the design of multi-functional, biocompatible hydrogels capable
of delivering multiple therapeutically relevant proteins to promote tissue regeneration and
wound healing.

Future studies will focus on the design and synthesis of hydrogels

copolymerized with other biological ligands, such as oligo-peptides, that yield affinity to
other therapeutically relevant growth factors.
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Figure 7.5 Selective stimuli-responsive hisGFP release from monolithic affinity hydrogels
containing 10mM GMIDA (GMIDA10) or GMIDA(Ni) (GMIDA10Ni10) ligands. After
releasing 10 days, gels with residual proteins were transferred into release medium (10mM
HEPES, pH8.0) containing 100mM EDTA for 24 hours. Protein release was quantified
prior to and 24-hr after EDTA addition. (Average ± Standard deviation, n=3, * p<0.0004)
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7.4 Conclusion
In conclusion, we have developed monolithic affinity hydrogels bearing well-defined
protein-binding sites that can simultaneously and selectively bind to native cationic proteins
and recombinant his-tagged proteins under physiological conditions. Since many therapeutic
growth factors (e.g. basic fibroblast growth factor (bFGF), nerve growth factor (NGF),
platelet-derived growth factor (PDGF), etc) are cationic at physiological conditions and
numerous proteins can be recombinantly engineered with hexahistidine tags without altering
the folding or bioactivity of the native protein, the versatility and biocompatibility of this
delivery scheme is advantageous for many tissue engineering applications that require
complex, simultaneous delivery of multiple proteins [46, 47]. To the best of our knowledge,
this is the first published hydrogel delivery system with protein-binding affinity that can
significantly sustain protein release, independently control delivery of multiple proteins, and
exhibit selective stimuli-responsive behavior. The monolithic affinity hydrogels developed
herein discard the need for complex composite matrix fabrication with non-uniform protein
distributions, crosslinking densities or degradation rates.

The one-step, biocompatible

hydrogel fabrication method described in this work can also be easily modified, based on
well-established chemistries, to accommodate matrix degradation or specific protein-binding
mechanisms to achieve more sophisticated protein delivery profiles and therapeutic needs.
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CHAPTER EIGHT
CONCLUSIONS AND RECOMMENDATIONS
8.1 Conclusions
The rational design and facile fabrication of biocompatible yet versatile protein
delivery matrices require the cooperative knowledge of biocompatibility, protein/peptide
chemistry, polymer science and engineering, and molecular transport theories. To this end,
the major objectives of this dissertation were to understand protein-polymer interactions
during in situ photopolymerization and to design/fabricate affinity hydrogels that allow for
effectively tuning delivery of bioactive proteins without sacrificing the preferential
hydrophilicity of the hydrogel carriers.

In this research project, the investigation and

optimization of reaction conditions were performed for in situ photopolymerization in an
attempt to design a better hydrogel-based protein delivery system that can prevent adverse
protein-polymer conjugation and hence increase the bioavailability of the loaded protein
therapeutics. Furthermore, systematically controlled single or multiple protein delivery from
highly permeable hydrogel matrices was made possible by incorporating robust proteinbinding ligands into the otherwise inert PEG hydrogel networks. Collectively, these efforts
will lead to the successful development of biocompatible hydrogel matrices that can
simultaneously deliver multiple bioactive protein therapeutics at optimal doses and delivery
rates.
A better understanding of protein stability and their potential conjugation to the
growing polymer chains during in situ photopolymerization permits one to evaluate the
critical factors affecting the structural integrity and bioactivity of the encapsulated proteins.
The detrimental effects of photoinitiators and free-radicals on protein bioactivity and
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structural integrity during in situ photopolymerization were analyzed and demonstrated to be
directly related to the type and concentration of photoinitiator used during the UVirradiation process.

The addition of hydroxyl-terminated high molecular weight

poly(ethylene glycol) at high concentrations only slightly increased lysozyme bioactivity,
presumably due to a molecular crowding effect that decreases the exposure of lysozyme to
free radicals generated from photoinitiators. On the other hand, the addition of acrylated
PEG macromers effectively decreases lysozyme damages caused by free-radicals and
enhances its bioactivity during in situ photopolymerization. Although the use of acrylated
polymers preserves the bioactivity of lysozyme, it does not prevent the formation of proteinpolymer conjugates that decrease total protein release. To further eliminate protein-polymer
conjugation, a pseudo-specific metal-ion chelating ligand was used for binding to
encapsulated proteins such as bovine serum albumin (BSA).

This ligand binds to the

copper-binding site of BSA, which was suggested to be the site vulnerable to free-radical
attack, and prevents the growing of polymer chain from there. The prevention of proteinpolymer conjugation is critical for in situ photopolymerization as it not only increases
protein bioavailability but also decreases the risk of undesired immune response induced by
the conjugates.
An ideal carrier loaded with protein therapeutics must deliver its payloads with the
appropriate spatial and temporal control in order to maximize therapeutic efficacy while
preventing harmful side effects. Being a class of biomaterial that resembles natural tissue,
hydrogels have drawn tremendous interest and have been used extensively in controlleddelivery and tissue-engineering applications. Locally delivering protein therapeutics is less of
an obstacle due to the advances in in situ polymerization techniques. However, a more
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challenging task is how to systematically control the delivery of single or multiple proteins
with distinct and highly tunable release profiles. The novel affinity hydrogel platform based
on reversible and specific protein-ligand binding developed in this dissertation work
demonstrated that protein delivery rate can indeed be systematically controlled without
changing the matrix crosslinking density or degradation rate.

In conjunction with

experimental results, a mathematical model accounting for protein diffusion and reversible
protein-ligand binding was developed to predict protein delivery profiles from this novel
affinity hydrogel platform.
A thorough assessment of any protein delivery matrix should include an evaluation of
the routes of network fabrication and the safety of the device (both to the host and to the
encapsulated proteins) as well as the available methods of protein encapsulation and their
subsequent release rate and therapeutic efficacy. In the context of protein-loading and its
subsequent release, it was found that the delivery rates of protein from post-loaded gels were
faster than the in situ-loaded gels. This phenomenon can be attributed to the excessive
swelling of affinity hydrogels caused by the influx of not only proteins but also other
electrolytes and water molecules. The increased mesh size has profound effects on the
release rate of the encapsulated protein and therefore must be carefully evaluated in order to
obtain optimal protein release profiles.
The sequential appearance of multiple proteins responding to tissue injury is an
important characteristic of in vivo wound healing. The one-step in situ photopolymerized
affinity hydrogel platform developed in this dissertation greatly simplifies matrix fabrication
yet still permits independent control over dual-delivered proteins. This novel dual-protein
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delivery strategy offers immense opportunities for tissue engineering applications requiring
temporal control over multiple biological agents such as growth factors and other proteins.
8.2 Recommendations
Future work in the area of protein stabilization should be focused on the evaluation of
other biocompatible protein-binding ligands for therapeutic growth factors such as vascular
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived
growth factor (PDGF), and so on. The delivery of these growth factors from injectable
polymeric scaffolds for regenerative medicine has evolved as a standard strategy. However,
their conjugation to the chemically crosslinked polymer networks has largely being ignored.
Hence, challenges and opportunities exist for improving the bioavailability and safety of
these therapeutic proteins.

Since every protein possesses a distinct tertiary/quaternary

structure and exposed active amino acid residues, it is not surprising to observe different
extents of protein-polymer interaction/conjugation for each therapeutic growth factor
during in situ photopolymerization. Therefore, it is expected that different protective ligands
will be needed for each protein and techniques for identifying these ligands will be needed.
A high-throughput screening technique that allows for the screening of peptide ligands
expressed on the cell surface of bacteria, phages, or other microorganisms can be utilized for
this purpose. Highly efficient screening methodologies will greatly facilitate the design of
protein-binding ligands. Once appropriate peptide ligands are identified for therapeuticallyrelevant proteins, the hydrogel matrices can be designed and fabricated in a more
biocompatible manner that allow for the delivery of optimal amounts of protein therapeutics
to prevent waste of the valuable therapeutic agents and hence provide maximal therapeutic
efficacy.
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Future efforts in fabricating affinity hydrogels for protein delivery should focus on
identifying unique peptide-ligand chemistries for use with native protein therapeutics.
Although the binding of hexa-histidine tagged protein to the metal-ion chelating ligand is
shown by the current research to be robust and reversible, it requires modification of
proteins through genetic engineering and may not be acceptable when used clinically.
Therefore, opportunities for the high-throughput screening and rational design of
polymerizable peptide ligands that can reversibly bind to native protein therapeutics with
adjustable affinity also exist in the arena of controlled drug delivery. Once identified, the
potential of peptide ligands can be further enhanced by manipulating the chemistry by which
the ligand is incorporated within the polymer network. For example, a peptide with a
flexible PEG spacer arm can be synthesized, based on established chemistries, to improve
protein binding and provide more predictable release profiles. Alternatively, multi-valent
ligand-binding strategies can be integrated into the design of crosslinkable ligands or
interpenetrating networks (IPNs). This would allow for strong protein-binding through the
collaborative efforts of several neighboring, low-affinity ligands.

Finally, biodegradable

hydrogels should be used, in conjunction with the versatile protein-binding affinity
mechanism, to maximize the clinical efficacy of the hydrogel matrices.
An important application for this type of affinity hydrogels is to promote or accelerate
chronic/impaired wound healing such as diabetic foot ulcers. Impaired wound healing is
characterized by an imbalance of growth factors and proteases at the wound site. One
available treatment for impaired wounds is to locally apply growth factors, such as plateletderived growth factor (PDGF). However, due to the extreme short half-lives of growth
factors (only few minutes) in the biological environment, this strategy achieves very limited
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clinical success even at high dosing. Furthermore, single growth factor therapy does not
mimic the synergistic production of multiple growth factors that naturally occurs during
normal wound healing. The novel concept of injectable affinity hydrogels capable of delivering
multiple fragile protein therapeutics sequentially in distinct release profiles enables the
rationale design of wound dressing and tissue filler loaded with multiple growth factors. For
in vivo testing of this multiple protein delivery strategy, a diabetic animal model can be used
to promote impaired wound healing by locally photo-curing affinity hydrogels that
sequentially deliver two key growth factors – basic fibroblast growth factor (bFGF) and
PDGF – at rates and doses that optimize clinical efficacy.

232

APPENDIX

233

APPENDIX A
BIODEGRADABLE HYDROGELS: TAILORING PROPERTIES AND FUNCTIONS
THROUGH CHEMISTRY AND STRUCTURE
(Chapter appearing in Biomaterials, CRC Press, June 2007)
A.1 Introduction
Hydrogels are water-swollen polymeric networks. They remain insoluble when placed
in aqueous environments due to chemical or physical crosslinking of individual polymer
chains. Chemical crosslinks may be ionic or covalent while physical crosslinks may be
entanglements, crystallites, or weak associations such as hydrogen bonding or van der Waals
interactions (Lowman and Peppas 1999).
Hydrogels have played an important role in biomedical applications since the late
1950s and the development of poly(2-hydroxyethyl methacrylate) (PHEMA) as a soft contact
lens material (Wichterle and Lim 1960). Since that time they have found application in drug
delivery.

In the last decade hydrogels have played an ever-increasing role in the

revolutionary field of tissue engineering where they are used as scaffolds to guide the growth
of new tissues. Their widespread acceptance in these fields is primarily due to the structural
similarity hydrogels exhibit compared to macromolecular-based components in the body and
the ability of hydrogels to replicate the properties of natural tissue better than any synthetic
material. Hydrogels such as those produced from PHEMA have high water contents at
equilibrium, exhibit rubbery behavior, and show low surface coefficients of friction.
Biocompatible hydrogels are currently used in numerous biomedical applications including
opthalmological devices, biosensors, biomembranes, and carriers for controlled delivery of
drugs and proteins (Wichterle and Lim 1960; Andrade 1976; Lowman and Peppas 1999;
Peppas, Huang et al. 2000).
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More recently, the design and application of biodegradable hydrogels has dramatically
increased the potential impact of hydrogel materials in the biomedical field and enabled the
development of exciting advances in controlled drug delivery and tissue engineering. While
all polymers will eventually degrade under extreme environmental conditions (i.e., high
temperatures or low pH solutions), biodegradable hydrogels of interest to this discussion
degrade over clinically relevant timescales under relatively mild conditions (i.e., aqueous
solutions, physiological temperature and pH). This degradation capability eliminates the
need for long-term in vivo biocompatibility or surgical removal of the gels. Biodegradable
hydrogels, if correctly designed, will break down into lower molecular weight, water-soluble
fragments in vivo that can then be resorbed or excreted by the body once the desired
function of the gel is accomplished. In addition to minimizing surgical invasiveness, the use
of these erodible gels facilitates a wide variety of new applications and delivery strategies
such as degradation-controlled drug delivery, in situ scaffold formation and tissue
regeneration, and controlled release via intravenous or pulmonary administration of
degradable polymeric microspheres.
This chapter provides an overview of the chemistry, design, fabrication, and
application of biodegradable hydrogels for drug delivery and tissue engineering. The first
section briefly describes the various structural classes of degradable hydrogels that exist.
Following an overview of the most commonly used gel types, the next section focuses on
the fabrication and characterization of bulk-degrading, covalently crosslinked hydrogels. The
chemical and structural parameters that quantify the physicochemical properties of these gels
before and during gel degradation are identified and detailed from an experimental and
theoretical perspective.

The inherent factors that are known to significantly impact
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degradation rates and macroscopic degradation behavior are also described in an effort to
demonstrate how efforts to intelligently engineer the chemistry and structure of these gels on
the molecular level directly correlate with improved device performance in tissue engineering
and drug delivery applications.
The final section of this chapter delivers an overview of degradable hydrogel
chemistries with proven or potential applications in tissue engineering and/or drug delivery.
Gels are divided into two categories according to the natural or synthetic origin of their
predominant polymer chemistry. Hydrogels from natural polymers have already gained
widespread use in the biomedical field. However, gels obtained from natural polymers
exhibit distinct limitations that have motivated approaches to modify these naturally
occurring polymers as well as to develop synthetic derivatives and entirely novel synthetic
chemistries. An emphasis of this concluding section is to highlight recent efforts to develop
hybrid hydrogel systems that display the most advantageous properties derived from both
natural and synthetic materials.
A.2 Hydrogel Classifications
A.2.1 Degradation versus Erosion
For the discussions in this chapter, degradation refers to bond cleavage or crosslink
dissolution within a network, while erosion refers to the subsequent mass loss from the
network that occurs as a result of gel degradation. Degradation can occur via dissolution of
physical crosslinks. It can also occur in covalently crosslinked systems through the cleavage
of hydrolytically labile bonds such as anhydride or ester groups, or enzymatically cleavable
peptide or protein linkages. These labile bonds can be present in the crosslink segments
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(predominant in synthetic polymer networks) or along the backbone chains (predominant in
naturally derived polymer networks).
The degradation behavior of a hydrogel pertains to the time-dependent evolution of the
chemical, physical, and structural properties of the crosslinked network that occur as labile
bonds on the surface or within the bulk of the gel are cleaved. Important phenomena that
occur to varying extents during gel degradation include changes in hydrogel swelling ratios or
equilibrium water contents, network mechanics, and solute diffusivities within the swollen
matrices. The rate and profile of mass loss from the hydrogel is also important. One or
more of these listed properties will play a role in determining the successful function of a
degradable gel for a particular drug delivery or tissue engineering application. In addition,
the molecular weight, chemistry, and local concentration of the degradation products
produced by an eroding gel must always be considered to ensure complete biocompatibility.
In addition to the macroscopic gel properties themselves, the rate of hydrogel
degradation must be carefully controlled both in drug delivery and tissue engineering
applications.

In drug delivery systems, hydrogel degradation and erosion rates help

determine drug availability and pharmacokinetic effects on surrounding cells and tissues.
For tissue engineering applications, it is usually desirable to have biodegradable scaffolding
to promote cell infiltration and tissue growth.

It is a commonly believed that the

degradation rates of tissue scaffolds must be matched to the rates of various cellular
processes in order to optimize tissue regeneration (Hubbell 1999; Lee, Alsberg et al. 2001).
Therefore, the degradation behavior of all biodegradable hydrogels should be well defined,
reproducible and tunable via hydrogel chemistry or structure.
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For physically crosslinked gels, the degradation kinetics of dissolving crosslinks are
hard to define and control. The degradation kinetics of chemically crosslinked gels are,
however, more easily defined and much work has recently been done to link the kinetics of
labile bond degradation to the overall gel degradation behavior in hopes of engineering
biodegradable hydrogels with precise properties.
A.2.2 Bulk versus Surface Degradation
In general, degradation of crosslinked networks occurs in one of two forms: nonuniform, surface degradation or uniform, bulk degradation (Kohn and Langer 1996).
Surface-degrading networks maintain their crosslinking density and structural integrity
throughout the degradation process, because degradation is limited to the surface of the
material. As an example, surface degradation often results when the rate of bond hydrolysis
is much faster than the rate of water transport into a polymeric device. Surface degrading
networks are advantageous for drug delivery applications because zero-order release of
entrapped species at a desired rate can be obtained by choosing the appropriate device
geometry or altering the kinetics of degradation (Davis and Anseth 2002).
In bulk-degrading networks, infiltration and transport of species critical to the
particular degradation mechanism employed by the hydrogel chemistry are faster than the
inherent degradation kinetics. By definition, all hydrolytically degradable hydrogels will
exhibit bulk-degrading characteristics due to the presence of a relatively high concentration
of water molecules throughout the gel architecture. The same water that swells these gels
will also homogeneously degrade the labile bonds present throughout the network.
However, hydrogels that are degraded by species other than water may degrade by a bulk,
surface, or combined mechanism depending on the permeability of the degrading species
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within the gel. For example, peptide-crosslinked hydrogels that degrade through the actions
of a particular enzyme may exhibit extremely high water contents in excess of 90% by
volume. However, because the gel chemistry or limited mesh size prevents the uptake of the
degradative, macromolecular enzyme within the bulk of the gel, only the labile peptide bonds
at the surface will be exposed to the enzyme. The limited enzyme permeation will produce
the observation of surface-mediated gel degradation and erosion.
While the crosslinking density and physical properties of surface-degrading gels
remain constant during the biodegradation process, the properties of bulk-degrading gels are
altered in a systematic fashion. The evolution of microscopic and macroscopic properties in
bulk-degrading hydrogels is inherently tied to their polymer chemistry, network structure,
and degradation kinetics.

For example, highly swollen hydrogels formed from

dimethacrylated poly(lactic acid)-b-poly(ethylene glycol)-b-poly(lactic acid) (PLA-PEG-PLA)
undergo bulk degradation. The modulus, solute permeability, water content, and many other
gel properties depend on the crosslinking density of the PEG-based hydrogel (Sawhney,
Pathak et al. 1993; Metters, Anseth et al. 2000). As the lactic acid bonds are cleaved
uniformly throughout the gel via hydrolysis, the crosslinking density of the still insoluble
network systematically decreases, increasing swelling and network mesh size while lowering
gel modulus. These property changes then, in turn, lead to macroscopically observable
changes in the water content, permeability, and elasticity of the hydrogel as it degrades. The
quantitative relationships between these dynamic properties during hydrogel degradation are
detailed later in the chapter.
A.2.3 Homogeneous versus Heterogeneous Networks
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Because the microscopic structure of a degradable hydrogel network plays such an
important role in its degradation behavior, degradable hydrogels can be classified according
to their network structure. Hydrogel network morphologies can be described as being
homogeneous or heterogeneous.

Homogeneous gels exhibit a random distribution of

relatively mobile chains and pores within the crosslinked network.

Examples of

homogeneous gels include networks derived from synthetic polymers such as poly(ethylene
glycol), poly(vinyl alcohol), or poly(acrylamide). Homogeneous gels may be amorphous or
semi-crystalline. They may be crosslinked using ionic, covalent, or non-covalent methods.
They can also be either neutral or ionic depending on the ionization of their pendant groups
(Peppas 1986).
Heterogeneous hydrogels, on the other hand, exhibit an anisotropic network structure
characterized by a high degree of inter-polymer interaction. Examples of heterogeneous
hydrogels include many insoluble networks derived from naturally occurring polymers such
as calcium alginate, agarose, and κ-carrageenan (Muhr and Blanshard 1982). Additionally,
supermolecular fibrils and fiber bundles of size-scales much greater than individual polymer
chains can be formed in these networks via complex, thermodynamically driven selfassembly processes (Stupp 2005). While such structures exhibit high porosities between
immobile, large-scale fiber bundles, their overall degradation more closely resembles the
characteristics of surface-eroding systems due to the inability of water or macromolecular
enzymes to penetrate within the small-scale, self-assembled architectures (Ehrbar, Metters et
al. 2005). Fibrous, anisotropic networks are found in gels made of natural or synthetic
macromolecules such as collagen, fibrin, and synthetic polypeptides (Voet and Voet 1995;
Lutolf and Hubbell 2005).
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Both homogeneous and heterogeneous networks may be cast in the form of
macroporous, microporous, or nonporous gels (Peppas 1986). Both types of morphologies
may also display anisotropies in macroscopic properties such as swelling, elasticity, and
porosity. Furthermore the degradability of both gel types is based on a limited number of
biodegradable bonds. Therefore their degradation during biomedical application occurs due
to identical mechanisms – hydrolytic or enzymatic cleavage of covalent crosslinks or
dissolution of physical crosslinks (Shalaby, Blevins et al. 1991; Sawhney, Pathak et al. 1993;
West and Hubbell 1999; Jeong, Kim et al. 2002).
However, the effect of labile bond cleavage on the evolution of macroscopic gel
properties differs significantly between homogeneous and heterogeneous gels due to
differences in crosslinking, supermolecular polymer-chain organization, and overall network
structure. Thermodynamic relationships developed for non-degradable, homogeneous gels
have been applied to help understand the dynamic degradation behavior of homogeneous
gels. These relationships are detailed in the next section of this chapter. However, the
anisotropic network structure present in heterogeneous gels greatly limits our current ability
to correlate the extent of gel degradation with predicted or experimentally measurable
changes in gel properties. While advances in the design and application of heterogeneous
hydrogels for biomedical applications have been made and will be discussed in this review,
the overview of structural characteristics presented in the next section focuses on identifying
the key parameters that determine the microscopic and macroscopic behavior of bulkdegrading, homogeneous hydrogels.
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A.3 Bulk-Degrading, Covalently Crosslinked Hydrogels
As detailed in the final section of this chapter, a large array of techniques exists for
creating biodegradable hydrogels from both synthetic and naturally derived polymer
chemistries. In recent years, covalent crosslinking has emerged as a preferred method due to
its wide compatibility with a number of polymer chemistries and its ability to fine tune
hydrogel properties (Hennink and van Nostrum 2002).

Therefore in this section the

fabrication and characterization of covalently crosslinked, degradable hydrogels are detailed.
The quantitative analyses provided for correlating degradation behavior to labile bond
cleavage kinetics apply to a specific class of covalently crosslinked, bulk-degrading hydrogels
with hydrolytically degradable crosslinks. However, the observed degradation behavior is not
necessarily unique to this class of hydrogel and many of the structure-function relationships
developed to describe this system can readily be extended to describe the degradation
behavior of other types of degradable hydrogels.
A.3.1 Fabrication and Network Structure
The degradation behavior of a biodegradable hydrogel depends significantly on its
method of fabrication.

Various mechanisms for forming these materials have been

investigated, including ionic crosslinking, thermally induced physical crosslinking, and
enzymatic or pH-induced gelation. Unfortunately, most of these methodologies yield limited
control over the gelation kinetics, material properties, and degradation behavior. In contrast,
covalent crosslinking methods remove the need for interpolymer interactions and lead to the
formation of homogeneous networks with uniform and precise crosslinking densities. This
high degree of engineerability permits fine-tuning of polymer diffusivity and permeability,
degradation rate, equilibrium water content, elasticity, and modulus.
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Three main polymerization mechanisms are used to form covalently crosslinked,
degradable hydrogels including step-growth, chain-growth, and mixed-mode chain and step
growth mechanisms. Figure A.1 illustrates the methods of gel fabrication and potential
degradation for each of these polymerization techniques (Rydholm, Bowman et al. 2005). It
should be noted that the distinct site of bond cleavage within each of these biodegradable
networks depends on the method of polymerization as well as on the chemistry and
functionality of the chosen macromers and/or monomers. Modifications to the monomer
chemistry or reaction conditions directly impacts the density and/or degradability of the
network crosslinks and allows the degradation behavior as well as the moduli, elasticity,
permeability, and gel water content to be tailored in each system.
Network formation via the step-growth mechanism is based on the reaction of gel
precursors exhibiting a stoichiometric ratio of at least two mutually reactive chemical groups
(Figure A.1a). These traditional A-B type polymerizations lead to the formation of an
insoluble network if the average precursor functionality is greater than or equal to two as
first dictated by Flory (Flory 1953). The simplest form of the step-growth mechanism
related to biodegradable hydrogel fabrication is the straightforward crosslinking of highly
multifunctional natural polymers using small, bifunctional crosslinking agents. For example,
hyaluronic acid or other polysaccharides can be crosslinked with glutaraldehyde. For these
networks, degradation will occur via cleavage of chemical bonds along the backbone of the
naturally derived polymer chain. Alternatively, biodegradable hydrogels can also be formed
via the step-wise crosslinking of nondegradable, synthetic polymers using degradable
crosslinkers such as peptides, proteins, or even cells.
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As the size and number of reactive functionalities per monomer molecule decrease,
the step-growth mechanism assumes the character of a true polymerization rather than a
simple crosslinking reaction.

Degradable networks that result from step-growth

polymerizations of small, multifunctional monomers have been developed. For example, as
illustrated in Figure A.1a, Hubbell and coworkers developed degradable networks using
Michael-type addition reactions between thiol and acrylate-functionalized monomers (West
and Hubbell 1999; Elbert, Pratt et al. 2001; Lutolf and Hubbell 2003; Lutolf, Lauer-Fields et
al. 2003; Pratt, Weber et al. 2004; Seliktar, Zisch et al. 2004). Since gel degradation occurs by
hydrolytic cleavage of a thio-ether ester bond formed during thiol-acrylate coupling, low
molecular weight, nondegradable monomers can be used to form degradable hydrogels.
Elbert et al. fabricated hydrolytically degradable hydrogels from multi-armed PEG acrylates
and linear PEG di-thiols. Additionally, enzymatic degradability was imparted to these gels
through the use of protease-sensitive di-thiols made from short oligopeptide sequences
(Lutolf and Hubbell 2003; Lutolf, Lauer-Fields et al. 2003).
As shown by Metters and Hubbell, the degradation rates of networks formed via the
step-growth mechanism depend on the molecular weight, hydrophilicity, and degree of
functionality of the starting monomers (Metters and Hubbell 2005).

Step-growth

polymerizations are known to produce few structural defects during network formation
which permits precise control of the crosslinking density and degradation behavior (Dusek
and Duskov-Smrckova 2000). Additionally, using relatively low molecular weight monomers
to form the degradable, Michael-type gels eliminates the subsequent production of high
molecular weight degradation products that commonly result from using polymeric gel
precursors (Metters, Bowman et al. 2000; Lovestead, Burdick et al. 2002).
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Contrary to the high concentration of reactive intermediates present during stepgrowth network formation, a low concentration of active centers is generated during
formation of a typical chain-growth network (Figure A.1b).

These active centers are

typically radicals and are generated by a variety of methods including thermal energy, redox
reactions, and cleavage of a photoinitiator molecule when irradiated with UV or visible light
(Odian 1991).

They rapidly propagate through monomers containing multiple carbon-

carbon double bonds to form high molecular weight, kinetic chains that are covalently
crosslinked.

The highly stable carbon-carbon bonds that result from chain-growth

polymerization are generally non-degradable under biological conditions.

Rather,

degradation is incorporated into the networks through specially designed multi-vinyl
macromers with hydrolytically or enzymatically cleavable segments (Sawhney, Pathak et al.
1993; Davis, Burdick et al. 2003; Lutolf and Hubbell 2005). Upon network formation, these
linkages are present in the network crosslinks.

The degradation products from such

networks are comprised of the degraded segments from the crosslinking molecules as well as
the higher molecular weight kinetic chains generated during polymerization (Anseth, Metters
et al. 2002).
An illustration of degradable, chain-polymerized networks comes from the pioneering
work of Sawhney et al. where linear PEGs of various molecular weights were used as
initiators for the ring-opening polymerization of a-hydroxy acids (lactic, glycolic), followed
by reaction with acid halides to produce vinyl terminated macromonomers containing
degradable ester linkages (Figure A.2) (Sawhney, Pathak et al. 1993).

Chain-growth

polymerization of the poly(lactic acid)-b-poly(ethylene glycol)-b-poly(lactic acid) (PLA-PEG-
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PLA) tri-block copolymer macromers was accomplished using mild photopolymerization
conditions that permitted in situ network formation under physiological conditions.

(a)

(b)

(c)

Figure A.1 Pictorial representation of the initial monomer molecules, cross-linked polymer
networks, and degradation products for materials formed from (a) step-growth
polymerizationmechanism, (b) chain-growth polymerization mechanism, and (c) mixedmode chain and step-growth mechanism. (From Rydholm, A.E., Bowman, C.N., et al. 2005.
Biomaterials 26: 4495–4506.With permission.)
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Figure A.2 Illustration of three different stages during the bulk degradation of a PLA-bPEG-b-PLA hydrogel network: (a) initial, nondegraded PLA-b-PEG-b-PLA network, (b)
primary erosion products that are released during degradation, and (c) final degradation
products after complete hydrolysis. (From Metters, A.T., Bowman, C.N., et al. 2000. J. Phys.
Chem. B 104: 7043–7049.With permission.)
The degradation behavior of chain-polymerized networks with hydrolytically or
enzymatically labile crosslinks can be tailored through a variety of parameters. Although
physically crosslinked networks can also be formed using degradable ABA block copolymers
such as non-acrylated PLA-PEG-PLA, Sawhney’s work was the first to incorporate
polymerizable moieties into the macromer design. Covalent crosslinking of the degradable
macromers provides dramatically improved control over the resulting network structure and
subsequent degradation rate. For example, the degradation rate of covalently crosslinked
(PLA-PEG-PLA) hydrogels can be tailored by varying the molecular weights of the PEG
and/or PLA copolymer blocks within the crosslinker, the chemistry and degree of vinyl
group functionalization, or the type and amount of comonomers added to the system
(Metters, Anseth et al. 2000; Metters, Bowman et al. 2000; Metters, Anseth et al. 2001).
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Finally, as their name suggests, networks formed from mixed-mode polymerizations
exhibit characteristics between chain and step-growth polymerizations (Figure A.1c). One
relatively new type of degradable hydrogel based on the mixed-mode polymerization of
acrylated PLA-PEG-PLA monomers and multifunctional thiols has been developed by
Bowman and coworkers (Cramer, Reddy et al. 2004; Reddy, Cramer et al. 2004; Lu, Carioscia
et al. 2005; Okay and Bowman 2005; Okay, Reddy et al. 2005; Reddy, Anseth et al. 2005).
The network structure that results from this mixed-mode polymerization mechanism is
unique from networks formed by chain and step-growth polymerizations and is directly
impacted by reactive group ratios. As the ratio of thiol to acrylate groups increases in the
system, the networks transition from being chain-like to more step-like. In addition, the
erosion profile and swelling changes that occur during degradation are controlled by
variations in thiol-acrylate ratios that impact network structure. Additionally, changing the
thiol mole fraction in the network provides control of the degradation products’ molecular
weight distributions (Reddy, Anseth et al. 2005).
A.3.2 Function and Degradation
In addition to the obvious need for biocompatibility during the lifetime of the
degradable hydrogel, three material properties critical to the successful biomedical
application of any hydrogel are water content, mechanical stiffness or elasticity, and
permeability. By definition hydrogels must exhibit high water contents. While no exact
water content value is required to describe a hydrophilic, crosslinked material as a hydrogel,
most hydrogels currently used to encapsulate living cells, for example, swell to greater than
90% water by weight when placed in suitable physiological fluids. The highly solvated gel
environment is critical to maintaining cell viability and also minimizes nonspecific adsorption
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of proteins and other macromolecules present in a biological environment that would
otherwise lead to harmful inflammatory responses (Bryant and Anseth 2002).
The mechanical properties of hydrogels are also particularly important in tissue
engineering applications where the gel must create and maintain a space for cell infiltration
and tissue development.

In addition, results from a number of investigations have

demonstrated that the adhesion, structure, metabolism, and gene expression of encapsulated
cells are strongly influenced by the mechanical properties of the polymer scaffold (Huang
and Ingber 1999).
Finally, gel permeability is important to successful gel function.

Controlled gel

permeability permits sustained drug release over long periods as well as prevents the
infiltration of harmful species such as enzymes or inflammatory/immune cells that would
affect the stability of encapsulated proteins or transplanted cells respectively (Langer 1990;
Langer 1991). In addition, correct gel permeability is also important for the transportation
of nutrients and metabolic wastes to support growth of gel-encapsulated cells and tissues.
The swelling characteristics, mechanical properties, and permeability of hydrogels
depend on several factors including the supermolecular structure of the original polymer
chains; the type of crosslinking molecules and the crosslinking density; and the
hydrophilic/hydrophobic balance of the crosslinks and backbone polymer chains within the
crosslinked network (Lee and Mooney 2001). As previously mentioned, the high degree of
interpolymer interactions and structural anisotropies that occur in heterogeneous gels can be
extremely difficult to characterize. However, to describe the structure, chemistry, and
resultant material properties of homogeneous gels, the multitude of system design variables
can generally be condensed to a few critical parameters: (1) the polymer volume fraction in
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the swollen state, v2,s, (2) the number average molecular weight between crosslinks, M c , (3)
the degree of polymer-solvent interaction, χ12, and (4) the network mesh size, ξ (Peppas
1986).
A.3.3 Swelling
By definition, the equilibrium polymer volume fraction in a degradable or
nondegradable hydrogel, v2,s, is the ratio of the volume of polymer, Vp, to the volume of the
swollen gel, Vgel, and the reciprocal of the volume swelling ratio Q:
v2 , s =

Vp
Vgel

= Q −1

The polymer volume fraction can be determined by equilibrium swelling measurements
before or during degradation (Peppas 1986; Metters, Anseth et al. 2000). The degree of
swelling is also commonly reported as a mass swelling ratio, Qm or q, which can also be
related to v2,s as follows (Kong, Lee et al. 2002):
v 2, s = Q −1 =

where

Qm =

1/ ρ2
[Qm / ρ1 + 1 / ρ 2 ]
M gel
Mp

Here, Mgel and Mp are the masses of the swollen gel and dried polymer respectively. ρ1 and ρ2
are the densities of the solvent and polymer respectively.
For further hydrogel characterization, the number-average molecular weight between
crosslinks, M c , is the most common parameter used to represent the level of crosslinking
within the network. Assuming an ideal network structure is formed, M c can be theoretically
calculated based on the size, chemistry, and functionality of the gel precursors. However,
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defects in network structure that increase its value occur during the fabrication of almost
every hydrogel (Dusek and Duskov-Smrckova 2000; Elliott, Nie et al. 2003; Elliott,
Macdonald et al. 2004; DuBose, Cutshall et al. 2005). Therefore, M c is best-determined
using theories that correlate its true value to experimental measurements of gel swelling and
mechanical strength.
The swelling behavior of hydrogels in biological fluids can be reasonably described by
a variety of non-ideal thermodynamic models. Due to the highly complex behavior of
polymer networks in electrolyte solutions, no theory can predict exact swelling behavior.
However, the Flory-Rehner analysis and its various modifications, continues to be used with
reasonable success (Flory and Rehner 1943). This theoretical framework describes gels as
neutral, crosslinked networks with a Gaussian distribution of polymer chains. When placed
in aqueous solution this model assumes that swelling equilibrium will occur at the point
where the swelling force due to the thermodynamic compatibility of the polymer and water
balances the retractive force induced by the stretching of the network crosslinks. This
analysis leads to the Flory-Rehner expression for the true M c of a nonionized hydrogel:

(

)[

v / V1 ln (1 − v 2, s ) + v 2, s + χ 12 v22, s
1
2
=
−
v12,/s3 − (2 / φ )v 2, s
Mc Mn

(

)

]

Here, χ12 is the polymer-water interaction parameter, V1 is the molar volume of water, v is
the specific volume of the polymer, M n is the average molecular weight of linear polymer
chains prepared at the same conditions without crosslinking, and φ is the functionality of the
crosslinker (e.g., φ = 4 for a chain-polymerized, divinyl crosslinker).
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Under the common conditions of high network swelling where Q > 10 (v2,s < 10%)
the original Flory-Rehner Equation can be simplified to show a more direct relationship
between Q and M c :
 v (1 / 2 − 2 χ 12 )M c 
Q=

V1



3/ 5

( )

=β Mc

3/5

Here, β is a constant. This simplification assumes that chain-end effects can be neglected
( M c << M n ) and that all physical parameters remain constant (Flory 1953).
Although M c cannot be directly measured, the power-law relationship between Q
and M c outlined above is indirectly evident in the experimentally observed swelling behavior
of degrading hydrogels. In a bulk-degrading hydrogel, degradable linkages present along
network crosslinks or backbone polymer chains will be cleaved homogeneously throughout
the entire gel at a rate controlled by the reaction kinetics of labile bond cleavage (e.g.,
hydrolysis of PLA ester bonds within PLA-PEG-PLA crosslinks). This ongoing bond
cleavage systematically decreases the crosslinking density of the overall network and
increases M c . As predicted by the simplified equation given above, the hydrogel swelling
ratio will increase as degradation proceeds and M c increases. This behavior is observed
during the bulk degradation of a wide variety of hydrogels where Q and Qm are seen to
increase with degradation time (Figure A.3) (Lee, Bouhadir et al. 2000; Metters, Anseth et al.
2000; Elbert, Pratt et al. 2001; Lutolf, Lauer-Fields et al. 2003; Metters and Hubbell 2005).
The exact function describing the rate of increase in gel swelling with degradation time will
depend on the kinetics of individual bond cleavage as well as the gel structure (Metters,
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Bowman et al. 2000; Metters, Anseth et al. 2001; DuBose, Cutshall et al. 2005; Metters and
Hubbell 2005).

Figure A.3 Examples of systematically increasing network swelling ratio with degradation
time for different bulk-degrading hydrogels. (a) As the molecular weight of an octa-acrylate
PEG precursor is increased, both the initially observed swelling ratio (at t0) and the apparent
rate of degradation (slope of swelling curve) increase (Metters, A. and Hubbell, J. 2005.
Biomacromolecules 6: 290–301.). (b) Swelling measurements of enzymatically degradable
hydrogels with three different peptide cross-linkers exhibiting varying susceptibility to
exogenously added proteases (Lutolf, M.P., Lauer-fields, J.L., et al. 2003. Proc. Natl Acad. Sci.
USA 100: 5413–5418.). (c) Gel swelling and (d) calculated polymer volume fraction during
degradation of gels made from PEG-dithiol and PEG-multiacrylates (Elbert, D.L., Pratt,
A.B., et al. 2001. J. Control. Release 76:11–25.)
In some covalently crosslinked, degradable hydrogels the swelling behavior as a
function of degradation and the dependence of M c on the labile-bond cleavage kinetics can
be described more quantitatively.

For example, dimethacrylated PLA-b-PEG-b-PLA
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macromers, once polymerized, form hydrolytically degradable crosslinks within swollen
hydrogel structures as shown in Figures A.1b and A.2 (Metters, Anseth et al. 2000;
Rydholm, Bowman et al. 2005). Assuming pseudo first-order hydrolysis kinetics of the
individual PLA ester bonds leads to a first order decrease in the gel crosslinking density since
the cleavage of any ester bond in the macromer will lead to crosslink cleavage (Metters,
Bowman et al. 2000). Combining the ester-bond hydrolysis kinetics with knowledge of the
triblock crosslink structure yields the following exponential relationship for M c as a
function of degradation time (t):
M c (t ) = M c

'

t =0

e 2 jk E t

Where t=0 represents the initial time prior to any network degradation, j is the degree of
polymerization of the two PLA blocks in the PLA-PEG-PLA macromer (equivalent to the
number of ester bonds per block), and k’E is the pseudo first-order kinetic rate constant for
hydrolysis of those ester bonds. Combining this time-dependent expression for M c with
the simplified form of the Flory-Rehner Equation provided above yields an equation
predicting a similar exponential increase in gel swelling with degradation time:
'

Q (t ) = Q t = 0 e 6 / 5 jk E t

Thus, for a system where mass-transfer limitations are not significant and the system is
reaction controlled, the swelling ratio of the hydrogel at any point during degradation can be
predicted based on knowledge of the hydrolysis kinetics of the individual bonds as well as
the composition of the crosslinks and overall network structure of the degradable gel. As
shown in Figure A.4, the typical swelling behavior of a degrading PLA-PEG-PLA hydrogel
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exhibits this predicted exponential increase in gel swelling ratio with degradation time
(Metters, Anseth et al. 2000; Anseth, Metters et al. 2002).
The time or degradation-dependent swelling behavior of highly permeable, degradable
hydrogels formed via step-growth polymerizations can also be predicted with adequate
knowledge of bond cleavage kinetics and network structure. DuBose et al. showed how the
bond hydrolysis kinetics and network structure could be varied independently to affect the
dynamic swelling profiles of PEG-based hydrogels formed using Michael-type addition
reactions with small-molecule di-thiols (DuBose, Cutshall et al. 2005).

Figure A.5

demonstrates how the rate of swelling can be increased in a predictable fashion by increasing
temperature during degradation (i.e., increasing the rate constant for bond hydrolysis) or by
decreasing the number of acrylate groups per PEG crosslink in the gel network.

Figure A.4 Typical in vitro degradation behavior of a PLA-b-PEG-b-PLA hydrogel:
compressive modulus (●) and volumetric swelling ratio (■). The solid and dashed lines are
exponential curves fit to each propertywith time constants of τQ = 4200 min and τK = 2000
min. (From Anseth, K.S., Metters, A.T., et al. 2002. J. Control. Release 78: 199–209. With
permission.)
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Figure A.5 Swelling of degradable PEG-acrylate/dithiol gels formed via step-growth
polymerization. (a) Gels fabricated from 30 wt % eight-armed PEG-acrylate/DTT precursor
solutions and degraded at varying temperatures: 37°C (▲), 46°C (), and 57°C (■). (b) Gels
fabricated with either four-arm/10 kDa (■) or eight-arm/20 kDa () PEG were measured
and compared with model predictions (– – –). (FromDuBose, J.W., Cutshall, C., et al. 2005. J.
Biomed. Mater. Res. A 74A: 104–116.With permission.)
A.3.4 Mechanics
The mechanical behavior of hydrogels is best described using the theories of rubber
elasticity and viscoelasticity (Flory 1953; Treloar 1975; Aklonis and MacKnight 1983). These
theories are based on the time-independent and time-dependent recovery of the chain
orientation and structure, respectively. Rubbers are materials that respond to stresses with
nearly instantaneous and fully reversible deformation (Bueche 1962). Normal rubbers are
lightly crosslinked networks with a rather large free volume that allows them to respond to
external stresses with a rapid rearrangement of the polymer segments. In their swollen state,
most hydrogels satisfy these criteria. When a hydrogel is in the region of rubber-like
behavior, the mechanical behavior of the gel is dependent mainly on the architecture of the
polymer network. Only at very low temperatures will these gels lose their rubber elastic
properties and exhibit viscoelastic behavior.

General characteristics of rubber elastic

behavior include high extensibility generated by low mechanical stress, complete recovery
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after removal of the deformation, and high extensibility and recovery that are driven by
entropic rather than enthalpic changes.
By using rubber elasticity theory to describe the mechanical behaviors of biomedical
hydrogels, it is possible to analyze the polymer structure and determine the effective
molecular weight between crosslinks ( M c ) as well as elucidate information about the
number of elastically active chains and deviations from ideal network structure (defects) that
occur under a variety of reaction conditions. Using this theory, the shear modulus of an
unswollen, dry gel (Gd) depends on the average molecular weight between crosslinks as
follows (Anseth, Bowman et al. 1996):
Gd =

ρRT 
MC

2M C
1 − M n







Here ρ is the polymer density, R is the gas constant (8.314 J mol-1 K-1), and T is temperature
(K). The effects of chain ends have been included. This equation is easily modified to
describe the mechanical behavior of swollen hydrogels. The shear modulus of a swollen gel
(Gs) is dependent on its network structure and degree of swelling as given by:
Gs =

ρRT 
MC

2M C
1 − M n



ρRT
(v 2, s )1 / 3 =

MC


 2M C
1 −

Mn


 1
 1/ 3
Q


Therefore, for a given hydrogel at a fixed temperature, a higher degree of swelling results in a
reduction of the shear modulus. Alternatively, if the degree of crosslinking is increased (i.e.,

M c is decreased), the modulus is increased. This interpretation is adequate for low strains.
Assuming analysis of a bulk-degrading hydrogel exhibiting a high degree of swelling
(Q > 10), as well as neglecting the influence of chain ends, the relationship between Q and
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M c obtained from using the simplified Flory-Rehner Equation can be inserted to yield Gs as
a function of M c :
Gs =

ρRT

1
M C β M c 3/ 5

[(

)

]

1/ 3

=

γ
MC

6/5

Here β and γ are constants. This equation explains why the modulus of a bulk-degrading
PLA-PEG-PLA hydrogel decreases exponentially with time as shown in Figure A.4. As

M c increases exponentially with time for the PLA-PEG-PLA hydrogel, Gs decreases in the
following manner:
G s (t ) =

G s ,o
e

12 / 5 jk E' t

'

= G s ,o e −12 / 5 jk E t

Here, Gs,o is the initial shear modulus of the swollen hydrogel network prior to degradation.
As shown by the equation above, the elasticity of a bulk-degrading network is
dependent upon bond cleavage kinetics and gel microstructure. These dependencies are
similar to what were previously calculated for gel swelling. However, comparison of the
exponential rate constants for the modulus and swelling degradation curves reported in
Figure A.4 indicate that the rate of modulus decay is approximately twice as fast as the rate
at which swelling increases for degrading PLA-PEG-PLA gels. These experimental results
are supported through first-principle predictions based on the simplified thermodynamic
relationships given above which relate both gel swelling and modulus to M c and predict
(Metters, Bowman et al. 2001).
Gs =

γ
Mc

6/5

=

γ
 Q 
 
 β 
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5/3





6/5

∝

1
Q2

This scaling argument shows that for degradable and non-degradable hydrogels, the shear
modulus of the gel (Gs) is approximately twice as sensitive to changes in M c as the
volumetric swelling (Q).
It is important to note that while the results presented in Figure A.4 illustrate good
agreement between experimental observations of hydrogel degradation and the predictive
thermodynamic equations, many assumptions were made to reach the scaling argument
provided above. These assumptions include a high degree of swelling, constant physical and
thermodynamic parameters, and an ideal network structure founded on degradable
crosslinks. The presence of non-idealities in the network structure, changes in hydrogel
chemistry during degradation (e.g., production of numerous carboxylic acid end groups
during PLA ester bond cleavage), mass transfer limitations, or auto-catalytic effects will
produce characteristics in the gel degradation behavior that cannot be appropriately
described by the simplified analysis presented in this section (Metters, Anseth et al. 2001).
For example, Amsden et al. have developed an alternative strategy for modeling the
degradation of hydroxyethylmethacrylate-grafted dextran hydrogels where bond cleavage
occurs along the backbone chains of the network and changes in polymer chemistry during
degradation are significant (Amsden, Stubbe et al. 2004).
A.3.5 Diffusivity
The ability of a hydrogel to restrict the diffusive movement of a solute plays a key role
in applications as diverse as cell encapsulation, chromatography, biosensors, and drug
delivery (Langer and Peppas 1981). Diffusion-controlled drug-delivery systems based on
hydrogel materials, for example, can be matrix or reservoir systems (Lowman and Peppas
1999; Mallapragada and Narasimhan 1999). In the reservoir system, the active agent is
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located in a core and a polymer membrane surrounds it. In matrix systems, the drug or
protein is homogeneously distributed throughout the membrane and is slowly released from
it. In either system the hydrogel membrane can be biodegradable (Heller 1980).
It is important to have an understanding of the mechanisms and underlying
parameters governing solute diffusion within hydrogels. For this reason, a number of
mathematical relationships have been developed in an effort to model solute diffusion in
hydrogels. Drug or protein diffusion within swollen hydrogel networks is best described by
Fick’s equation or by the Stefan-Maxwell equations that correlate the flux of a particular
solute with its chemical-potential gradient in the system (Peppas, Huang et al. 2000). For
porous gels with pore sizes much larger than the molecular dimensions of the solute, the
diffusion coefficient is related to the porosity and the tortuosity of the porous structure
(Peppas 1986). For porous hydrogels with pore sizes comparable to the solute molecular
size and for nonporous hydrogels, various expressions have been proposed for the diffusion
coefficients (Peppas 1986; Amsden 1998; Masaro and Zhu 1999). The polymer chains
within these crosslinked networks have been proposed to retard solute movement by
reducing the average free volume per molecule available to the solute, by increasing the
hydrodynamic drag experienced by the solute, or by acting as physical obstructions that
increase the solute path length (Mackie and Meares 1955; Cohen and Turnbull 1959; Bird,
Stewart et al. 1960). Model complexity increases as these mechanisms are combined as well
as when non-spherical solutes (e.g., linear polymer chains of high molecular weight) and
polymer-solute interactions are considered (Muhr and Blanshard 1982). An excellent review
of the most prevalent models along with a quantitative assessment of their predictive abilities
has been presented by Amsden (Amsden 1998).
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Solute transport within hydrogels is assumed to occur primarily within the water-filled
regions delineated by the polymer chains. The average size of these spaces can be quantified
through the correlation length, ξ, also known as the network mesh size (Peppas 1986; Lustig
and Peppas 1988). The mesh size of a hydrogel network can be determined as described by
Canal and Peppas (Canal and Peppas 1989).

( )

ξ = v 2, s −1 / 3 ro2

( )

where ro2

1/ 2

( )

1/ 2

= Q 1 / 3 ro2

1/ 2

is the root-mean-squared end-to-end distance of network chains in the

unperturbed state and is directly proportional to M c . Any factor that reduces the relative
size of these solvent-filled spaces compared to the size of the solute will further retard solute
diffusion. In general, the diffusivity of a solute through a covalently crosslinked hydrogel
decreases as crosslinking density increases ( M c decreases), as the size of the solute (rs)
increases, and as the volume fraction of polymer within the gel (v2,s) increases (Yasuda,
Lamaze et al. 1968; Peppas 1986; Johansson, Skantze et al. 1991).
An exponential increase in both Q and M c with degradation time has already been
predicted for bulk degrading gels with crosslinks that degrade according to pseudo-first
order kinetics. Therefore the network mesh size for these systems will also increase in an
exponential manner with degradation time as shown below (Mason, Metters et al. 2001):

( )

[

ξ = Q1/ 3 ro2 ~ M c 7 /10 = M c

'

t =0

e 2 jk E t

]

7 / 10

'

= ηe 7 / 5 jk Et

where η is a constant.
Theoretical models for predicting solute diffusion coefficients take the form:
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Dg
Do

= f (rs , v 2, s , ξ )

where, Dg is the solute diffusion coefficient in the swollen hydrogel network, Do is the
diffusion coefficient of solute in pure solvent, and rs is the size of the solute molecules.
Thus, the structure and pore size of the gel, the polymer composition, the water content, and
the nature and size of the solutes are all taken into account by the diffusion coefficient of the
solute (Peppas, Huang et al. 2000). This general framework can be used to predict the rate
of diffusion of all species within the gel network including the influx of degrading moieties
(e.g., water or enzymes) as well as the release rate of encapsulated species such as drugs and
other therapeutic agents. For a degradable hydrogel the previously discussed increase in
mesh size and decrease in polymer volume fraction with network degradation will influence
Dg and cause it to change with the extent of degradation as well.
Numerous variations of the general framework given above have been developed by
several research groups to more clearly describe the relationship between solute diffusivity
and network structure for non-degrading gels. As an example, one such model is given by:
 r
= 1 − s
Do  ξ

Dg

  v

 exp − Y  2, s
  1 − v 2,s

 






Here Y is physically defined as the ratio of the critical volume required for a successful
translational movement of the solute molecule and the average free volume per molecule of
solvent. For most purposes a good approximation for Y is unity. This model was developed
by Lustig and Peppas using a free-volume approach and has proven useful for predicting
solute diffusivities within poly(ethylene glycol) (PEG) networks (Lustig and Peppas 1988).
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For highly swollen, degradable PLA-PEG-PLA gels the diffusivity correlation
provided by Lustig and Peppas can be simplified to:
 r
= 1 − s
Do  ξ

Dg

r
 
 = 1 − −7 s/ 5 jk ' t

E
  ηe






using the time-dependent expression for the mesh size given above. From this modified
expression it can be clearly observed that as degradation proceeds, solute diffusivity within
the gel (Dg) will increase in a systematic, predictable fashion and approach Do. Like the shear
modulus of the degrading gel (Gs), the rate of decrease in solute diffusivity depends on
network structure and bond cleavage kinetics. This type of analysis has been used to explain
the diffusivities and release profiles of various drugs from bulk degrading networks
compared to non-degrading matrices (Lu and Anseth 2000; Mason, Metters et al. 2001). It
can also be used with alternative free-volume approaches, hydrodynamic scaling models, and
obstruction theories to predict the time-dependent solute diffusivities within other
degradable gels.
A.3.6 Characteristic Erosion
Mass loss or erosion from bulk-degrading, covalently crosslinked hydrogels is a
complex process that depends upon the network structure and degradation kinetics (Heller
1980; Metters, Anseth et al. 2000; Metters, Bowman et al. 2000). In this respect, mass loss
from degrading hydrogels is similar to the swelling or mechanical properties. However,
unlike most other macroscopic gel properties that are only related to the time-dependent
crosslinking density or average molecular weight between crosslinks ( M c ), mass loss also
relies upon additional structural parameters. For example, models developed to predict mass
loss from photocrosslinked PLA-PEG-PLA hydrogels show that the erosion profiles for
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these systems are linked to network parameters such as the number of crosslinks per
backbone chain and the mass fraction of the network contained in the backbone chains
relative to the crosslinks (Metters, Bowman et al. 2000; Martens, Metters et al. 2001; Metters,
Anseth et al. 2001; Martens, Bowman et al. 2004).

Predictions of mass loss versus

degradation time also depend upon kinetic parameters such as the order and rate constant of
the degradation reaction.
In Figure A.6, experimental and predicted mass loss profiles are plotted versus
degradation time for two PLA-PEG-PLA hydrogels polymerized in solution at different
macromer concentrations (Metters, Bowman et al. 2000). These degrading hydrogels have
the same chemical composition, yet different initial crosslinking densities and
microstructures that result from the behavior of the chain-growth polymerization used in
their fabrication.

Increasing the initial macromer concentration during polymerization

increases the average length and functionality of the backbone polymer chains and decreases
the number of structural defects within the network.

These architectural changes are

reflected in an increased time until complete network dissolution as well as a lower apparent
degradation rate (slope of linear portion of curve) due to the additional crosslinking and
lower swelling ratios of these networks.
A characteristic of bulk-degrading gels that is evident in Figure A.6 is the occurrence
of gel dissolution prior to 100% bond degradation. Gel dissolution, or reverse gelation as it has
been termed, is an abrupt solid to liquid transition that leads to almost instantaneous erosion
of a substantial fraction of the crosslinked gel mass (Metters, Bowman et al. 2000). It is
analogous to the liquid to solid transition that occurs at the gel point during hydrogel
formation (Flory 1953). The exact fraction of the total network mass lost during reverse
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gelation increases as the number of crosslinks per backbone chain decreases as shown in
Figure A.6.

Figure A.6 Experimental mass loss data as a function of degradation time for two identical
PLA-PEG-PLA macromers polymerized at different concentrations to formgels with unique
degradation behavior: (■) 25 wt% and (●) 50 wt%. The solid and dashed lines represent the
percent mass loss predicted by a statistical model: (dashed) 25 wt%and (solid) 50 wt%.
(From Metters, A.T., Bowman, C.N., et al. 2000. J. Phys. Chem. B 104: 7043–7049.With
permission.)
The burst of mass loss that occurs at the onset of reverse gelation can have broad
implications on the successful application of the degradable hydrogel. A large fraction of
network mass lost during reverse gelation will result in a large, localized concentration of
potentially cytotoxic degradation products.

For example, there is evidence that the

macrophage response to implanted PLA-PEG-PLA gels appears strongest immediately
following gel dissolution. This is most likely a response to the high concentration of soluble,
acidic degradation products that are commonly seen with PLA-based materials and can lead
to adverse cellular responses in vivo. These acidic degradation products can also decrease the
stability of encapsulated proteins when these hydrogels are used for the controlled release of
pharmaceutics.

Therefore to ensure biocompatibility and proper application of any
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degradable hydrogel it is important to understand the factors that determine when gel
dissolution will occur.
Finally, the erosion profiles of bulk degrading hydrogels can also be engineered for
specific drug delivery applications. The same kinetic and structural factors that impact mass
loss from a crosslinked gel can also be used to control the delivery of therapeutic
biomolecules covalently attached to the gel network (Heller 1980; Zhao and Harris 1997;
Zhao and Harris 1998; Seliktar, Zisch et al. 2004; DuBose, Cutshall et al. 2005). For
example, fluorescently labeled probe molecules resembling clinically relevant peptide drugs
were covalently incorporated within the three-dimensional network structure of PEG-based
hydrogels formed via step-growth polymerizations. As shown in Figure A.7, hydrolytic
cleavage of the covalent bonds within the crosslinked PEG network, including those used to
immobilize the probe molecule, resulted in a biphasic release profile consisting of a relatively
slow, constant release rate of probe prior to gel dissolution and an almost instantaneous
release following the onset of gel dissolution (DuBose, Cutshall et al. 2005). The various
release profiles shown in Figure A.7 demonstrate how the release rate as well as the fraction
of probe released prior to network dissolution can be controlled through intelligent choice of
crosslinker functionality (tetra-functional PEG versus an octa-functional PEG in Figure
A.7a) or degradation kinetics (varying temperature, pH, or chemistry of the degradable thioether ester bond in the network in Figure A.7b). Such characteristic erosion profiles are
seen in a variety of bulk-degrading hydrogel systems.
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Figure A.7 Fractional probe release from degradable PEG-acrylate/dithiol gels formed via
step-growth polymerization (a) Gels fabricated from 30 wt % eight-armed PEGacrylate/DTT precursor solutions and degraded at varying temperatures: 37°C (▲), 46°C
(), and 57°C (■). (b) Gels fabricated with either four-arm/10 kDa (■) or eight-arm/20
kDa () PEG were measured and compared with model predictions (– – –). (From DuBose,
J.W., Cutshall, C., et al. 2005. J. Biomed. Mater. Res. A 74A: 104–116.With permission.)
A.4 Degradable Hydrogel Chemistries
Degradable hydrogels can be prepared from naturally derived biopolymers, synthetic
polymers or the combination of the two. The major advantages of using naturally derived
biopolymers such as chitosan, alginate, fibrin, collagen, gelatin and hyaluronic acid
derivatives include their inherent biodegradability and biocompatibility. However, natural
biopolymers may not provide adequate mechanical strength as well as precise functionalities
compared to synthetic polymers. Moreover, precautions against pathogenic contamination
must be taken when many natural biopolymers are used in clinical applications.
On the other hand, many synthetic polymers, although not inherently degradable
themselves, can be modified or copolymerized with labile groups to create degradable
hydrogels. The good mechanical properties and well-defined chemistries enable hydrogels
made from synthetic polymers such as poly(ethylene glycol) (PEG), poly(vinyl alcohol)
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(PVA), poly(N-isopropylacrylamide) (PNIPAAM), and poly(methyl methacrylate) (PMMA)
to be used for many biomedical applications.
Recently, many fundamental studies as well as clinical applications using degradable
hydrogels derived from natural or synthetic polymers have been conducted. In this final
section of the chapter, the chemistries as well as applications that comprise the most
common degradable hydrogels are described.
A.5 Degradable Hydrogels Derived from Natural Biomaterials
A.5.1 Chitosan-based Hydrogels
Chitosan, with a subunit of β-(1,4)-2-amido-2-deoxy-D-glucopyranose, is a form of
deacetylated chitin that has been shown to be biocompatible. Chitosan can be dissolved in
weak acidic solution and is positively charged in natural or basic environment due to its
amino groups.

It has been demonstrated that chitosan can accelerate wound healing

processes and therefore is a well accepted material for various biomedical applications
including tissue engineering, controlled delivery of proteins, and gene delivery. Several
review papers have been published addressing the chemistry and applications of chitosan
hydrogels. For example, Berger et al. have reviewed the chemistry of chitosan hydrogels
formed via electrostatic assembly (Berger, Reist et al. 2004).

Kumar et al. extensively

reviewed chitosan chemistry as well as its pharmaceutical applications (Kumar, Muzzarelli et
al. 2004).
Chitosan hydrogels can be fabricated via either physical or chemical crosslinking. In
previously used methods to induce physical crosslinking, positively charged chitosan was
mixed with negatively charged polymers including alginate (Murata, Kontani et al. 2002; Lee,
Yoon et al. 2004; Lin, Liang et al. 2005) and poly(vinyl alcohol) (Koyano, Minoura et al.
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1998; Shin, Kim et al. 2002; Wang, Turhan et al. 2004) to form a hydrogel network via
electrostatic interaction.

By adjusting the ratio of the positive and negative charged

components during the fabrication process, a tunable gel swelling behavior can be readily
achieved. Although physical crosslinking may be a convenient way to prepare chitosan
hydrogels, disadvantages also exist such as poor mechanical strength and uncontrollable
dissolution.
Chemical or covalent crosslinking is favorable for tissue engineering applications when
adequate mechanical strength is required. In order to form covalent crosslinks, additional
functionalities must be introduced onto the chitosan backbone. Modifications have been
made to the hydroxyl or amino groups on chitosan to facilitate covalent crosslinking. For
example, several chemistries have been proposed to graft synthetic polymers or reactive
groups onto chitosan including PEG (Gupta and Kumar 2001; Park, Kim et al. 2001; Hu,
Jiang et al. 2005), PNIPAAM (Cho, Kim et al. 2004; Lee, Ha et al. 2004), polyurethane
(Gong, Zhang et al. 1998; Silva, Menezes et al. 2003), and glycidyl methacrylate (GMA)
(Navarro and Tatsumi 2001; Flores-Ramirez, Elizalde-Pena et al. 2005).

Figure A.8

illustrates the chemical structure of chitosan and summarizes chitosan-based hydrogels
fabricated via both electrostatic and covalent crosslinking.
Chitosan hydrogels can be degraded via its β-1,4-glycosidic linkage by various enzymes
including chitosanase and lysozyme. The degradability of chitosan-based hydrogels can be
controlled by the degree of substitution of grafted side chains such as PEG. For example,
the degradation rate of chitosan-g-PEG hydrogels by lysozyme has been shown to decrease
with increasing degree of substitution of PEG on chitosan backbone (Hu, Jiang et al. 2005).
This behavior is attributed to the fact that the grafted PEG increases the hydrostability of
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chitosan which disrupts the accessibility of lysozyme to chitosan and thus decreases its
enzymatic degradability.
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Figure A.8 Structure of chitosan and its derivatives for hydrogel synthesis.
A.5.2 Alginate-based Hydrogels
Alginate is a linear polysaccharide composed of 1,4-linked poly(α-L-guluronic acid)
andpoly(β-D-mannuronic acid).

Alginate can be physically crosslinked through its

poly(guluronic acid) residues by adding calcium ions. Ionically crosslinked alginate does not
form a stable hydrogel because the gel can be disintegrated or dissolved once calcium ions
diffusive away or are stripped off by chelating agents. This disadvantage can be overcome
by introducing cationic chitosan or polylysine to form a polyelectrolyte reinforced
composite, or by grafting covalent crosslinking functionalities to alginate chains. The use of
alginate hydrogels has been primarily in the field of controlled release of growth factors such
as VEGF (Lee, Yoon et al. 2004), BMP2 and TGF-β3 (Simmons, Alsberg et al. 2004) as well
as the encapsulation and transplantation of pancreatic islet cells for diabetes treatments (Sun
1988).
Differing from chitosan, alginate is negatively charged at physiological pH because of
the carboxylic acid groups on the backbone. Because of this negative charge, alginate can be
fabricated electrostatically via self-assembly. Multilayers of hydrogel microspheres have been
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successfully produced by non-covalent conjugation of cationic polymers such as chitosan
and polylysine to the anionic alginate.
In addition to ionic crosslinking, alginate hydrogels can also be formed via covalent
crosslinking.

As shown in Figure A.9, Mooney and coworkers developed a chemical

crosslinking method for alginate-based hydrogels where they oxidized poly(guluronate), the
crosslinking portion of alginate, and used adipic dihydrazide as the crosslinking agent to
form poly(aldehyde guluronate) hydrogels (Bouhadir, Hausman et al. 1999; Lee, Bouhadir et
al. 2000). The resulting alginate-derived hydrogels possess a wide range of mechanical
properties and are suitable for tissue engineering application when cell-adhesive peptides
were incorporated onto the otherwise non-adhesive alginate backbone.

Figure A.9 Scheme for the synthesis and cross-linking of poly(aldehyde guluronate). (From
Bouhadir, K.H., Hausman, D.S., et al. 1999. Polymer 40: 3575–3584.With permission.)
While physical and chemical crosslinking of alginate hydrogels have been explored
extensively by several research groups, few reports have been made regarding the biological
crosslinking of alginate gels. In this particular area, Mooney’s group developed a novel
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crosslinking method based on cell-ligand interaction (Lee, Kong et al. 2003). They first
immobilized RGD peptide sequences on an alginate backbone and then utilized the integrin
receptors on cell surfaces to crosslink the alginate into a three-dimensional hydrogel
structure. There are several advantages of using this novel method for gel crosslinking. First
of all, the immobilization of the target cells can be achieved simultaneously during gel
formation. Secondly, this biological crosslinking system can be used to study cell-ligand
interactions. Figure A.10 shows the structure of sodium alginate and the methods for
hydrogel fabrication including electrostatic, chemical, and cellular crosslinking.

COONa

COONa

O

O

Chemical Crosslinking
Adipic dihydrazide crosslinked
alginate hydrogel

O

O
OH

Electrostatic Interaction
Alginate – chitosan
Alginate – polylysine

OH

OH

Sodium Alginate

OH

n

Biological Crosslinking
Cell-ligand interaction

Figure A.10 Structure of sodium alginate and methods for hydrogel fabrication.
Unlike chitosan hydrogels, which degrade by bond cleavage along the chitosan
backbone, the degradation of ionically crosslinked alginate hydrogels occurs when calcium
ions, the crosslinker, are removed from the hydrogel network. If alginate is oxidized to form
a covalent crosslinked network, the hydrolytic degradation takes place on the acyl hydrazone
bonds grafted onto alginate (Bouhadir, Hausman et al. 1999). Mooney and colleagues have
extensively studied the degradation behavior (Kong, Alsberg et al. 2004; Kong, Kaigler et al.
2004) as well as biomedical applications of alginate hydrogels (Simmons, Alsberg et al. 2004).
They showed that the mechanical rigidity and the degradation rate of alginate hydrogels can
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be controlled by adjusting the molecular weight distribution of alginate hydrogels assembled
from ionic or covalent crosslinking (Kong, Alsberg et al. 2004; Kong, Kaigler et al. 2004).
By controlling the molecular weights of alginate hydrogels in conjunction with delivery of
multiple growth factors (TGF-β3 and BMP2), they were able to enhance bone regeneration
in vivo (Simmons, Alsberg et al. 2004).
A.5.3 Fibrin-based Hydrogels
Fibrin, another source of polymer for fabricating degradable hydrogels, has undergone
extensive investigation.

Fibrin, derived from fibrinogen, is found in the blood and

polymerized by factor XIIIa to form a clot in response to injuries. Fibrin clot degradation is
associated with a series of cellular enzymatic activities during wound healing. The most
important fibrin-degrading enzyme is plasmin. Clinically, fibrin is applied to wound sites as a
glue to stop bleeding after surgeries or dental procedures. Fibrin glue is obtained from
mixing fibrinogen and thrombin solutions to form a fibrin clot (Thompson, Letassy et al.
1988).

Although not approved in the US because of the potential for blood-borne

transmission of diseases, fibrin glue is commonly used in Europe for controlling blood loss.
Due to the delicate design of fibrin activation and degradation by nature, researchers
are able to fabricate degradable hydrogels based on fibrin chemistry. Hubbell and coworkers
utilized modified fibrin hydrogels as matrices for various biomedical applications such as the
controlled delivery of vascular growth factor (VEGF) (Zisch, Schenk et al. 2001; Hubbell,
Zisch et al. 2003; Zisch, Lutolf et al. 2003; Ehrbar, Djonov et al. 2004; Ehrbar, Metters et al.
2005; Urech, Bittermann et al. 2005). There are several novelties of their fibrin-based
materials.

First, VEGF was covalently incorporated into fibrin hydrogels utilizing the

transglutaminase activity of factor XIIIa. Second, the delivery of VEGF was mediated by
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cellular activity. As shown in Figure A.11, the liberation of growth factors was achieved
either non-specifically by the degradation of fibrin network by plasmin (Zisch, Schenk et al.
2001; Hubbell, Zisch et al. 2003; Zisch, Lutolf et al. 2003; Ehrbar, Djonov et al. 2004) or
specifically by the incorporation of substrate peptides for enzymes such as matrix
metalloproteinases (MMPs) secreted by cells (Ehrbar, Metters et al. 2005; Urech, Bittermann
et al. 2005). Not only can this release strategy largely preserve the bioactivity of the growth
factors, the cell-demanded release profile can also match to the rate of cell infiltration or
tissue regeneration.

Figure A.11 Model schemes: Differential
control of VEGF release from fibrin gel
matrices by differential susceptibility to
local cell-associated proteolytic activities.
Top box. Native VEGF121 is freely
diffusible in the aqueous milieu of the
fibrin matrix. Middle box, VEGF variant,
a2PI1–8-VEGF121, is protected from
diffusion, and its liberation is dependent
on the cleavage of the fiber network by
cell-associated fibrinolytic enzymes (slow,
cell-demanded release). Bottom box, a
new VEGF variant, a2PI1–8-Pla-VEGF121,
was designed to couple to fibrin networks
via a plasmin-sensitive anchor. Cleavage
of this plasmin-sensitive site by low and
local plasmin could occur independent of
fiber network degradation and enhance
VEGF release rate (accelerated, celldemanded release). (From Ehrbar, M.,
Metters, A., et al. 2005. J. Control. Release
101: 93–109.With permission)
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Sakiyama-Elbert and Hubbell have developed fibrin hydrogels containing linker
peptides and heparins for affinity-based drug delivery specifically used in promoting nerve
regeneration (Sakiyama-Elbert and Hubbell 2000; Sakiyama-Elbert and Hubbell 2000).
Theoretical model predictions indicate that the release rate of growth factors from these gels
can be modulated through the affinity between the peptides and heparin and the
concentration of heparin presented in the fibrin gels (Taylor, McDonald et al. 2004). Figure
A.12 shows the schematic diagram of the heparin-containing fibrin hydrogels for growth
factor delivery (Taylor, McDonald et al. 2004).

Figure A.12 Diagram showing the components of the heparin-binding delivery system.
a2PI1–7–ATIII121 – 134 peptide is cross-linked into the fibrin gel via the transglutaminase activity
of Factor XIIIa; heparin can bind to the peptide by electrostatic interactions. NT-3 can bind
to the bound heparin, creating a gel-bound ternary complex that is not diffusible. NT-3 can
also exist in the diffusible state, alone, or in a complex with free heparin. (From Taylor, S.J.,
McDonald, J.W., et al. 2004. J. Control. Release 98: 281–294.With permission.)
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In addition to controlled growth-factor delivery, fibrin hydrogels have also been used
as tissue engineering scaffolds.

For example, fibrin hydrogels have been used as 3-

dimensional cell-culture matrices for cardiovascular tissue engineering. It was shown that
fibrin gels can support homogenous cell growth, confluent collagen production, and tissue
development (Ye, Zund et al. 2000; Jockenhoevel, Zund et al. 2001).
Fibrin hydrogels have also been shown to be biocompatible and can be formed in situ
during cartilage repair (Homminga, Buma et al. 1993). However, a potential shortcoming of
fibrin hydrogels is that they do not possess significant mechanical strength when applied on
load-bearing tissue such as cartilage. Composite scaffolds made form fibrin-polyglycolic acid
(Ameer, Mahmood et al. 2002) and fibrin-polyurethane (Lee, Grad et al. 2005) have been
developed to increase the mechanical properties of fibrin-based gels for articular cartilage
tissue engineering.
A.5.4 Collagen and Gelatin-based Hydrogels
Collagen, a triple helix protein, is the major component of connective tissues. Due to
its physiological abundance, collagen is considered biocompatible.
biodegraded by enzymes such as collagenase.

Collagen can be

The application of collagen hydrogels,

however, is limited due to its laborious, batch-production procedures as well as the
inconsistency of its biological and mechanical properties between batches.
Modified collagen gels are still favored for many tissue-engineering applications.
Composite scaffolds such as collagen-alginate (Bohl, Shon et al. 1998) or collagenhyaluronan (Segura, Anderson et al. 2005; Segura, Chung et al. 2005) have been fabricated
and used for several tissue engineering and DNA delivery applications. Matrigel, a type IV
collagen-based and a commercially available hydrogel, mimics the ECM environment and is

276

commonly used in in vivo or in vitro studies including cell growth and differentiation (Taub,
Wang et al. 1990), angiogenesis, and tumor augmentation (Benelli and Albini 1999;
Auerbach, Lewis et al. 2003). Collagen hydrogels have also been used to immobilize human
neuroblastoma cells for cell-based biosensing (Mao and Kisaalita 2004).
An important consideration of using collagen hydrogels in tissue engineering is that
the gels significantly shrink after cell-seeding (Bell, Ivarsson et al. 1979; Nakagawa, Pawelek
et al. 1989). Several methods have been developed to suppress the contraction of the
collagen hydrogels such as increased crosslinking with glutaraldehyde (Torres, Freyman et al.
2000) or incorporation of short collagen fibers (Gentleman, Nauman et al. 2004).
Increasing the crosslinking density of collagen in the scaffold has also been shown to
decrease the degradation rate of the gels (Meinel, Hofmann et al. 2004; Meinel, Karageorgiou
et al. 2004; Meinel, Karageorgiou et al. 2004; Hu, Jiang et al. 2005).
Gelatin, a natural glycine-rich polymer derived from hydrolyzed collagen, is widely
used in food industry as well as in pharmaceutical devices for the controlled release of
growth factors. Besides its advantageous biodegradability and biocompatibility, the most
attractive characteristic of gelatin is its ability to form polyion complexes. Depending on the
manufacturing process, the isoelectric point (PI) of gelatin can be adjusted to yield a
positively or negatively charged polymer. This flexibility makes gelatin a suitable matrix for
controlled delivery of charged growth factors such as anionic basic fibroblast growth factor
(bFGF) (Tabata, Hijikata et al. 1999) and bone morphogenetic protein-2 (BMP-2)
(Yamamoto, Takahashi et al. 2003).
Different gelatin formulations have been studied to evaluate the drug loading capacity
and release rate. Like the other hydrogels, drug release profiles obtained from gelatin
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hydrogels can be readily adjusted by changing the network crosslinking density. Several
methods have been developed to crosslink gelatin hydrogels including glutaraldehyde,
dehydrothermal treatment, UV or electron beam irradiation (Liang, Chang et al. 2004).
The preparation of gelatin hydrogels is rather easy compared to other natural
polymers. For example, gelatin hydrogels can be formed by simply mixing gelatin solution
with small amount of the crosslinker (e.g., glutaraldehyde) and left for several hours at 4°C.
In addition to the conventional gelation methods such as freeze-drying, gelatin hydrogels can
also be prepared via photopolymerization. For example, Matsuda and colleagues have
synthesized photocurable, tissue-adhesive gelatin hydrogels for drug release (Okino,
Nakayama et al. 2002; Okino, Manabe et al. 2003; Manabe, Okino et al. 2004; Masuda, Furue
et al. 2004), arterial repair (Li, Sajiki et al. 2003) as well as for nerve-guidance prosthetic
scaffolds (Gamez, Ikezaki et al. 2003). The major advantage of these gelatin hydrogels is
that they are photocurable and can be formed via in situ polymerization.
Burmania et al. prepared interpenetrating networks containing gelatin and PEGdiacrylate and further characterized the protein release, fibroblast adhesion, and in vivo host
response to these gels (Burmania, Martinez-Diaz et al. 2003; Burmania, Stevens et al. 2003).
The chemical and mechanical properties of these gelatin hydrogels can be controlled by
changing the weight percentage of gelatin in the IPN network or through chemical
modifications of the gel precursors.
A.5.5 Dextran-based Hydrogels
Dextran, with subunits consisting of α-1,6-linked D-glucopyranose, is another
common, naturally occurring polymer used in the fabrication of degradable hydrogels.
Dextran can be readily produced by bacteria or yeast via fermentation and is therefore an
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ideal polysaccharide for industrial as well as clinical usage. Dextran is also water-soluble and
has been widely used in surgery owing to its antithrombotic effect.
Similar to other hydrogels, dextran hydrogels can be formed via physical or chemical
crosslinking. Physically crosslinked dextran hydrogels can be fabricated via electrostatic
interaction.

Hennink and coworkers have fabricated microspheres with positive and

negative charges by modifying dextran with dimethylaminoethyl methacrylate (DMAEMA)
and methacrylic acid (MAA), respectively (Figure A.13) (Van Tomme, van Steenbergen et al.
2005). Dextran hydrogels are formed when microspheres with opposite charges were mixed
together. One interesting characteristic of this physical hydrogel is that, when sufficient
shear is applied, the viscosity of the gel decreases, rendering the gel injectable. After
injection the shear is removed and the hydrogel spontaneously reforms.

Figure A.13 Chemical structures of dex-HEMA (A), methacrylic acid (B) and
dimethylaminoethyl methacrylate (C). (From Van Tomme, S.R., van Steenbergen, M.J., et al.
2005. Biomaterials 26: 2129–2135.With permission.)
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Another method for fabricating physically crosslinked dextran hydrogels was
developed by Hennink and coworkers. It is based on stereocomplexation between D-lactate
and L-lactate oligomers (de Jong, De Smedt et al. 2000; Hennink, De Jong et al. 2004).
Enantiomeric lactic acid oligomers were grafted to dextran and the dex-lactate hydrogels
were formed by stereocomplex formation between D-lactate and L-lactate. The sustained
release of pharmaceutical proteins (Cadee, de Groot et al. 2002; Hennink, De Jong et al.
2004) as well as the biocompatibility (Cadee, van Luyn et al. 2000; Cadee, Brouwer et al.
2001) have been demonstrated for these dextran-based hydrogels.
Several modification schemes have been proposed to fabricate degradable dextran
hydrogels via chemical crosslinking. For instance, Hennink and coworkers have modified
dextran with hydroxyethyl methacrylate (HEMA). The resulting dex-HEMA hydrogels can
be formed via free-radical polymerization and crosslinking of the methacrylate side groups
(vanDijkWolthuis, Tsang et al. 1997). Degradable hydrogels were formed by incorporating
lactate into the modified dextran chains to form dex-lactate-HEMA hydrogels (Figure
A.14A). The degradation rate of these hydrogels can be tailored by varying the length of a
spacer unit within the crosslink (Cadee, De Kerf et al. 1999; Cadee, van Luyn et al. 2000;
Cadee, Brouwer et al. 2001; Cadee, de Groot et al. 2002). Increasing the size of the crosslink
lowers the overall crosslinking density, increases the degree of swelling and water content
within the gel, and results in a faster rate of degradation.
PEGylation of dextran is another means of fabricating dextran hydrogels. Moriyama
et al. have prepared multi-layered PEG-g-dextran hydrogels for pulsatile drug delivery. In
this two-phase system, grafted-PEG chains act as an insulin depot while dextran domains
form the main matrix. Upon surface-limited degradation by dextranase, a pulsatile release
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profile appears due to the multi-layered structure of the polymer formulation (Moriyama and
Yui 1996; Moriyama, Ooya et al. 1999).
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Figure A.14 Structures of (A) Dex-lactate-HEMA, (B) Dex-maleic acid, and (C) Dexmethacrylate.
Dextran hydrogels can also be prepared via photopolymerization. For example, Kim
et al. synthesized dex-maleic acid macromers by reacting dextran with maleic anhydride
(Figure A.14B) (Kim, Won et al. 1999). Glycidyl methacrylate has also been reacted with
dextran to form dex-GMA photocrosslinkable hydrogels (Figure A.14C) (Pitarresi, Palumbo
et al. 2003; Li, Williams et al. 2004).
Interpenetrating networks (IPN) (Kurisawa, Terano et al. 1995; Yamamoto, Kurisawa
et al. 1996; Kurisawa, Terano et al. 1997) or semi-IPNs (Kumashiro, Lee et al. 2002)
consisting of dextran and other components provide another route for dextran hydrogel
preparation. Kurisawa et al. have prepared a series of dextran-based IPNs including Dex-
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PEG (Kurisawa, Terano et al. 1995; Kurisawa, Terano et al. 1997) and Dex-Gelatin
(Yamamoto, Kurisawa et al. 1996; Kurisawa and Yui 1998; Kurisawa and Yui 1998). These
dextran-based hydrogels have been shown to exhibit a double-stimuli-response function and
are degradable only when two enzymes, which independently degrade distinctly different
substrates, are both present.
A.5.6 Hyaluronic Acid
Hyaluronic acid (HA) is another natural polymer derived from glycosaminoglycan
composed of D-glucuronic acid and N-acetylglucosamine.

Physiologically, HA is the

backbone of connective tissues such as cartilage. In addition to its structural importance,
HA also possesses many characteristics that make it suitable for biomedical application. For
example, HA mediates angiogenesis, wound healing, metastasis, inflammation, and
granulation (Chen and Abatangelo 1999). Because of these favorable properties, HA has
been used in many clinical applications. However, disadvantages of using HA as tissue
engineering scaffolds include its non-adhesive property which prohibits cell adhesion.
Furthermore, when HA is used as a scaffolding material, it does not provide enough
mechanical strength, which largely limits its application. Fortunately, the first disadvantage
can be overcome by grafting cell-adhesive peptides, such as arginine-glycine-aspartic acid
(RGD), to HA molecules. By incorporating reactive side functionalities such as acrylate or
methacrylate groups (Figure A.15), linear HA chains can be crosslinked to form waterswellable hydrogels with adequate mechanical strengths.
Collagen, glycidyl methacrylate, methacrylic anhydride, and gelatin have been used to
crosslink HA chains and form cell-adhesive, mechanically stable hydrogels. For example,
Park et al. have prepared methacrylated, RGD-containing HA-based hydrogels via
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photopolymerization (Park, Tirelli et al. 2003). The cellular response as well as the gel
swelling ratio and mechanical properties were extensively studied.

Leach et al. have

synthesized a photocrosslinkable HA by reacting it with the epoxy group of glycidyl
methacrylate (GMA) (Leach, Bivens et al. 2003). The pendant methacrylate bonds present
on the resulting GMA-modified HA molecules (GMHA) facilitate photopolymerization and
crosslinking of the polymer chains.

Furthermore, an acrylated PEG-peptide can be

copolymerized into the GMHA hydrogels to render them cell adhesive (Leach, Bivens et al.
2004).
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Figure A.15 Reaction schemes for methacrylation of hyaluronic acid through (A) N-(3aminopropyl)-methacrylamide, (B) glycidyl methacrylate, and (C) methacrylic anhydride.
When presented in vivo, hyaluronic acid hydrogels can be degraded by hyaluronidase
(Menzel and Farr 1998) or hydroxyl radicals (Yui, Nihira et al. 1993; Hawkins and Davies
1998) produced at the inflammation sites. Hyaluronidase-mediated degradation is relatively
slow compared to degradation by hydroxyl radicals. This is mainly because of the low
physiological concentration of hyaluronidase.

On the other hand, hydroxyl radicals

generated in the inflammation sites can effectively degrade HA via glycosidic cleavage (Yui,
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Nihira et al. 1993; Hawkins and Davies 1998). As shown in Figure A.16, the degradation
rate of GMHA hydrogels is slower than native HA hydrogels (Leach, Bivens et al. 2003).
Leach et al. have also tested the in vitro degradability of the GMHA hydrogels using
hyaluronidase (Leach, Bivens et al. 2003; Leach, Bivens et al. 2004). Finally, Langer and
coworkers were able to better control the resulting GMHA-hydrogel swelling and
degradation behavior by partially oxidizing or grafting an oligomer onto the multifunctional
HA chains prior to conjugation with GMA (Jia, Burdick et al. 2004).

Figure A.16 Enzymatic degradation of HA hydrogels. (a) Native HA (shown schematically)
is quickly degraded in vivo by the enzyme hyaluronidase. (b) Cross-linking the HA chains
forms an insoluble hydrogel matrix that is more resistant to enzymatic degradation. (From
Leach, J.B., Bivens, K.A., et al. 2003. Biotechnol. Bioeng. 82: 578–589. With permission.)
Methacrylic anhydride has also been reacted with HA to form methacrylated HA
(HAMA) for subsequent gel formation (Masters, Shah et al. 2004; Burdick, Chung et al.
2005; Masters, Shah et al. 2005). Applications of HA hydrogels based on this chemistry
include the incorporation of specialized peptides to enhance the adhesion and proliferation
of valvular interstitial cells (Masters, Shah et al. 2004; Masters, Shah et al. 2005) as well as the
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photoencapsulation of chondrocytes for cartilage regeneration (Burdick, Chung et al. 2005).
Smeds and Grinstaff have prepared photocrosslinkable HA hydrogels by reacting HA with
excess methacrylic anhydride (Smeds and Grinstaff 2001). The gel formation was rapid and
its in situ photopolymerization enables minimally invasive implantation when used on an
articular cartilage repair application (Nettles, Vail et al. 2004).
A.6 Degradable Hydrogels Derived from Synthetic Biomaterials
Degradable hydrogels made from synthetic polymers have recently gained
considerable interest. The most common synthetic polymers used to construct hydrogel
networks include poly(ethylene glycol) or poly(ethylene oxide), poly(vinyl alcohol), poly(Nisopropylacrylamide), and others. The most apparent advantage of using synthetic polymers
is the high degree of control over the polymer chemistry, architecture, and physical hydrogel
properties including degradation behavior. Hydrogels made from synthetic polymers can be
engineered with tailorable hydrophilicity, crosslinking density, and degradability. In addition,
when degraded in vivo, there is no immune recognition associated with the low molecular
weight degradation products if the polymer and hydrogel fabrication technique are carefully
chosen.
A.6.1 Poly(ethylene glycol)-based Hydrogels
Poly(ethylene glycol) is a non-ionic, hydrophilic polymer. Because of this, PEG is
widely used to create nonfouling surfaces which repel non-specific protein adsorption and
cell adhesion.

Many researchers have utilized the terminal hydroxyl groups on PEG

molecules to modify PEG into a crosslinkable material. The most commonly used chemistry
is the acrylation or methacrylation to endcap linear, branched, or star-shaped PEG molecules
with reactive vinyl species (Figure A.17). Free-radical polymerization of these methacrylate
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or acrylate groups results in crosslinked hydrogels that are stable over clinically relevant
timescales.
Hydrolytically or enzymatically labile groups can be introduced into crosslinked PEG
networks by modifying the soluble PEG precursors with ester-containing

-hydroxy acid

oligomers or protease-sensitive peptide blocks prior to vinyl-group endcapping. Upon
polymerization and crosslinking, these bonds will render the resulting hydrogels degradable.
In particular, the incorporation of hydrolytically degradable poly(lactic acid) (PLA) groups
greatly increase the potential applications of PEG hydrogels (Figure A.2). Sawhney et al.
pioneered the acrylation of PLA-PEG-PLA diblock macromers for in situ formation of
degradable hydrogels (Sawhney, Pathak et al. 1993). Since that time, Bowman and Anseth
and their colleagues have synthesized a series of degradable PLA-PEG-PLA hydrogels and
extensively characterized their degradability via experimental observation as well as
theoretical verification (Metters, Anseth et al. 2000; Metters, Anseth et al. 2000; Metters,
Bowman et al. 2000; Mason, Metters et al. 2001; Metters, Anseth et al. 2001; Metters,
Bowman et al. 2001).
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Figure A.17 Poly(ethylene glycol) and its derivatives for PEG-based hydrogel synthesis.
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Mikos and colleagues have synthesized a series of PEG-containing, water-soluble
block copolymers, including poly(proplyene fumarate)-co-ethylene glycol) (Suggs, Kao et al.
1998; Behravesh, Jo et al. 2002; Tanahashi, Jo et al. 2002) and oligo(poly(ethylene glycol)
fumarate) (Figure A.17) (Jo, Shin et al. 2001; Shin, Jo et al. 2002; Temenoff, Athanasiou et
al. 2002). These hydrogels are biodegradable, injectable, in situ photocrosslinkable, and
biocompatible. Because of these properties, they hold great potential both in drug delivery
(Holland, Tabata et al. 2003; Kasper, Kushibiki et al. 2005; Park, Temenoff et al. 2005) and
tissue engineering applications (Shin, Jo et al. 2002; Behravesh and Mikos 2003; Shin, Ruhe
et al. 2003; Temenoff, Shin et al. 2003; Fisher, Jo et al. 2004; Shin, Zygourakis et al. 2004).
The degradation of these hydrogels occurs at the ester linkage within the poly(propylene
fumarate) block (Suggs, Krishnan et al. 1998) and can be accelerated by decreasing pH and
crosslinking density (Timmer, Ambrose et al. 2003).
Recently, Hubbell and coworkers have used Michael-type addition reactions to form
PEG-based hydrogels by reacting vinyl-sulfone functionalized PEG chains with thiol groups
present on other macromers.

This conjugation reaction can be carried out under

physiological conditions without the use of initiators (Elbert, Pratt et al. 2001; Heggli, Tirelli
et al. 2003; Lutolf and Hubbell 2003; van de Wetering, Metters et al. 2005) which produce
free radicals and often induce damage to the encapsulated protein (Lin and Metters 2005),
DNA (Quick and Anseth 2003; Quick and Anseth 2004; Quick, Macdonald et al. 2004) or
cells (Quick and Anseth 2003).
West and colleagues have incorporated enzyme-sensitive peptides into PEG-based
hydrogels. The resulting peptide-incorporated PEG-based hydrogels can be degraded by
collagenase or plasmin (West and Hubbell 1999; Mann, Gobin et al. 2001; Gobin and West
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2002). The incorporation of enzyme-sensitive peptides not only facilitates gel degradation
but also enhances cell migration (Gobin and West 2002). Hubbell and coworkers have also
modified PEG hydrogels with recombinantly produced peptides that are proteolytically labile
(Park, Lutolf et al. 2004). The main advantage of these approaches is that the cellularly
controlled gel-degradation rate self-adjusts to the rate of cell infiltration, making these gels
extremely attractive for tissue regeneration applications.
A.6.2 Poly(vinyl alcohol)-based Hydrogels
Poly(vinyl alcohol) hydrogels were one of the earliest hydrogels to play an important
role in biomedical applications (Brinkman, Vanderdoes et al. 1991). Unlike PEG, which has
at most two derivatizable hydroxyl groups at the chain termini, PVA possesses numerous
pendant hydroxyl groups which can be modified for crosslinking or ligand attachment. Both
physical and chemical crosslinking methods can be used to fabricate PVA hydrogels. Peppas
pioneered the fabrication of PVA hydrogels by the freeze-thaw process (Peppas and Scott
1992; Stauffer and Peppas 1992; Mongia, Anseth et al. 1996). The resulting PVA hydrogels
were used for controlled release (Peppas and Scott 1992) and wound healing applications
(Mongia, Anseth et al. 1996).
In addition to the freeze-thaw process, PVA hydrogels can be physically crosslinked
using blend copolymers. Some examples of polymers that can be blended with PVA to
create stable hydrogels are polysaccharides including chitosan and dextran. Cascone et al.
reviewed the fabrication and applications of several PVA/polysaccharide blend hydrogels
(Cascone, Barbani et al. 2001). These hydrogels could be used in drug delivery systems and
are capable of delivering human growth hormone in physiological amounts.
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To create chemically crosslinked PVA hydrogels that can be formed in situ, Anseth
and coworkers synthesized a series of photocurable PVA-based hydrogels and characterized
their mechanical properties as well as degradability (Martens and Anseth 2000; Nuttelman,
Henry et al. 2002; Bryant, Davis-Arehart et al. 2004). Specifically, fibronectin-modified PVA
hydrogels were found to enhance NIH3T3 cell adhesion, proliferation, and migration
(Nuttelman, Mortisen et al. 2001). PLA-g-PVA hydrogels were found to improve valve
interstitial cell adhesion by increasing gel hydrophobicity (Nuttelman, Henry et al. 2002).
PEG-PVA hydrogels with tailorable characteristics were used in cartilage tissue engineering
(Figure A.18) (Martens, Bryant et al. 2003).

West and coworkers also prepared

photocrosslinkable PVA hydrogels modified with cell-adhesive peptides for encouraging cell
attachment (Schmedlen, Masters et al. 2002).

Figure A.18 An idealized schematic of the structure of hydrogels formulated by
copolymerizing poly(ethylene glycol)-lactic acid-dimethacrylate (PEG-LA-DM) with acrylateester-poly(vinyl alcohol) (Acr-Ester-PVA). The network consists of kinetic chains (light lines)
connected via PEG cross-links (dotted lines) and the multifunctional PVA chains (bold lines).
(From Martens, P.J., Bryant, S.J., et al. 2003. Biomacromolecules 4: 283–292. With permission.)
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A.6.3 Polyacrylamide-based Hydrogels
Polyacrylamide gels are widely used for protein separation (e.g., SDS-PAGE) and are
prepared from free-radical polymerization of acrylamide monomer and N,N’-methylene
bisacrylamide (BIS) crosslinker. The free radicals are typically generated via a redox reaction
involving two components, ammonium persulfate (APS) and tetramethylethylenediamine
(TEMED). To fulfill the desired protein separation requirements, the crosslinking density of
these gels can be increased by increasing the monomer concentration or crosslinker to
monomer ratio.

While acrylamide bonds are considered to be stable in aqueous

environments, the unique architecture of the bisacrylamide crosslinker enables it to be
cleaved via hydrolytic attack.

Hydrolytic cleavage of the crosslinker leads to eventual

degradation of the polyacrylamide gel.
Hydrogels made from N-(2-hydroxypropyl)-methacrylamide (HPMA) have been
prepared via radical polymerization (Figure A.19) (Ulbrich, Subr et al. 1993; Ulbrich, Subr et
al. 1995). The resulting poly(HPMA) hydrogels have been shown to be stable in acidic
environments but hydrolytically degradable at pH 7.4 (Ulbrich, Subr et al. 1995).
Applications of these degradable methacrylamide-based hydrogels include controlled drug
delivery (Ulbrich, Subr et al. 1995; Stastny, Plocova et al. 2002) and gene therapy (Howard,
Dash et al. 2000; Oupicky, Ogris et al. 2002). Poly(HPMA) hydrogels have also been used to
conjugate doxorubicin, an anti-cancer drug, via enzymatically or hydrolytically labile linkages
(St'astny, Plocova et al. 2002; Stastny, Plocova et al. 2002).

Prolonged, degradation-

controlled release of this drug from poly(HPMA) gels has been shown to effectively reduce
tumor size as well as increase survival time in an animal model (St'astny, Plocova et al. 2002).
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Another well-known application of polyacrylamide-based polymers is the fabrication
of thermally responsive poly(N-isopropylacrylamide) (PNIPAAM) hydrogels. PNIPAAM,
with a lower critical solution temperature (LCST) around 32°C, exhibits a reversible thermosensitive swelling behavior.

Above the LCST, the PNIPAAM polymer collapses and

precipitates from the surrounding solution due to strong intra-molecular hydrophobic
interactions. Below the LCST, the polymer chain swells and is soluble. This attractive
feature allows PNIPAAM at a temperature below the LCST to be readily injected into the
body. Immediately following injection, the system temperature increases to 37°C and the
PNIPAAM gel forms in situ.

Figure A.19 Structure of poly(HPMA) hydrogel. (From Ulbrich, K., Subr, V., et al. 1995. J.
Control. Release 34:155–165.With permission.)
Although PNIPAAM itself is a non-degradable polymer, many efforts have been
made to incorporate degradable functionalities to render degradable PNIPAAM hydrogels.
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These copolymers include dextran (Huh, Hashi et al. 2000; Kumashiro, Huh et al. 2001;
Kumashiro, Lee et al. 2002; Huang and Lowe 2005), acrylic acid (Kim and Healy 2003),
dimethylacrylamide (Kurisawa, Matsuo et al. 1998; Kurisawa and Yui 1998), poly(amino
acids) (Yoshida, Aoyagi et al. 2003), and poly(lactic acid) (Xiao, Nayak et al. 2004). The
temperature-responsiveness and biodegradability of these gels make them unique and in
many cases allows better control over physical gel properties and function. For example, the
degree of swelling, degradation rate, and release rate of drugs from hydrogels containing
PNIPAAM can be modulated by small temperature changes (Kurisawa, Matsuo et al. 1998).
A.6.4 Polyphosphazene-based Hydrogels
As a degradable synthetic hydrogel for biomedical applications, polyphosphazene has
gained much attention for controlled drug release. Readers are referred to recent review
articles for a more in-depth discussion of polyphosphazene polymers (Andrianov and Payne
1998).

Unlike most of the other synthetic polymers with carbon-carbon backbones,

polyphosphazene, on the other hand, possesses a backbone with alternative phosphorus and
nitrogen atoms and two substitutive groups on phosphorus atoms. Polyphosphazenes can
be synthesized from precursor macromers poly(dichlorophosphazene) into water soluble
polyphosphazene polyacid.

The resulting polyacid can then be crosslinked into ionic

hydrogels (Figure A.20) (Andrianov, Chen et al. 1998; Andrianov, Svirkin et al. 2004). The
degradation rate of polyphosphazene has been shown to depend on the degree of
substitution of the pendant groups. Specifically, the degradation rate decreases with a
decreasing degree of substitution (Andrianov, Svirkin et al. 2004).
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Figure A.20 Synthetic pathway to polyphosphazene polyacids. (From Andrianov, A.K.,
Svirkin, Y.Y., et al. 2004. Biomacromolecules 5: 1999–2006.With permission.)
Many modifications have been proposed in the fabrication of polyphosphazene
hydrogels. For example, Allcock et al. have synthesized a series of phosphazene hydrogels for
biomedical applications including, but not limited to, poly[(amino acid-ester) phosphazenes]
(Allcock, Pucher et al. 1994), poly(alkyl oxybenzoate) phosphazene (Greish, Bender et al.
2005), tyrosine-bearing polyphosphazenes (Allcock, Singh et al. 2003), and polyphosphazene
blend copolymers (Ibim, Ambrosio et al. 1997; Ambrosio, Allcock et al. 2002).
Polyphosphazene can also be fabricated as thermo- or pH-responsive hydrogels.
A.6.5 Protein-Crosslinked Hydrogels
Hydrogels made from synthetic polymers exhibit many favorable characteristics as
discussed in the previous sections. However, one of the drawbacks of using pure synthetic
hydrogels is that they do not possess biological recognition sites for cell-material interactions
that may be advantageous for tissue engineering applications. For this reason, efforts have
been made to develop hydrogels with synthetic polymer backbones and biologically derived
crosslinks. The use of proteins as crosslinkers for synthetic hydrogels can be traced back to
the early 90’s where albumin was used to crosslink poly(1-vinyl-2-pyrrolidinone) (PVP)
hydrogels (Shalaby, Blevins et al. 1990; Shalaby, Blevins et al. 1991) The crosslinking density

293

of the PVP hydrogels can be controlled by the degree of albumin functionality and the
concentration of albumin. Furthermore, albumin-crosslinked hydrogels can be enzymatically
degraded by pepsin via surface erosion or bulk degradation depending on the functionality of
the albumin and the overall crosslinking density of the gel.
More recently, PEGylated fibrinogen has also been used to crosslink PEG hydrogels.
Several advantages exist for using fibrinogen as a hydrogel crosslinking agent. For example,
fibrinogen possesses inherent cell-recognition sites for cellular ingrowth as well as
enzymatically degradable peptide sequences for gel degradation (Almany and Seliktar 2005).
While protein-crosslinked hydrogels provide sites for cell-material interactions,
genetically engineered or artificial proteins have emerged as alternative tools for crosslinking
synthetic, polymer-based hydrogels. Recombinant DNA technology was used to create
artificial proteins or peptides as building blocks within otherwise synthetic hydrogels.
Hydrogels composed or crosslinked by genetically engineered proteins preserve all the
favored characteristics of natural-protein crosslinkers while eliminating excessive recognition
sites that may prove detrimental to successful application. Differing from conventional
synthetic polymers and natural proteins, genetically engineered proteins have monodisperse
molecular weights and precisely engineered functionalities.
Owing to this fine tuning over polymer size and chemistry, researchers are able to
better predict and determine the physiological or biological fate of the artificial biopolymers
(Haider, Megeed et al. 2004).

Examples of genetically engineered proteins used for

degradable hydrogels are elastin-like proteins (ELPs) (Megeed, Haider et al. 2004), silkelastinlike proteins (SELPs) (Megeed, Cappello et al. 2002) and coiled-coil proteins (Petka,
Harden et al. 1998; Wang, Stewart et al. 1999; Wang, Kopecek et al. 2001; Kopecek 2003).
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Hydrogels made from these materials have been used in many biomedical applications
focusing on drug release (Kopecek 2003; Haider, Megeed et al. 2004), gene delivery (Megeed,
Cappello et al. 2002; Megeed, Haider et al. 2004), and tissue engineering (Panitch, Yamaoka
et al. 1999).
Tirrell and coworkers pioneered the study of artificial-protein hydrogels in which the
synthetically engineered proteins retain at least two domains, one for water retention and
another for hydrogel network formation (Petka, Harden et al. 1998). The resulting hydrogels
can be delicately designed so that the gel is stimuli-sensitive. The mechanical properties of
artificial-protein matrices were also determined and used to control cell and tissue behavior
(Di Zio and Tirrell 2003). In addition to the stimuli-controlled swelling, another advantage
of incorporating artificial proteins into synthetic hydrogels is that many key features of the
extracellular matrix, including fibrinogen and elastin domains, can be engineered in vitro and
used to promote tissue regeneration in vivo (Di Zio and Tirrell 2003).
Kopecek and coworkers have developed genetically engineered stimuli-sensitive
hydrogels based on coiled-coil proteins for controlled release and tissue engineering (Wang,
Stewart et al. 1999). As shown in Figure A.21, recombinant coiled-coil protein was used to
crosslink N-(2-hydroxypropyl)-methacrylamide (HPMA) hydrogels containing metalchelating monomer N-(N’,N’-dicarboxymethylaminopropyl) methacrylamide (DAMA)
(Wang, Stewart et al. 1999). The resulting poly(HPMA-co-DAMA) hydrogels can swell or
shrink in response to environmental changes and are very useful in stimuli-sensitive drug
release (Xu, Breedveld et al. 2005). On the other hand, the designed protein or peptide
sequence can be used as an epitope when incorporated into hydrogels for cellular
recognition (Tang, Wang et al. 2000; Tang, Wang et al. 2001).
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Figure A.21 Structural representation of the hybrid hydrogel primary chains and the
attachment of His-tagged coiled-coil proteins. (From Wang, C., Stewart, R.J., et al. 1999.
Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains.
Nature 397: 417–420.With permission.
Hubbell and coworkers have also devoted significant efforts to the design and
fabrication of PEG-based hydrogels containing artificial-proteins.

They created several

model synthetic polymeric systems containing molecularly engineered peptides or proteins
for mimicking the natural ECM (Halstenberg, Panitch et al. 2002; Lutolf, Lauer-Fields et al.
2003; Lutolf, Weber et al. 2003; Seliktar, Zisch et al. 2004; Raeber, Lutolf et al. 2005). In
these systems, the proteins are incorporated as highly mobile pendant chains rather than as
crosslinks. The pendant protein systems are not stimuli-sensitive, but do facilitate the
development of synthetic scaffolds for use in tissue engineering. They also provide a
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platform for investigating some of the fundamental yet critical cellular behavior such as
migration, secretion, and proliferation. For example, a PEG-based hydrogel bearing a matrix
metalloproteinase (MMP) inhibitor and tumor necrosis factor-alpha (TNF-α) was used to
investigate cellular protease activity as well as cell migration (Raeber, Lutolf et al. 2005).
A.7 Conclusions
Degradable hydrogels have already been successfully employed in numerous
biomedical applications. Because of their unique combination of properties, they have the
potential to dramatically impact the future of biomaterials and biomedicine, especially in the
fields of controlled drug delivery and tissue engineering.

Irregardless of their chosen

application, degradable hydrogels must meet a number of design criteria to function
appropriately in complex biological environments.

They must be biocompatible,

mechanically resilient, selectively permeable, and degradable over appropriate timescales.
Furthermore, the degradation behavior of all biodegradable hydrogels should be well
defined, reproducible and tunable via precursor chemistry and structure.
The chemistries of all hydrogel components are critical to maintaining sufficient
biocompatibility, degradability and hydrophilicity. Many polymers derived from biological
sources are readily crosslinked into biocompatible, resorbable hydrogels. However, these
materials suffer from concerns of reproducibility and engineerability. Synthetic polymers
offer better engineerability in the chemistry, structure, and physicochemical properties of
biodegradable hydrogels, but are not necessarily biodegradable nor biocompatible.
Degradability is typically engineered into these systems via unique macromonomer designs
(e.g., dimethacrylated PLA-PEG-PLA triblock copolymers) or specialized polymerization
reactions that create labile bonds (e.g., Michael-type additions between an acrylate and thiol).
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Future designs of biodegradable hydrogels will rely on synthesizing gels exhibiting the
advantages of both natural and synthetic polymers. Novel methods of genetic engineering
and controlled polymerizations such as atom-transfer radical polymerizations (ATRP) are
currently producing polymers with precisely defined molecular weights and functionalities
that can be used to fabricate biodegradable hydrogels with exact physicochemical properties
and degradation behaviors.
Finally, network structure also plays a key role in determining the elasticity, water
content, permeability, and degradation behavior of biodegradable hydrogels. The significant
majority of biodegradable gels currently used in biomedical applications degrade via cleavage
of a small number of known hydrolytically or enzymatically labile bonds. However, the
progression in observable hydrogel properties such as degree of swelling, modulus, and mass
loss during degradation varies greatly due to differences in the location, arrangement,
distribution, and total concentration of these labile bonds within the network structure.
Network structure is a function of precursor chemistry, precursor architecture, and method
of gel fabrication (e.g., chain versus step-growth polymerization). In most cases it cannot be
experimentally characterized and is made more complex by interpolymer interactions as well
as the occurrence of structural defects during fabrication. While physical crosslinking is
readily accomplished in a number of systems, covalent crosslinking methods remove the
need for interpolymer interactions and lead to the formation of homogeneous networks with
relatively uniform chain distributions and crosslinking densities. In addition, fundamental
thermodynamic principles can be used to relate experimentally observable gel properties
during degradation of these gels to their time-dependent crosslinking density or average
molecular weight between crosslinks (Mc). These relationships have already been verified
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for covalently crosslinked PLA-PEG-PLA gels. Development of the next generation of
biodegradable hydrogels with precise combinations of properties (e.g., in situ formation, cellmediated degradation, high mechanical strength and solute permeability, etc.) will depend on
furthering our understanding of hydrogel structure while also increasing our library of
available biodegradable and biocompatible polymer chemistries.
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